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Some individuals with chronic HIV-1 subtype C infection are able to suppress viral 
infection without antiretroviral drugs.  However, viral control can be temporary, with 
subsequent rise in viremia and associated disease progression.  The immunological 
mechanisms associated with control or loss of viral control are not fully understood. 
We characterized longitudinally the immunological and virological features that may 
explain the divergence in disease outcome in 70 HIV-1 C-clade infected antiretroviral 
therapy (ART)-naïve South African adults from Durban, 35 of whom possessed 
protective HLA class I alleles.   
We demonstrate that in this cohort, some individuals with protective HLA class I 
alleles lost viral control upon longitudinal follow up while the majority of individuals 
without protective HLA class I alleles maintained viral control. Sustained HIV-1 
control in viremic controllers with protective HLA class I alleles (VC+) was related to 
the breadth of HIV-1 CD8+ T-cell responses against Gag and enhanced ability to 
suppress viral replication in an ex vivo viral inhibition assay. The loss of virological 
control among some individuals with protective HLA class I alleles (failing viremic 
controllers- fVC+) was associated with reduction in the total breadth of CD8+ T-cell 
responses in the absence of differences in HIV-1-specific CD8+ cell polyfunctionality 
or proliferation. At the time point of virological control, fVC+ subjects already 
displayed a reduced capacity to suppress viral replication in an ex vivo viral inhibition 
assay, compared to others who did not subsequently experience loss of control. 
Additionally, we showed that CD8+ T cell escape mutations were common in the 
fVC+ subgroup and in some instances the loss of CD8+ T cell responses could be 
explained by immune escape, however, in some cases the loss of CD8+ T cell 
responses could not be explained by viral escape. Interestingly some VC+ maintained 
 xviii 
viral control throughout despite the presence of escape mutations within Gag, and 
persistence of CD8+ T cell responses irrespective of sequence variation appeared to be 
a correlate of viral control. Controllers without protective HLA class I alleles (VC-) 
showed low breadth of HIV-1 CD8+ T cell responses and a reduced ability (compared 
to viremic controllers with protective HLA class I alleles who never lost control) to 
suppress viral replication in an ex vivo viral inhibition assay. Furthermore, these VC- 
subjects had fewer escape mutations within Gag and maintained low viral load 
throughout. 
Our data suggest that the control of HIV-1 in individuals with protective HLA class I 
alleles may be driven by broad CD8+ T cell responses targeted towards Gag with 
potent viral inhibitory capacity while control among individuals without protective 
HLA class I alleles may be linked to alternative non-CD8+ T cell mechanisms. These 
alternative mechanisms require further investigation. The data further suggest that the 
loss of virologic control is related to the loss of CD8+ T cell responses. However, viral 
escape does not fully explain the loss of CD8+ T cell responses in chronic HIV 
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CHAPTER 1: INTRODUCTION TO THE 
HISTORY, EPIDEMIOLOGY AND IMMUNE 
RESPONSES TO CHRONIC HUMAN 
IMMUNODEFICIENCY VIRUS (HIV) TYPE 1 
INFECTION  
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1.1 THE DISCOVERY AND GLOBAL PANDEMIC OF HIV/AIDS 
The first cases of acquired immune deficiency syndrome (AIDS) were recognised in 
1981 in the United States. This syndrome was first identified amongst young 
homosexual men who presented with similar symptoms of unusual opportunistic 
infections and a rare skin malignancy called Kaposi’s sarcoma (1, 2). A few years 
later the human immunodeficiency virus (HIV) was isolated and identified as the 
causative agent of AIDS (3–5). Thirty-four years since its discovery, HIV remains a 
public health threat having claimed the lives of an estimated 35 million people (6). 
An estimated 75 million people have been infected since the beginning of the 
epidemic and 36.9 million people were reported to be living with HIV in 2014, 
Figure 1.1. Sub-Saharan Africa still bears the brunt of the epidemic accounting for 
70% (25.8 million) of the infected population worldwide (7, 8).  
Figure 1.1. A global view of the adults and children estimated to be living with 
HIV/AIDS in 2014 (7)  
Although there is still no cure for AIDS, the introduction, implementation and 
accessibility of antiretroviral therapy (ART) from the mid-1990s onwards has proven 
to be successful in prolonging the lives of those infected and reducing mortality and 
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morbidity rates caused by the HIV epidemic. This is clearly evident as the number of 
people estimated to have died from AIDS related illnesses has reduced from 2.0 
million in 2009 to 1.5 million in 2013 (7). New infections have declined by 35% since 
the year 2000 where by worldwide, 2 million (1,9 million – 2.2 million) people 
became newly infected with HIV in 2010, a decrease from 3.1 million (3.0 million – 
3.3 million) documented in 2000 (8). New infections among children have also 
declined by 58% where by worldwide, 220,000 (190,000 – 260,000) children became 
newly infected with HIV in 2014, a decline from 530,000 (470,000 – 580,000) in 
2000 (8). Despite efforts being made to combat HIV, there is still no effective HIV 
vaccine available. 
1.2 HIV PREVALENCE IN SOUTH AFRICA 
South Africa is one of the hardest hit countries in the world with an HIV prevalence 
rate of 12.2% recorded amongst adults in 2012, an increase compared to 10.6% 
prevalence rate reported in 2008. Additionally, an estimated 6.4 million people were 
living with HIV in 2012 (9). Furthermore, HIV prevalence by province showed that 
KwaZulu-Natal continues to have the highest HIV prevalence rate of 16.9% when 
compared to other provinces in South Africa. Mpumalanga and Free State provinces 
follow with 14.1% and 14.0% respectively. The Western Cape province has the 
lowest HIV prevalence rate of 5%, Figure 1.2.  
 
 4 
 Figure 1.2. HIV prevalence rates by province in South Africa (9). Key: KZN- KwaZulu-
Natal, MP- Mpumalanga, FS- Free State, NW- North West, GP- Gauteng Province, EC- 
Eastern Cape, LP- Limpopo, NC- Northern Cape, WC- Western Cape. 
In South Africa, female HIV prevalence is on the rise with a rate of 14.4% compared 
to males (9.9%) and has reached a peak in the age group 30 – 34 years with a 
prevalence of 36.1% higher than their male counterparts whose HIV prevalence was 
recorded to be 25.6% in 2012 (9). The highest HIV prevalence among males is in the 
age group 35 – 39 years (28.8%), still lower than their female counterparts with a rate 
of 31.6%, (Figure 1.3). The introduction of ART has increased survival of people 
living with HIV (PLWH), with 31.2% of PLWH having access to ART (9).  
Figure 1.3. HIV prevalence rates by age and sex in South Africa, 2012. (9).  
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1.3 THE RETROVIRUS 
1.3.1 HIV Classification 
HIV is classified as a Lentivirus, a subgroup of the Retroviridae family. This 
classification is based on the morphological, genetic and biological properties of the 
virus. In particular HIV is enveloped, contains reverse transcriptase and comprises of 
two identical copies of positive sense, linear ribonucleic acid (RNA) genome (10, 11). 
There are two types of HIV described so far; HIV-1 (3, 4) and HIV-2 (12). HIV-2 is 
commonly found in West Africa and is known to be a less transmissible and less 
pathogenic virus than HIV-1, which is responsible for the global pandemic. Previous 
studies have demonstrated that HIV-2 infected patients survived longer than HIV-1 
infected patients, the transmission rate was lower than that of HIV-1 and that HIV-2 
infected individuals had lower viral load and slower rate of CD4+ T cell decline (13–
15),  supporting the view that HIV-2 is less pathogenic. Because HIV-2 is known to 
be less transmissible compared to HIV-1 (16), this implies that fewer individuals 
exposed to HIV-2 will be infected. In this thesis, the use of the term ‘HIV’ will refer 
to HIV-1. 
HIV has four phylogenetically distinct groups, namely: M (the Main group), O (the 
Outlier group), N (non-M, non-O group) (17) and finally P, recently isolated from a 
woman in Cameroon (18). Groups O, P and N are very rare and mostly common in 
Central-West Africa (Cameroon) (19, 20) while group M is the most prevalent and is 
responsible for the global HIV/AIDS pandemic (21, 22). Group M comprises of 
eleven clades; A – K, denoted subtype A, B, C, D, F, G, H, J and K and this group 
accounts for about 90% of the global pandemic (17, 23, 24). There are also 
recombinant forms, which derive from a combination of different subtypes (22, 25). 
Figure 1.4 shows the global distribution of the major subtypes and recombinants of 
 6 
HIV-1, (26). The most dominant HIV-1 subtypes are B and C, with subtype C being 
the predominant subtype found in southern Africa, parts of eastern Africa, India, and 
parts of China and is responsible for the AIDS pandemic in the region while subtype 
B is most commonly found in Europe, the Americas, Japan, and Australia (22, 26, 
27). 











1.3.2 HIV structure 
 
Figure 1.5. A schematic representation of the structure of HIV virion (29). 
 
Retroviruses are enveloped viruses that replicate inside the host cell. HIV is roughly 
spherical in shape with a diameter of about 120nm (30). A schematic representation 
of the virion structure is shown in Figure 1.5. HIV is characterised by 2 identical 
copies of positive sense single stranded RNA that codes for the virus’s nine genes 
enclosed by a conical capsid (CA) that comprises of about 2,000 of the viral protein 
p24 (29). HIV, just like any other lentivirus has an inner and outer membrane. The 
outer membrane comprises of the lipid bilayer where surface glycoprotein (gp120 or 
SU) is anchored through its interaction with trans-membrane glycoprotein (gp41 or 
TM) (31, 32). Other host cellular proteins such as major histocompatibility antigens, 
actin and ubiquitin also contribute to the formation of the outer membrane (33). On 
the other hand, the inner membrane comprises of the matrix proteins (MA or p17). 
The nucleocapsid protein (CA or p24) encompasses the two RNA molecules, which 
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are anchored together in a ribonucleoprotein complex formed by several nuclear 
capsid proteins (NC or p7), integrase (IN or p31), reverse transcriptase (RT or 
p66/p51) and protease (PR or p11) (29). 
Upon entry in to the host cell, the RNA is reverse transcribed into complimentary 
DNA by the viral reverse transcriptase, which is contained in the infecting virion. The 
DNA is then transported into the nucleus with host proteins as part of a pre-
integration complex and integrated into the host genome with the help of another viral 
enzyme integrase and other cellular factors.  The viral DNA can now function as a 













1.3.3 HIV genome 
Figure 1.6. A schematic diagram of the HIV genome showing the long terminal repeats 
that flank either side of the genome and the 9 open reading frames. The gag gene 
encodes the viral proteins that form the capsid; the pol gene encodes the three enzymes, 
protease (PR), reverse transcriptase (RT) and integrase (IN); the env gene encodes the 
envelope surface protein. The remaining six open reading fames encode the accessory 
proteins; Vif, Vpr, Vpu, Tat, Rev and Nef (29).  
 
The HIV genome, approximately 9.5 kilobases long comprises of nine genes. The 
HIV genome is flanked by long terminal repeat (LTR) sequences on either ends (five 
prime and 3 prime ends) (32, 35). There are three major structural proteins; Gag 
(group specific antigen polyprotein) that comprises the core structural proteins, Pol 
(polymerase) polyprotein that is processed into three viral enzymes and Env 
(envelope) that consists of the gp120 and gp41 proteins. These major structural 
proteins are essential for the formation of new viral particles.  Furthermore, there exist 
six additional proteins namely two regulatory proteins; Tat (transcriptional 
transactivator) and Rev (regulator of virus protein expression) required for viral 
replication (36, 37) and four accessory proteins; Nef, Vif, Vpr and Vpu (Figure 1.6) 
required for regulatory functions and virion assembly (35, 37, 38). 
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1.3.4 Viral proteins and function 
Gag – codes for the core structural proteins of the virus; capsid protein p17 (Matrix), 
p24 (capsid), p7 (nucleocapsid) and p6. The latter protein mainly associates and 
interacts with the plasma membrane to allow assembled virions to be released from 
the cell surface (39) as well production of the Vpr protein (40, 41). 
Pol  – codes for the viral enzymes; Protease (PR), Reverse Transcriptase (RT) and 
Integrase (IN).  The RT is responsible for the conversion of the single stranded RNA 
in to single copy DNA (29, 42), which is then integrated into the host genome with 
the help of the IN. The IN facilitates the insertion of the linear double stranded DNA 
into the host cell chromosome (42). The PR then cleaves the Gag and Gag-Pol 
polyproteins to facilitate conformational changes required for the production of 
mature infectious viruses (35). 
Env – the envelope is the most variable protein and comprises of the viral envelope 
glycoproteins; i. Subunit (SU) gp120. ii. Transmebrane (TM) gp41. The two derive 
from the cleavage of the highly glycosylated polyprotein gp160 by cellular proteases 
(43, 44). Both the gp120 and gp41 glycoproteins are essential for virus attachment 
and fusion to the target cell during the early stages of infection (29). 
Tat – the transactivator of HIV gene expression activates initiation of transcription 
(45, 46). 
Rev – a trans-activating protein that codes for a 19kD phosphoprotein, which 
functions include promotion of nuclear export, stabilization and usage of the viral 
mRNAs (45, 47). 
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Vif - the viral infectivity factor codes for a cytoplasmic protein required for 
subsequent infectivity of new viral particles. It disrupts the antiviral function of the 
human apolipoprotein B mRNA-editing enzyme-cytidine deaminase enzymes  
(APOBEC) enzyme hence preventing APOBEC3G protein from entering the virion 
during budding from a host cell by targeting it for proteasomal degradation (48–52).  
Vpr – the Viral Protein R is a 96 amino acid 14-kDa protein which is required for 
virus replication in non-diving cells such as macrophages, regulation of the nuclear 
import of the HIV pre-integration complex and induces arrest of host cells at the 
G2/M phase of the cell cycle (43, 45).  
Vpu – the Viral protein U is mainly involved in the late stages of infection and is 
known to enhance virion release from the plasma membrane of infected cells by 
counteracting host restriction by tetherin (45, 53, 54). 
Nef – the negative regulatory factor is known to promote viral spread by down 
regulation of CD4 through endocytosis from plasma membrane and Major 
histocompatibility complex (MHC) class I molecules from the cell surface hence 
protecting the infected cells from cytotoxic T lymphocyte (CTL) recognition (45). 
1.4 HIV REPLICATION 
1.4.1 HIV tropism 
HIV has the ability to infect a number of cell types including CD4+ T cells as their 
main target and several others such as macrophages and microglial cells. Entry into 
CD4+ T cells and macrophages involves an interaction between the CD4 molecule on 
the target cell and the virion envelope glycoprotein (gp120) together with chemokine 
co-receptors differentially expressed on CD4+ T cells (55, 56). The different virus 
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strains can exhibit different affinities for either of the following chemokine receptors 
for entry into the target cell resulting in distinct tropisms: i. The -chemokine 
receptor, chemokine receptor type 5 (CCR5), hence the viruses using this route are 
known as R5 isolates. ii. The -chemokine receptor, chemokine receptor type 4 
(CXCR4), hence the viruses using this route of entry are known as X4 isolates (57–
59). Both the R5 and X4 isolates can infect and replicate in primary CD4+ T cells. 
However, some viruses can use both chemokine receptors for entry into the host cell 
and these are known as R5X4 or dual tropic isolates. HIV has a bias towards utilizing 
CCR5 during acute infection which has been documented to facilitate rapid spread of 
infection, however during the course of the disease progression, there tends to be a 
switch either to dual tropism or CXCR4 co-receptor usage (56, 60, 61).  
Other immune cells that HIV can infect are the myeloid dendritic cells in which virus 
entry occurs via either the CD4-R5 route or another route using mannose-specific C-
type lectin receptors such as the Dendritic Cell-Specific Intercellular adhesion 
molecule-3-Grabbing Non-integrin (DC-SIGN) (62, 63). The infection of dendritic 
cells is very critical for maintenance of the viral reservoir in cases where the number 
of target cells (CD4+ T cells) has declined to very low levels (62). In addition, other 
types of DCs such as plasmacytoid DCs and Langerhans can be infected by HIV (64). 
Furthermore, monocytes and other cell types may also be infected by HIV (65).  
It is important to note that there exist a group of individuals who are resistant to HIV 
infection. These few individuals have a 32 base pair deletion on their CCR5 receptor 
sequence; a mutation known as CCR5 delta 32 (CCR532). Individuals with this 
mutation are resistant to infection with R5 - using viruses which are then unable to 
bind or enter the target cell and establish successful infection (61, 66–68). There are 
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very few people with this mutation. The frequency of individuals with this mutation is 
as low as 0.10 recorded in a cohort in the USA (69) and 0.01 in a cohort in Western 
Europe (66).  
1.4.2 HIV infection 
Once HIV comes into contact with a target cell, infection and further production of 
new infectious virions take place in a process known as viral replication. Viral 
replication steps include the following; virus attachment, fusion and entry, uncoating 
and reverse transcription, importation of the pre-integration complex into the nucleus, 
integration, transcription and translation, assembly and budding and finally 
maturation (29). These steps are discussed in detail below and summarized in Figure 
1.7. 
Figure 1.7. Schematic representation of the life cycle of HIV inside a host cell. HIV 
replication begins with the interaction of a virus particle with a receptor on the cell 
surface, resulting in the fusion of the viral and cellular membranes and transfer of the 
viral contents into the cell.  The viral RNA genome is reverse transcribed resulting in 
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the production of a DNA copy, which is then imported into the nucleus.  Inside the 
nucleus, the viral DNA is integrated into the host-cell genome. This is followed by 
transcription process from within the host genome, which is then exported from the 
nucleus. The translation of the viral proteins by host-cell machinery begins and the 
major structural protein, Gag, is transported to the plasma membrane where it directs 
assembly of the viral coat and incorporates other viral proteins and the viral genome. 
The virus buds through the cell membrane, and Gag is cleaved by the viral protease 
leading to a structural change of the virion into its mature infectious form, which is 
capable of fusing with a new susceptible cell (figure adapted from (70). 
 
1.4.2.1 Virus fusion and entry 
The CD4 molecule expressed on the surface of the target cell, serves as a binding 
receptor for HIV, which interacts and binds with high affinity to gp120 found on the 
surface of the virus (71–74). This interaction triggers a conformational change of the 
envelope glycoprotein facilitating the virus to fuse with the target cell membrane (75, 
76). However, the interaction between CD4 and gp120 alone is not sufficient to 
trigger conformational change adequate enough for virus entry. Therefore, co-
receptors (CCR5 or CXCR4) must be expressed on the surface of the target cell in 
order to provide a much stronger conformational change of the glycoprotein necessary 
for successful virus entry (77–79). The conformational changes that occur following 
interaction of the CD4 with gp120 allow exposure of the chemokine binding domains 
of gp120 hence leading to their interaction with the target cell chemokine receptors 
(44, 58, 60, 75, 80). The interaction between CD4-gp120 and co-receptors leads to a 
prolonged attachment facilitating the N-terminal fusion peptide gp41 to penetrate the 
cell membrane therefore allowing fusion and entry to occur (72). 
1.4.2.2 Uncoating and reverse transcription 
Following virus entry is the uncoating and delivery of the viral core into the 
cytoplasm of the target cell (29, 81–83). During this process the nucleocapsid protein 
(CA) is lost and the viral core is retained which comprises of the viral RNA genome, 
tRNA primers and enzymes; reverse transcriptase (RT), integrase and protease (29). 
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The virus RT then facilitates the conversion of the virus RNA into a single copy of 
double stranded deoxyribonucleic acid (DNA) by a process known as reverse 
transcription (29, 84, 85). The virus RT has a low fidelity rate and has no 
proofreading capabilities, meaning it is extremely error-prone leading to high 
mutation rates of the HIV reverse transcription process (86–88), which may also later 
cause drug resistance and evasion of the virus from the host’s immune responses (85). 
The newly sysnthesized DNA and the rest of the viral core contents are retained and 
form what is known as the pre-integration complex (PIC) (89, 90). 
1.4.2.3 Integration 
The PIC is then transported to the nucleus of the target cell. This is where the viral 
DNA is incorporated into the host genome catalyzed by the viral enzyme integrase 
(IN) in a process known as integration. The integrated viral DNA now known as the 
provirus will act as a template for further synthesis of viral RNA (29, 43, 85). The 
provirus may remain latent and inactive for many years before being activated via the 
transcription process (91, 92). 
1.4.2.4 Transcription and translation 
The integrated DNA is then transcribed into messenger RNA (mRNA), by a process 
known as transcription. This process is tightly controlled by Tat (transcription factor) 
and host cell’s own machinery used for transcription of genes (93). The mRNAs are 
then spliced into smaller pieces and later exported out of the nucleus into the 
cytoplasm where they will undergo translation into proteins. The spliced mRNAs can 
be divided into 3 groups: i. Full length mRNA that encodes for structural proteins 
Gag-Pol polyproteins. ii. Singly spliced mRNA that encodes for Env, Vif, Vpr and 
Vpu. iii. The multiply spliced mRNA that encodes for the early regulatory proteins 
(Tat, Nef and Rev) (94, 95). 
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1.4.2.5 Assembly and release 
The viral proteins formed from the spliced mRNA now move towards the outer cell 
membrane where they assemble. This process occurs in a series of steps, firstly the 
Env gp160 is transported via the endoplasmic reticulum to the Golgi complex where it 
is cleaved in the gp120 and gp41 by furin (96). Both the gp120 and gp41 then move 
to the plasma membrane where gp41 facilitates anchoring of gp120 to the membrane 
of the infected cell. Gag and Gag-Pol together with the viral genomic RNA associate 
with the inner surface of the plasma membrane and form a virion that will eventually 
bud out of the infected cell. Vif is also required for the stability of the viral core and 
its interaction with the antiviral restriction factor APOBEC3G hence preventing the 
latter from incorporation into the virion (49, 97, 98). The interaction between Gag and 
cellular proteins is critical for virion release. Viral protein U (Vpu) is also involved in 
the budding and interacts with tetherin, a membrane-associated protein that has the 
ability to block release of the virus particle (53, 54, 98).  
1.4.2.6 Maturation 
Shortly after release of an immature virus particle, the maturation process occurs. 
This process involves cleavage of the immature Gag and Gag-Pol polyproteins 
precursors by viral proteases to produce functional mature Gag and Gag-Pol proteins 
leading to the generation of a mature infectious HIV particle capable of initiating 
infection (29, 99).  
1.4.3 HIV modes of transmission 
Transmission of HIV occurs via direct transfer/exchange of bodily fluids; blood and 
blood products, semen, genital secretions and breast milk from infected mother to the 
newborn. The primary means of HIV transmission is via unprotected sexual contact 
with an infected person. In the 1990s it was documented that there was an increasing 
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incidence of HIV infection in the US and Europe amongst gay men and ethnic 
minority people and such infection rates accounted for 50% of new infections in the 
US (100). The majority of HIV infections worldwide is via heterosexual intercourse 
(101, 102) while non-sexual HIV transmission may occur through occupational 
exposure through needle sticks, blood transfusion with HIV contaminated blood 
products, injection drug use and mother to child (103). 
Mother to child transmission cases in the absence of antiretroviral therapy have been 
documented in 25% of births from HIV infected mothers (104). Breastfeeding is 
another mode of mother to child transmission (105). However, with the 
implementation and availability of ART, the rate of perinatal HIV transmission has 
been reduced by 50% (106–108). Low viral load has also been associated with 
reduced HIV transmission (109).  
In addition, HIV has been isolated from bodily fluids including; blood, semen, 
cerebral spinal fluid, tears, vaginal secretions, breast milk and saliva of HIV infected 
people (110–113). Although low HIV concentrations have been isolated from saliva 
and tears, there is no evidence that contact with these fluids can cause infection (114). 
1.4.4 HIV transmission 
The biology of HIV transmission is a complex process.  Most transmissions occur 
heterosexually at the epithelial layer of the mucosal surfaces especially the genital and 
rectal mucosal surface (101, 115). At the epithelial layer, the founder virus undergoes 
a genetic bottleneck, resulting in only one virus being able to establish successful 
infection. Although the mechanisms by which infection occurs are not fully 
understood, previous work has shown that in about 80% of the cases, a single founder 
virus is responsible for successful infection (116). Furthermore, these founder viruses 
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are capable of infecting CD4+ T cells to much greater extent as opposed to infecting 
monocytes and macrophages (117) and show resistance to type I interferons (118). 
Previous studies suggest that the first cellular targets of SIV and HIV reside in the 
lamina propria of the cervicovaginal mucosa. Two days following infection, the 
cervix is infected and the virus then spreads most likely through dendritic cells and 
CD4+ T cells, which then migrate to regional lymph nodes and subsequently into the 
blood stream (119).  HIV is also able to infect Langerhans cells, in addition to other 
dendritic cells and CD4+ T cells that reside in the lamina propria of the cervicovaginal 
mucosa. These cell types express CD4 and CCR5; both essential for viral entry (120, 
121). Studies on rhesus macaques have confirmed that successful infection arose from 
a single infecting virus when the animals were inoculated intra-rectally with a 
complex SIV quasispecies thus further supporting the use of SIV infection of rhesus 
macaques as a model for HIV-1 transmission and vaccine studies (122, 123). 
1.4.5 Course of HIV infection 
HIV infection is a chronic disease and progressively causes damage to the immune 
system from the time of infection to the manifestation of severe immunologic damage 
represented by a number of opportunistic infections, neoplasms, wasting, or low CD4 
lymphocyte count that define AIDS (Figure 1.8). There are 3 main phases that define 
the course of HIV infection; acute phase, chronic phase and AIDS. 
1.4.5.1 Acute Phase 
Acute HIV infection is characterized by a burst of a to more than a million copies per 
ml of blood and a dramatic but temporal decline of CD4+ T cells prior to detectable 
antibody responses or seroconversion. The acute phase normally lasts for up to 
several weeks and newly infected individuals may present with flu-like symptoms 
such as fever, disseminated lymphadenopathy, headache, myalgia, anorexia, rash, 
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and/or diarrhoea (124).  Although there is a slight recovery of peripheral CD4+ T cell 
counts in the blood following peak viremia, massive depletion of CD4+ T cells occurs 
in the gut associated lymphoid tissue (GALT) where most of the CD4+ T cells reside 
(125). Additionally, peripheral blood CD4+ T cell counts eventually decline to a level 
that allows opportunistic infections (126, 127).  
The peak in viremia is followed by a significant reduction to a viral set point. The 
viral set point predicts disease progression; the higher the viral set point, the faster the 
disease progression (128–131). Coincidental to the reduction of viral load to a set 
point is the emergence of HIV-specific CD8+ T cells. HIV specific CD8+ T cell 
activity has been shown to be involved in the reduction of viremia to a viral set point 
(132–134). Subsequent to CD8+ T cell responses is the emergence of antibody 
responses. However, antibody responses do not appear to play a major role in 
reducing viremia during cute infection (135–138). Increased viral load (VL) is 
associated with increased risk of transmission, therefore persons with acute HIV-1 
infection are more likely to transmit the virus to uninfected individuals (139–141). 
1.4.5.2 Chronic Phase 
This phase is asymptomatic and may last for years with viral load remaining relatively 
stable followed by a steady increase until the onset of AIDS (142, 143). However, 
persistent viral replication especially in the lymph nodes, fluctuating plasma viral load 
and a steady decline of the main target cell population is observed during chronic HIV 
infection (129, 144, 145). During this phase, HIV is able to trigger or activate potent 
host inflammatory and adaptive immune responses including CTL and antibody 
responses (146). However, the virus is able to evade these responses hence 
maintaining a significant level of viral replication that in turn sustains the state of 
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chronic immune activation, which eventually causes progressive immune dysfunction 
finally leading to progression to AIDS. 
1.4.5.3 AIDS 
AIDS is the end stage of disease usually characterized by a number of opportunistic 
infections and malignancies that eventually lead to death due to the immune-
compromised state of the infected individual. The immune system is no longer able to 
control opportunistic pathogens culminating in life-threatening AIDS-defining 
diseases (147, 148). The CD4+ T cell count below 200 cells per mm3 of blood is a 
clinical indication of the onset of AIDS.  
Figure 1.8. A schematic representation of the course of HIV/SIV infection showing 
changes in viral load, antibodies, CD4 and CD8 T-cell counts in the absence of 




1.5 ANTIRETROVIRAL TREATMENT  
1.5.1 The role of ARVs 
There is currently no cure or effective HIV vaccine available. However, there is 
treatment available for HIV, which consists of highly active antiretroviral treatment 
(HAART). This treatment has proven to be effective at controlling the epidemic since 
its introduction in the 1990s as demonstrated by a reduction in the death rate of HIV 
infected people (150–152). There are 25 antiretroviral drugs (ARVs) approved to date 
for the treatment of HIV infection and successful treatment is associated with the 
continued durable suppression of HIV viremia. Standard antiretroviral treatment 
(ART) regimens consist of a combination of at least 3 drugs belonging to at least two 
classes of ARVs. The main role of ART is to stop viral replication and restore 
immune function by inhibiting crucial HIV replication steps as summarised in Figure 
1.9 below, and therefore preventing the onset of AIDS, AIDS-related illnesses, 
improving the quality of life and prolonging the life expectancy of those infected and 
finally preventing further transmission to the uninfected. 
The six different classes of ARV agents currently approved by the US Food and Drug 
Administration (US-FDA) for the treatment of HIV infection are shown below.  
a. Nucleoside reverse transcriptase inhibitors (NRTIs) target the reverse 
transcription step by interrupting the HIV replication cycle via competitive 
inhibition of HIV RT and termination of the DNA chain. Because they have a 
structure that is similar to that of the DNA nucleoside bases, they can be 
incorporated into the proviral DNA (153). 
b. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) also target the 
reverse transcription step by binding to the RT at a site distant to the active 
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site and therefore inducing a conformational change that alters the active site 
of the enzyme and limiting its activity (153). 
c. Protease inhibitors (PIs) function by binding competitively to the substrate site 
of the viral protease; an enzyme responsible for the post-translational 
processing and cleavage of polyprotein precursors that will generate core 
proteins and enzymes of mature virions during the budding from the infected 
cell. Inhibition of this process results in budding of immature viral particles 
(153, 154). 
d. Integrase inhibitors (IIs) function by inhibiting the strand transfer reaction of 
the proviral integration step through binding of the metallic ions in the 
enzyme’s active site (155, 156). 
e. Fusion inhibitors (FIs) function by interfering with the HIV fusion step by 
competitively binding to the gp41 and preventing the conformational changes 
required for gp41 to complete the fusion process (157). 
f. Chemokine receptor antagonists (CRAs) also known as CCR5 antagonists 
bind to the CCR5 co-receptor hence blocking the gp120-CCR5 interaction. 
However these drug types only inhibit CCR5 tropic HIV strains and not 
CXCR4 or dual tropic HIV strains (158, 159). 
World Health Organization (WHO) has new recommendations that treatment should 
be initiated at 500 CD4+ cells or fewer per mm3 of blood of HIV infected individuals 
(160). However the main challenge is the high number of people eligible for 
treatment. There is still a great challenge of making ARVs accessible to everyone 
who is eligible and infected with HIV especially in low and middle-income countries, 
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which bear the brunt of the HIV/AIDS epidemic. In South Africa alone, only about 
20% of the people who are HIV positive and eligible for treatment have access to 
treatment (152). The increasing evidence of resistance to treatment regimens available 
is of great concern. Additionally, HIV has a high mutation rate also contributing to 
the development of resistance to treatment (161, 162). Therefore, there are still 
milestones to be reached in order to combat the epidemic. 
 
Figure 1.9. Schematic representation of the replication cycle of HIV showing crucial 
steps targeted by the current antiretroviral treatment drugs (163). 
 
1.5.2 HIV Reservoirs 
Although HAART has proven effective at controlling HIV infection and reducing 
AIDS-related mortalities, the current drug regimens are not able to completely 
eradicate the virus from the body. The majority of HIV infected individuals on 
HAART achieve full suppression as indicated by the undetectable viral load levels for 
a long period of time. However, upon withdrawal the viral load rebounds rapidly and 
this is accompanied by a decline in CD4+ T cell count (164). Previous studies have 
shown the existence of the provirus in latently infected resting memory CD4+ T cells 
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(165) and these HIV reservoirs can later produce infectious virus even after successful 
treatment as a result of cellular activation (166–168). Because HIV DNA is already 
integrated into the host genome, it is believed that it can lie dormant for as long as the 
infected individual is alive. Some studies have attempted to see if activating the 
latently infected cells with reactivation drugs such as histone deacetylase (HDAC) 
inhibitors followed by ARVs would clear the virus from the body. Viral clearance 
was achieved when the HDAC inhibitor valproic acid was administered together with 
ART; the two studies assessed a small number of HIV infected individuals and hence 
provided proof of concept that HIV can be eliminated from persistent reservoirs and 
that HDAC inhibitors can be therapeutically used in man against HIV (169, 170). In 
parallel with treatment strategies and other measures for preventing infection and 
spread, more studies are needed to further explore the use of these inhibitors on 
clearing the viral reservoirs. An effective HIV vaccine is urgently needed. 
1.6 HIV VACCINE STRATEGIES 
The only way to combat the HIV/AIDS epidemic is through an effective HIV vaccine. 
An ideal HIV vaccine must completely block infection and provide sterilizing 
immunity and should be able to stimulate both broadly neutralizing antibodies and 
cell-mediated immune responses (171). However, a more realistic goal for an 
effective HIV vaccine would be one that is able to significantly reduce VL and delay 
clinical disease progression after infection hence reducing transmission to uninfected 
individuals (172).  Several vaccine concepts have been studied with no success 
mainly due to the high genetic variability of HIV, lack of knowledge of the immune 
correlates of protection, lack of generation of broadly neutralizing antibodies and the 
absence of a relevant animal model (149). There are no clear correlates of immune 
protection. Therefore, more research is still required to identify what immune 
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responses an effective HIV vaccine should elicit. The correlates of immune control of 
HIV infection still need to be clearly defined.  
1.6.1 The STEP and Phambili trials 
The STEP and Phambili vaccine trials assessed the efficacy of Merck Ad5 gag/pol/nef 
subtype B HIV-1 preventive vaccine in South Africa (Phambili trial) and in the 
Americas, Caribbean, and Australia (STEP trial) and was aimed at eliciting T-cell-
mediated immune responses that would provide complete or partial protection from 
HIV infection or a decrease in viral load after acquisition (173, 174). The trial was a 
was a double-blind, placebo-controlled, randomised trial that recruited HIV-1 
uninfected, sexually active adults and eligible participants were randomly assigned 
placebo or vaccine group by a computer program. Disappointingly, the MRKAd5 
HIV-1 vaccine in the Phambili trial did not prevent HIV-1 infection or lower viral 
load set point but managed to elicit interferon-γ (IFN-γ) - secreting T cells that were 
capable of recognizing both clade B (89%) and C (77%) antigens (174). In the STEP 
trial, the vaccine was also highly immunogenic as seen by induction of HIV-specific 
CD8+ T cells (175). However, there was increased HIV acquisition amongst the 
vaccinated group in both trials and so because of futility in the STEP trial, both 
vaccine trials were discontinued (174, 176–178).  
1.6.2 The RV144 HIV Vaccine trial 
In 2009 the first ever HIV vaccine reported to have shown a modest efficacy was the 
Thai HIV Vaccine efficacy trial also known as the RV144 trial conducted in Thailand. 
This vaccine combination, which was based on HIV strains commonly circulating in 
Thailand, showed a 31.2% reduction in the incidence of HIV infection. The trial was 
conducted as a community-based, randomized, multicenter, double-blind, placebo-
controlled efficacy trial, and evaluated four priming injections of a recombinant 
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canarypox vector vaccine (ALVAC-HIV [vCP1521]) including two booster injections 
of a recombinant glycoprotein 120 subunit vaccine (AIDSVAX B/E) (179). Following 
the exciting results of the Thai vaccine trial, a case-control analysis was conducted in 
order to identify antibody and cellular immune correlates of infection risk. It was 
concluded from the analyses that V1V2 antibodies may have contributed to protection 
against HIV-1 infection, whereas high levels of Env-specific IgA antibodies may have 
mitigated the effects of protective antibodies (180). Individuals presenting with high 
plasma levels of Env-specific IgA antibodies had a 54% increased HIV infection rate; 
same rate as for individuals in the placebo group suggesting that these antibodies 
disrupted the protective effect of the vaccine. Therefore, these findings suggest that an 
effective HIV vaccine with improved efficacy should elicit higher levels of V1V2 
antibodies and lower levels of Env-specific IgA antibodies (180).  
1.6.3 The CMV vector based SIV vaccine 
The negative human vaccine-trial results raised questions about the whole concept of 
a CTL-inducing vaccine against HIV. In the recent years another study took a 
different approach. In an animal model setting, a rhesus monkey cytomegalovirus 
(RhCMV) vector was employed together with recombinant SIV genes to act as 
immunogens that would elicit strong and persisting effector memory CTL responses 
in vaccinated animals (181, 182). Of the vaccinated monkeys that were challenged 
with pathogenic SIVmac239 virus, 50% cleared the virus soon after peak vireamia 
during the acute infection phase. This type of vaccine elicited atypical CD8+ T cell 
responses that were broad. However, it is not clear whether protection was dependent 
on these atypical CD8+ T cell responses (171). The in vivo removal of CD8+ T cells of 
the monkeys that had cleared the virus did not cause rebound of vireamia in these 
animals (181, 182), raising more questions about the immune correlates of protection 
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in these animals. It would be useful to further study the reasons for protection 
especially in the 50% of the monkeys that cleared the virus upon challenge. 
Nevertheless, these data further provide an opportunity to identify the correlates of 
protection and design an improved human HIV vaccine that would elicit strong and 
protective CD8+ T cell responses. 
1.7 IMMUNITY TO HIV 
1.7.1 Innate immune responses to HIV 
The innate immune response marks the very first line of defence against invading 
pathogens. Previous work has suggested that innate immune responses play an 
important role in the control of HIV infection especially during the early phase of 
infection as well as determining the establishment of infection and the subsequent rate 
of disease progression (183, 184). The reduction in viral replication observed during 
the acute phase often occurs prior to the induction of adaptive immune responses such 
as CD8+ T cell responses confirming the involvement of innate responses at this stage 
of infection (185).  
The innate immune system utilizes a number of cellular and soluble factors that work 
in order to elicit a rapid response following the recognition of pathogen associated 
molecular patterns (PAMPs) (186). There are several classes of pattern recognition 
receptors (PRR) and these including the three best known: the (RIG-I)-like receptors 
(RLRs), the toll-like receptors (TLRs), and the nucleotide oligomerization domain 
(NOD)-like receptors (NLRs) (186). Different combinations of these receptors can be 
activated primarily on innate immune cells hence leading to the induction of a 
nonspecific antiviral environment including release of cytokines such as interferons 
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(IFNs) (186). The IFNs can then blocking viral growth and finally initiate the 
induction of adaptive immune responses (186).  
The innate immune system comprises of a number of cell subsets which all derive 
from the bone marrow. These include phagocytes (monocytes, macrophages, dendritic 
cells (DCs)), cytolytic cells (Natural killer (NK) cells and neutrophils) and 
professional antigen-presenting cells (DCs). The phagocytes are responsible for 
antigen clearance, while the cytolytic cells are responsible for the destruction of 
pathogen infected cells and finally the antigen presenting cells function by 
recognizing antigens and presenting them to the adaptive immune cells for the 
induction of an immune response and memory (187). The innate immune response is 
not only vital in the early HIV infection phase, but is also required for the activation 
of the adaptive immune responses. The main innate cell players involved in the 
control of HIV infection are the NK and DC cell subsets. 
1.7.1.1 Natural killer cells 
Natural killer (NK) cells recognize and kill virally infected cells and do not require 
prior activation in order to perform this function. They have the ability to produce 
cytokines and chemokines that attract and activate cells of the adaptive immune 
system (183). NK cells, in particular KIR3DS1+ and KIR3DL1+ NK cells have been 
shown to be involved in the acute control of HIV infection as demonstrated by their 
expansion during the peak of vireamia prior to seroconversion and the appearance of 
HIV-specific CD8+ T cell responses (188).  There is another small subset of T 
lymphocytes expressing surface markers that are characteristic of both T cells and NK 
cells known as NKT cells. These are now known to form a link between the innate 
and adaptive immune responses (183, 185).  
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HIV has evolved and developed mechanisms to escape from the early innate immune 
responses suggesting that the NK cells are indeed involved during acute HIV 
infection and are able to mount pressure on the virus (185, 189). However, HIV Nef 
protein is able to down-regulate major histocompatibility complex (MHC) class I 
molecules, specifically the Human leucocyte antigen (HLA)-A and HLA-B molecules 
which allows escape from CTL responses, but does not down-regulate HLA-C 
molecules which are the dominant ligands for NK KIR2D receptors thus allowing the 
virus to escape NK responses (190–192). Therefore, there is still more work to be 
done to better understand NK responses in the control of HIV and also develop ways 
of harnessing NK cellular responses in effective HIV vaccine design. 
1.7.1.2 Dendritic cells 
Dendritic cells (DCs) are the professional antigen presenting cells. Their main role is 
to recognize and present pathogen products to T cells in order for an immune 
response to be elicited. They respond rapidly following infection through recognition 
of viral products via pattern recognition receptors (187). Human plasmacytoid DCs 
(pDCs) produce cytokines such as interferons which mediate direct effector and 
immune-regulatory functions, which stimulate adaptive immune responses as well as 
mediate rapid antimicrobial effector functions (193, 194). 
 Conventional DCs can be found in the skin, blood and mucosal surfaces. Because 
they can be found at the mucosal surfaces, they are able to come in to direct contact 
with the HIV. Following this encounter, they engulf HIV and are triggered to migrate 
to the draining lymph nodes where they can perform their function of eliciting the 
adaptive immune responses by presenting antigens to T and B cells (194, 195). The 
activation of pDCs by HIV occurs via upregulation of the expression of costimulatory 
and MHC molecules, maturation markers, increasing T cell stimulatory activity, and 
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induction of the production of type I interferons and tumour necrosis factor alpha 
(TNF-α) (195).  
A rapid decline of pDCs during HIV infection has been observed during both acute 
and chronic phases of infection and this decline was associated with high viral load 
and low CD4+ T cell count (196–198). In addition, HIV has evolved and developed 
mechanisms to prevent degradation by DCs in order to gain access to its primary 
target cells CD4+ T cells. DCs are also involved in the transmission of HIV to CD4+ T 
cells (199).  Thus DCs are a key target to investigate the ways of preventing HIV 
transmission.  
1.7.2 Humoral immune responses to HIV 
HIV infected individuals have the ability to develop antibodies against HIV early 
during infection soon after the onset of CD8+ T cell responses and establishment of 
viral set point following acute HIV infection. However, these antibodies are not able 
to neutralize HIV or resolve natural HIV infection (200–203) but can mount selective 
pressure on the virus hence causing it to evolve rapidly (138, 202, 203). The ideal 
neutralizing antibodies are usually detected several months later to 2 years following 
seroconvertion (201, 204). We know from other viral infections that the most 
effective vaccines produced to date elicit neutralizing antibodies (nAbs).  Since the 
envelope mediates HIV entry, it is ideal to design vaccines that act against the Env 
region in order to prevent viral entry and further infection (205). Most of the recent 
HIV vaccine research studies have focused on finding and understanding the possible 
mechanisms of virus inhibition and the development of strategies to prevent infection 
(206). In order to achieve full viral neutralization, HIV specific antibodies must 
recognize functional sites on the HIV-1 envelope spike, gp160, which is a hetero-
trimer composed of gp120 and gp41 protein subunits (207). Although there is still no 
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effective vaccine against HIV, the RV144 study showed some modest protection and 
demonstrated that antibodies raised against the variable loop 2 of gp120 in vaccinees 
were the main positive predictive factor for protection (180). 
Only a small percentage of HIV infected individuals known as ‘elite neutralizers’ are 
able to develop broadly neutralizing antibodies (bnAbs) (201, 208–210). These bnAbs 
are active against hundreds of different cell-free viral quasi-species from various 
HIV-1 subtypes (211). However, the bnAbs are not able to completely suppress viral 
replication in infected persons mainly due to viral escape (202, 203). Therefore, 
antibodies against HIV may play an important role by reducing the risk of infection 
and vertical transmission (211, 212). 
1.7.3 Host restriction factors 
Host restriction factors that are known to be potent inhibitors of HIV replication 
include APOBEC3G, TRIM5-alpha and Tetherin (213) and how they perform their 
function is discussed below. 
APOBEC3G (apolipoprotein B mRNA-editing enzyme-cytidine deaminase enzymes) 
is a strong inhibitor of HIV replication and is counteracted by the viral Vif protein 
(49). However, in the absence of Vif, APOBEC3G is able to convert cytosine bases of 
the viral minus‐ strand DNA to uracil, which results in a G to A hypermutation in the 
complementary positive sense DNA strand (214–216). The U-rich transcripts can 
either be degraded by activation of the cellular uracil-DNA glycosylase hence causing 
failure of the reverse transcription or can yield non-functional proviruses as a result of 
the G to A hypermutation (216, 217). HIV has evolved and developed some escape 
mechanisms and is then able to use its protein Vif, which then interacts with 
APOBEC3G and causes its degradation via the ubiquitin-dependent proteosomal 
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pathway (49, 97, 218) and therefore disrupting the inhibitory properties of 
APOBEC3G and allowing the virus to replicate (214, 217). 
Tetherin, which is also known as BST-2, CD317 or HM1.24 is a potent antiviral 
factor that inhibits HIV replication (53). It functions by inhibiting the release of newly 
formed virions from the host cell surface through binding to the cell surface at the 
virion budding site (53). HIV has evolved and developed some escape mechanisms 
and is then able to use its protein Vpu, which interacts directly with the 
transmembrane domain of tetherin and mediates down-regulation and degradation of 
tetherin levels at the cell surface (53). The exact mechanism of how tetherin functions 
is not fully understood.  
TRIM5 - tripartite motif-containing motif 5 alpha, the most studied TRIM family 
member is known to mediate species-specific and early block of retrovirus infection 
(219, 220). TRIM5α was first identified in rhesus monkeys (rh) as a factor that blocks 
HIV replication (220). It has been shown that the rhTRIM5α is a lot more potent than 
the human TRIM5α at inhibiting virus replication (220). The exact mechanism of how 
TRIM5α inhibits HIV replication is not fully understood. However, it is known that 
TRIM5α trimers interact with hexameric capsids and block replication (221). 
1.7.4 The major histocompatibility complex (MHC) class I molecules 
Genome-wide association studies (GWAS) have identified HLA class I molecules as 
the major determinant of HIV control (222, 223). The major histocompatibility 
complex (MHC) or in humans known as Human Leucocyte Antigen (HLA) class I 
molecules, are highly polymorphic and map to the short arm of chromosome 6.  They 
are responsible for processing and presenting antigens to T cells (224). Class I 
molecules present endogenous peptides to CD8+ T cells while class II molecules 
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(HLA-DR, -DQ, and –DP) bind to and present antigens of extracellular origin to 
CD4+ T cells (225). There are three classical human MHC class I alleles (HLA-A, -B 
and -C), which encode for cellular surface molecules responsible for processing and 
presenting antigens usually from intracellular pathogens to CD8+ T cells. The peptide-
binding groove of the HLA molecule is the most variable region and therefore dictates 
the binding motif for the peptides presented by each HLA allele. There are 6 pockets 
within the binding groove (A-F) and these differ in size. Of the six pockets, 2 exhibit 
a particular preference to one or two amino acids while the other 4 are flexible and 
function as secondary anchors (226).  
HLA typing may be performed serologically and by molecular methods. HLA 
nomenclature is usually resolved to 4 digits. For example, in the HLA-A*24:02, ‘A’ 
represent the locus, this is followed by an asterisk, the first two digits (number 24) 
represents the allele family/group mostly determined serologically. This is also 
referred to as the antigen level resolution. Finally the second set of digits (the number 
02) specifies the allele. For example, HLA-A*24:02 represents the second allelic 
member of the A*24 group. This is also known as the allele or subtype level 
resolution (227). HLA alleles can also be classified into supertypes that comprise 
HLA alleles of different types/subtypes that share peptide-binding specificities. The 
HLA B58 supertype, for example, comprises subtypes belonging to the B*57 and 
B*58 groups, among others (227). The HLA B7 supertype comprises subtypes 
belonging to the B*07:02, B*39:10, B*42:01, B*42:02 and B*81:01 groups. These 
alleles have similar peptide-binding motifs that can frequently bind the same peptides 
(228). 
The HLA class I loci has been shown to display the strongest effect on HIV disease 
control (222). HLA molecules are known to contribute to HIV disease control 
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primarily through CD8+ T cells. Additionally, HLA molecules also act as ligands for 
killer cell immunoglobulin-like receptors (KIRs), which are involved in controlling 
the NK cell activity. Furthermore, polymorphisms within the KIRs in particular 
KIR3DS1 have been associated with disease progression (229).  
1.7.5 Adaptive immune responses to HIV 
Adaptive immune responses or cell-mediated immune responses have been implicated 
in the control of HIV replication. Unlike the innate responses that occur rapidly, the 
adaptive immune responses are delayed and dependent on presentation of pathogen-
derived peptides in the context of HLA molecules by professional antigen presenting 
cells (APCs). The main players of the adaptive immune responses are the T cells 
including CD4+ and CD8+ T cells. HIV preferentially infects CD4+ T cells (230) and 
CD8+ T cell recognise viral peptides presented by antigen presenting cells in the 
context of MHC class I molecules in order for an immune responses to be elicited, 
which occurs when CD8+ T cells kill the virus infected cells. CD8+ T cells are known 
as effector cells due their ability to recognize and kill virus-infected cells.  
1.7.5.1 CD8+ T cells 
Immunological processes in the early phase of HIV infection shape the outcome of 
disease progression.  During the acute phase infected subjects experience a high level 
of vireamia, followed by a temporal reduction to a viral set point coincident with the 
appearance of HIV specific CD8+ T cells, and these cells are said to peak 1-2 weeks 
later following the decline in vireamia (133, 231–233). HIV-specific CD8+ T cells can 
recognise and kill virus infected cells by releasing soluble factors that suppress viral 
replication. CD8+ T cells respond in several ways during infection in order t clear 
virus infected cells. These include the production and release of various cytokines and 
chemokines and the exocytosis of pre-formed cytolytic granules containing perforin 
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and granzyme. The main functions known to be relevant in antiviral immunity are 
proliferative capacity, IL-2, IFN-, TNF-, and MIP-1 cytokine and chemokine 
secretion and cytotoxicity as measured by perforin/granzyme B release and CD107a/b 
mobilization as a marker of degranulation (234–236). 
 Subsequent to the initial CTL response is the emergence of an antibody response 
soon after the vireamia has been reduced to lower levels (149, 231). Previous animal 
model studies have shown that in simian immunodeficiency virus (SIV) infection, 
depletion of CD8+ T cells led to a rapid and marked increase in vireamia, and 
reconstitution of CD8+ T cells led to a decline in viral load (237, 238). In addition, 
several previous studies also demonstrated that vaccine-induced CD8+ T cell 
responses were able to protect macaques challenged with a SIV-HIV chimera from 
progression to AIDS (239–242). Furthermore, CD8+ T cells also play an important 
role in the control and limitation of viral replication during chronic HIV/SIV infection 
(243–247). These findings support the view that CD8+ T cell responses play a central 
role in the containment of vireamia in both HIV and SIV infection. 
It is clear that not all CTL responses are effective in mediating viral control since the 
majority of HIV-infected persons eventually progress to disease. In addition, lack of 
control has been partially explained by the emergence of escape mutations that evade 
CTL mediated immune control (248, 228). Previous studies have shown that escape 
occurs early during HIV infection and is driven by CD8+ T cell responses (234, 249–
251). The immune responses to the conserved Gag polyprotein in particular have been 
associated with favourable disease outcomes (252–257). On the other hand, the 
selection of escape mutations within functionally important Gag epitopes has been 
shown to occur at a cost to the virus hence reducing viral replication capacity and 
resulting in maintenance of low viral loads as a consequence of viral variants with 
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reduced viral replication capacity (258). Ultimately, compensatory mutations and 
immune relaxation occur and there is loss of viral control (259).  
1.7.5.2 CD4+ T cells 
CD4+ T cells also play a role in HIV infection. They are the main targets for HIV 
infection hence their decline during the course of infection through killing by the 
virus itself or via induced apoptosis (230, 260, 261). Activated CD4+ T cells function 
by mediating T helper 1 responses via secretion of cytokines (IL-2 and IFNγ); also 
required for the maintenance of the CD8+ T cell responses (253, 262–265). These 
effector functions of the CD4+ T cells are evident and persist during acute and chronic 
HIV infection (266).  Because high frequencies of dual IFNγ and IL-2 secreting CD4+ 
T cells have been seen in controllers, the suppression of viral replication observed in 
controllers was then associated with the presence of these polyfunctional HIV specific 
CD4+ T cell with proliferative capacity (267–269) However, CD4+ T cells may lose 
the functional ability to produce IL-2 and to proliferate resulting in the lack of viral 
control (268, 270, 271).  
1.8 HIV NATURAL CONTROLLERS 
Durable control of viral replication in the absence of ART is achieved in a small 
percentage of HIV infected individuals. These individuals can be divided into 
different categories depending on their viral load and CD4+ T cell count and are 
termed long-term nonprogressors (LTNPs).  LTNPs can be further divided into 
viremic controllers (VCs) and elite controllers (ECs). 
1.8.1 Long-term nonprogressors (LTNPs) 
Although different studies have varying definitions of LTNPs, most studies define 
this group as HIV seropositive individuals who lack disease progression, with a stable 
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to elevated CD4+ T cell count for a duration of 7 – 10 years of symptom free HIV 
infection (272). These individuals have never been on ART and some of the 
individuals are known to have been infected for 20 – 25 years (273). They account for 
2-5% of the HIV infected population (274) 
1.8.2 Elite controllers (ECs) 
Elite controllers (ECs) or elite suppressors (ESs) represent a small subset of the 
LTNPs that maintain HIV viral load of below the limit of detection (less than 50 HIV 
RNA copies/ml of blood) of the viral load assay for long periods in the absence of 
ART. They account for 1% of the infected population (274). 
1.8.3 Viremic controllers (VCs) 
Viremic controllers on the other hand display low but detectable viral load levels of 
between 50 and 2,000 HIV RNA copies/ml of blood in the absence of ART (274). 
They also display stable CD4+ T cell counts. 
1.9 FACTORS ASSOCIATED WITH NATURAL CONTROL OF HIV 
Studying the natural controller groups of HIV infected population can provide some 
invaluable information regarding HIV pathogenesis, effective HIV vaccine strategies 
and development of novel therapeutic agents to combat HIV. A number of studies 
have attempted to determine the possible mechanisms associated with the natural 
control of HIV in the absence of ART in LTNPs, ECs and VCs. The factors 
associated with viral control or disease non-progression include host factors (HLA 
alleles, mutations in co-receptors, restriction factors), viral factors (mutations and 
deletions) and immunological factors (cellular immune responses, protective HLA 
class I alleles, innate and humoral responses). 
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1.9.1 Viral factors 
Infection with attenuated virus strains has remained one of the reasons for non-
progression amongst LTNPs and ECs. Previous studies on these groups on individuals 
have demonstrated that LTNPs compared to progressors harboured replication 
incompetent virus strains that were less evolved and less capable of evading host 
immunological responses (275, 276) and attenuating gene deletions known to be 
associated with viral control (277, 278). In another study, it was demonstrated that 5 
out of 6 HIV infected individuals became LTNPs following blood transfusion from 1 
donor who was also a LTNP and it was concluded that they had been infected with a 
less virulent strain of HIV (279). In yet another study, 6 blood recipients from 1 donor 
became LTNPs and remained asymptomatic for 14 to 18 years following infection. 
Sequencing of the full HIV genome showed that they had been infected with a 
defective virus strain that contained a large deletion in the long-terminal repeat of the 
Nef gene (280). Additionally, the virus isolated from other LTNPs was found to 
replicate a lot slower and infection of the CD4+ T cells was less effective (281). These 
data may suggest that non-progression observed in LTNPs and ECs is due to their 
infection with attenuated viruses. However, in contrast, some studies have been able 
to demonstrate that some LTNPs harboured replication competent virus strains (282–
284) and are rarely infected with similar Nef-deleted attenuated strains of HIV (282, 
285, 286). The first study to sequence the whole HIV genome from ECs found some 
minor mutations that did not seem to affect HIV function (282) and another study 
showed that virus isolates from ECs were able to grow normally in CD4+ T cells 
(287). Furthermore, some data suggest that low viral load observed in some 
individuals may have been as a result infection with drug resistant HIV which may 
have had a fitness cost on the transmitted virus (288). Overall, the data remain 
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inconclusive and has not ruled out attenuated viruses as a possible explanation for 
disease non-progression observed in some LTNPs and ECs. 
1.9.2 HLA B*57/B*27 and other protective HLA class I alleles 
The majority of HIV specific CD8+ T cell responses are restricted by HLA-B alleles. 
Furthermore the expression of different HLA alleles has been found to be associated 
with differential control of vireamia where a number of HLA class I alleles are 
associated with low viral load (HLAs B*27, B*57, B*58:01, B*81:01 and A*74:01) 
while others are associated with disease progression or high viral load (HLAs 
B*18:01, B*58:02) (222, 223, 254, 289–293). 
HLA B*57 variants have been strongly associated with the control of HIV infection 
through the induction of cross-reactive responses that are mounted against 
immunodominant Gag epitopes (294–296). This allele has also been found to be 
overrepresented in HIV controller study groups where for example, in a cohort of 30 
or more individuals, between 8 and 63% of either LTNP or ECs carried the allele 
(272, 297), with ECs having the highest frequency of this allele.  The actual 
mechanism by which control occurs amongst HLA B*57 positive individuals is not 
fully understood. However, in addition to B*57 restricting broad and protective CD8+ 
T cell responses within the Gag region of HIV, these responses can put pressure on 
the virus leading to escape, which in turn has a significant negative impact on viral 
fitness (298, 299). 
HLA B*27 is another allele that has been associated with viral control (294, 300). 
Previous studies suggest that protection from non-progression amongst HIV subtype 
B clade B*27 positive individuals was achieved by responses to the KK10 Gag 
epitope (KRWIILGLNK, Gag263-272) (248, 301–305) while B*57 positive 
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individuals mainly responded to epitopes KF11 (KAFSPEVIMF) and TSW10 
(TSTLQEQIGW) (306).  
Other protective HLA class I alleles include HLAs B*13 (307), B*51:01 (292), 
B*58:01 (290), B*81:01 (258) and A*74:01 (293). In most of the cohorts, 90-95% of 
LTNPs carry at least one of the protective HLA class I alleles (297). The mechanism 
of control amongst individual with protective HLA class I alleles still remain 
understudied. 
1.9.3 The role of CD4+ T cells in viral control 
The role of CD4+ T cells in the control of HIV replication has not been very clear.  
However, robust, polyclonal and Gag specific CD4+ T cell responses have been 
detected in LTNPs and correlated directly with low viral load (308–311). These cells 
have been found to have a robust T helper 1 phenotype as evidenced by their 
production of cytokines; IL-2 and IFNγ (312, 313) and proliferative capacity (267–
269).  HIV-specific CD4+ T cells may also have a cytotoxic role (314, 315). 
Therefore, the role and contribution of CD4+ T cell in the control of viral replication 
amongst LTNPs and ECs is still debatable and needs to be resolved. 
1.9.4 The role of HLA and CD8+ T cells in viral control 
CD8+ T cell are the most important mediators of viral control especially amongst 
LTNPs (316). Previous work suggests that control of vireamia can be attributed to 
CD8+ T cell responses against Gag (252–256, 317–320) and these effective responses 
are mainly restricted by protective HLA class I alleles such as B*57/B*27 (317). 
Protective HLA class I alleles tend to present epitopes that are within the conserved 
region Gag p24 (321–323). In addition, CD8+ T cells from LTNPs were found to be 
more polyfunctional and to have a higher proliferative capacity compared to 
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progressors (235, 302, 324, 325). These data suggest that a more polyfunctional CD8+ 
T cell phenotype is associated with viral control. However, not all CD8+ T cell 
responses are truly protective, this is because these responses do not clear the 
infection and the individuals eventually progress to AIDS. CD8+ T cell exhaustion, 
viral mutational escape and non-mutational viral escape have been suggested as 
possible explanations for immune failure to clearing infection (203, 248, 249, 303, 
326). Hence, there is still a need to further identify CTL characteristics associated 
with viral control. 
1.10 GAPS IN KNOWLEDGE 
There are gaps in knowledge as to what really accounts for the control of HIV 
replication especially amongst individuals with protective HLA class I alleles. There 
is conflicting data regarding viral control amongst LTNPs and ECs, which still 
requires resolving. Although protective HLA class I alleles have been associated with 
control of viral replication, the majority of individuals expressing these protective 
HLA class I alleles eventually progress to disease. There is need to clearly identify 
and define the correlates of immune protection from disease progression in 
individuals with protective HLA class I alleles. Furthermore, amongst controllers with 
protective HLA class I alleles, the infection is so dynamic in that the loss of control is 
encountered in some individuals who were previous controllers. It is unclear whether 
immunological or virological mechanisms of viral control and lack of control are 
involved in such cases. 
In addition, there are some limitations to the findings from previous studies of HIV 
controllers; most of the studies have been cross-sectional in terms of study design 
such that the long-term outcome of infection was never investigated, some only 
analyzed individuals following acute HIV-1 infection when most persons are not 
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controlling viral replication, or have only investigated one specific T cell 
parameter.  Here, we had an opportunity to study individuals with and without 
protective HLA class I alleles in a longitudinal study design and investigated multiple 
T cell properties (breadth and magnitude of CD8+ T cell responses, ability of CD8+ T 
cells to induce escape within the conserved Gag region, CD8+ T cell proliferation and 
polyfunctionality and ex-vivo ability of the CD8+ T cells to inhibit virus replication) 
all at the same time. 
1.11 THE STUDY RATIONALE AND HYPOTHESIS 
There is compelling evidence linking the control of HIV replication to many host and 
viral factors including the expression of protective HLA class I alleles, strong immune 
pressure as represented by CD8+ T cells responses on the virus that targets conserved 
regions of the virus and selection of immune escape mutations that are associated with 
viral fitness cost.  Although individuals with protective HLA class I alleles are 
overrepresented among elite and HIV controllers, loss of viral control and disease 
progression is also encountered among these individuals. However, the exact events 
that lead to this loss of control have not been fully described. We aimed to study a 
group of individuals who possess protective HLA class I alleles in an attempt to 
explain the mechanisms associated with viral load control in these individuals and 
loss of viral control in some individuals by assessing the virological and 
immunological events that may be associated with control or loss of viral control 
amongst these individuals.  A control group of individuals without protective HLA 
class I alleles was included to compare and contrast mechanisms of control and lack 
of control. 
We hypothesised that a combination of the following factors will be responsible for 
the viral control in individuals with protective class I alleles: 
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1. Immune responses targeted towards specific epitopes located in highly conserved 
Gag regions, 
2. Viral evolution and/or unusual polymorphisms that affect viral fitness, 
3. And highly polyfunctional CD8+ T cells that are capable of inhibiting viral 
replication ex vivo.  
1.12 SPECIFIC OBJECTIVES  
1. To characterize viral load dynamics and clinical disease progression in ARV-
naïve HIV-1 subtype C chronically infected participants with and without 
protective HLA class I alleles. 
2. To study and describe the magnitude and breadth of HIV specific CD8+ T cell 
immune responses in individuals with and without protective HLA class I 
alleles and associate those with disease progression. 
3. To study and describe the evolution of HIV specific immune responses in 
individuals with and without protective HLA class I alleles and associate those 
with disease progression. 
4. To study viral evolution within Gag and its impact on disease progression. 
5. To study the function (in terms of polyfunctionality and proliferative capacity) 
of CD8+ T cells amongst individuals with controlled viremia and associate 
these CD8+ T cell properties with viral control or lack of control upon 
longitudinal follow up. 
6. To study the ex vivo ability of CD8+ T cells to suppress HIV replication 
associate this function with disease progression or the lack thereof.  
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1.13 OUTLINE OF THE THESIS 
Chapter 1 gives an overview of HIV epidemiology, replication, mechanisms of HIV 
control covering the role of innate, HLA and adaptive immunity in the control of HIV 
replication during chronic HIV-1 subtype C infection. 
Chapter 2 gives an overview of the methodology and techniques employed in the 
research study. 
Chapter 3 gives a comprehensive cohort description and defines and characterizes 
the immunological parameters (breadth and magnitude of CD8+ T cell responses) 
associated with differential control of vireamia amongst individuals with and without 
protective HLA class I ales at enrolment (at baseline). 
Chapter 4 describes the evolution of CD8+ T cell responses and how they associate 
with divergent disease progression patterns observed in individuals with and without 
protective HLA class I alleles. The chapter further describes the evolution of Gag and 
determines whether CD8+ T cell responses induced escape in the individual with and 
without protective HLA class I alleles and further associated escape with disease 
progression in these individuals. 
Chapter 5 provides the functional ability of CD8+ T cells to perform more than 1 
function (polyfunctionality), proliferate and suppress viral replication and associated 
these functions with disease progression in individuals with and without protective 
HLA class I alleles. 
Chapter 6 gives an overall discussion of the findings of this research project and 
highlights the findings’ contribution to the body of knowledge of mechanisms of HIV 
control. 
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CHAPTER 2: MATERIALS AND METHODS  
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2.1 STUDY COHORT 
Seventy HIV-1 subtype C chronically infected participants from the Sinikithemba 
(SK) cohort in Durban, South Africa (254, 258, 290) were included in the current 
study. Participants were ART-naïve at all time points analysed. Subtype had been 
determined previously by one of the researchers Dr. Jaclyn Mann.  The details can be 
found in the following publication (258).  The date of HIV infection is unknown for 
all participants. Viral loads (VL) for all subjects were measured every 6 months by 
the Roche amplicor version 1.5 and CD4 T cell counts were measured every 3 months 
by TruCount technology using flow cytometry. The University of KwaZulu-Natal’s 
Biomedical Research Ethics Committee approved the study and all subjects provided 
written informed consent for participation in the study. The characteristics and 
demographic data for the 70 subjects studied are presented in Table 2.1 below. 
Table 2.1. Clinical and demographic characteristics for the HIV-1 Clade C 
chronically infected individuals studied. 
Characteristic Median (interquartile range) or percentage 
(%) 
Gender 78.5% female, 21.4% male 
Age (at baseline) 32 (28 - 37) years 
Viral load (at baseline) 109,000 (637 – 189,000) HIV RNA copies/ml 
CD4+ T cell count (at 
baseline) 
446 (324.5 – 586.3) cells/mm3 
Median follow up time 48.50 (36 – 66.25) months 
 
2.2 DEFINITION OF GROUPS AND SUB-GROUPS 
We divided the 70 participants studied into two groups based on their VL at 
enrolment:  
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i. Baseline viremic controllers (bVC) were enrolled with a VL of equal to or 
below 2,000 HIV RNA copies/ml. 
ii. Baseline progressors (Prog) were enrolled with a VL equal to or above 
100,000 HIV RNA copies/ml.  
Longitudinal follow-up of bVCs allowed us to further distinguish this group in to 2 
subgroups based on progression stage: 
i. Viremic controllers (VC) were defined as individuals who were enrolled 
with a VL of less than 2,000 HIV RNA copies/ml and maintained this low 
viral load for the entire period of enrolment. 
ii. Failing viremic controllers (fVC) were defined as bVC that were enrolled 
with a VL of less than 2,000 HIV RNA copies/ml but lost virological 
control. We defined the loss of viral control as an increase in VL to more 
than 10,000 HIV RNA copies/ml at a minimum of 2 time points during the 
time of follow-up. 
These groups are illustrated in the following Figure 2.1. 
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Figure 2.1. Showing the distribution of study participants in to different groups and 
subgroups. The 70 HIV-1 subtype C chronically infected ARV naive participants were 
from the Sinikithemba (SK) cohort in Durban, South Africa. The 70 subjects were 
selected based on availability of samples over a minimum of 2-year follow up period. 
Viremic controllers (VC+/-) were enrolled with a VL of below 2,000 HIV RNA copies/ml 
and maintained this low VL for the entire enrolment duration. Failing VC (fVC) were 
enrolled with a VL of below 2,000 HIV RNA copies/ml and later VL increased to more 
than 10, 000 HIV RNA copies/ml at a minimum of 2 time points. Of the 20 bVC with 
protective HLA class I alleles, 7 were VC and 7 were fVC, while the remaining 6 did not 
fall in either of the 2 subgroups. Of the 10 bVC without protective HLA class I alleles, 6 
were VC and none lost viral control while the remaining 4 did not fall in either of the 2 
subgroups. 
 
2.3 IMMUNOLOGICAL METHODS 
2.3.1 Thawing of cryopreserved PBMCs 
Peripheral blood mononuclear cells (PBMCs) that had previously been cryopreserved 
in freezing solution (10% dimethyl sulfoxide (DMSO) in filtered heat inactivated fetal 
calf serum (FCS) (Gibco, NY, USA) were thawed quickly using a water bath set at 
37C and immediately transferred in to a 15ml falcon tube containing 9ml of R10 
medium (RPMI 1640 medium (Sigma, St. Louis, MO, USA) supplemented with 10% 
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FCS, 1% L-Glutamine (Sigma), and 1% penicillin/streptomycin (Gibco). This was 
followed by centrifugation at 1,800 rpm (Eppendorf centrifuge 5810R, Merck, 
Germany) for 10 minutes after which the supernatant was discarded into a waste 
bucket containing 2% Virkon (DuPont de Demours, South Africa). The cells were 
washed twice and left to rest in R10 medium at 37C with 5% CO2.  
2.3.2 Cell Counts 
Cell count was carried out using a hemocytometer in a ratio of 1:9 with trypan blue 
stain solution (Sigma). In brief, 10 μl of the cell suspended in 10ml of R10 was added 
to a centrifuge tube containing 90 μl of the trypan blue stain solution and mixed well. 
Ten μl of the cells plus trypan blue solution was dispensed on to the hemocytometer 
and viewed under an electronic microscope (Olympus CH20 Upright microscope) for 
counting. The blue stain solution selectively penetrates the membranes of dead cells 
hence colouring them blue, so when used one is able to differentiate live from dead 
cells. A magnification of x10 allowed easy recognition of the desired cell types, 
which in our case were the PBMCs.  The hemocytometer has 9 large squares and 
within each larger square are 9 squares. We counted round live cells in 3 large squares 
(top left, middle center and bottom right). The average of the 3 squares gave the 
number of million cells per 10 ml. The viability of the cells ranged from 0% to 
96.61%. The % cell viability was determined by a formula (number of live 
cells)/(number of live cells+ number of dead cells)*100. The median viability was 
86.36% (IQR) (64.86 – 92.06). Only cells with a viability of 65% or more were 
assessed. 
2.3.3 HLA typing 
HLA class I typing was performed on genomic DNA samples extracted from blood at 
the time of enrolment as described previously (290). The genomic DNA for HLA 
 50 
typing was extracted using the Puregene DNA isolation kit for blood (Gentra 
Systems, Minneapolis, Minn.) according to the manufacturer’s instructions. Genomic 
DNA samples were initially typed to an oligo-allelic level using Dynal RELITM 
reverse Sequence Specific Oligonucleotide (SSO) kits for the HLA-A, -B and -C loci 
(Dynal Biotech). Refining the genotype to the allele level was performed using the 
Dynal Biotech sequence-specific priming kits in conjunction with the previous SSO 
type. In cases where the alleles were still not defined to the allele level, bespoke 
sequence-specific priming primer mixes were then utilised. All HLA class I alleles in 
the IMGT allele release 2.4.0 were considered in the typing (327). Of the 70 patients 
identified for this study, 35 possessed protective HLA class I alleles (HLAs A*74:01, 
B*57:01/:02/:03, B*58:01 or B*81:01) (223, 289–291, 293, 328). 
2.3.4 Synthetic HIV peptides 
A panel of 410 peptides (18-mers overlapping by 10 amino acid residues), spanning 
the entire HIV-1 clade C consensus sequence together with optimal peptides with 
known HLA class I restriction patterns, were synthesized on an automated peptide 
synthesizer (MBS 396; Advanced ChemTech, Louisville, Ky. USA) and used in the 
Enzyme-linked immunosorbent spot (ELISpot) assay (329). 
2.3.5 ELISpot assay 
HIV immune responses were enumerated from freshly isolated whole PBMCs by the 
gamma interferon (IFN) ELISpot assay as previously described (290). PBMCs were 
stimulated with 410 consensus clade C 18-mer overlapping peptides (OLPs) covering 
the entire proteome followed by confirmations with individual peptides within a 
reactive pool at a final concentration of 2 g/ml and optimal peptides corresponding 
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to each patient’s HLA type, also at a final concentration of 2 g/ml per peptide. The 
following 3 tables 2.2, 2.3 and 2.4 show the matrix layout. 
 
The 96 well polyvinylidene difluoride-backed ELISpot plates (MAIP S45, Millipore, 
Bedford, Mass., USA) were pre-coated with 100 l of anti-IFN antibody (1-D1k, 0.5 
µg/ml, MabTech, Stockholm, Sweden) and incubated overnight at 4C before use. 
Following incubation, the wells were washed 6 times with blocking buffer (1% fetal 
calf serum (FCS) (Gibco) in phosphate-buffered saline (PBS)) before addition of 
peptides at a final concentration of 2 g/ml to a plate with 100 l of R10 medium at 
Table 2.2: Positioning of OLP used in the Megamatrix in rows A and B 
 
Pool  A OLPs  
No of 
Peptides  
in pool Pool B Peptides 
No Peptides  
in pool 
A1 1-11 11 B1 1 13 25 37 49 61 73 85 97 121 x x 10 
A2 12-22 11 B2 2 14 26 38 50 62 74 86 98 122 x x 10 
A3 23-33 11 B3 3 15 27 39 51 63 75 87 99 111 123 x 11 
A4 34-44 11 B4 4 16 28 40 52 64 76 88 100 123 124 x 11 
A5 45-55 11 B5 5 17 29 41 53 65 77 89 101 113 125 x 11 
A6 56-66 11 B6 6 18 30 42 54 66 78 90 102 114 126 x 11 
A7 67-77 11 B7 7 19 31 43 55 67 79 91 103 115 127 x 11 
A8 78-88 11 B8 8 20 32 44 56 68 80 92 104 116 128 x 11 
A9 89-99 11 B9 9 21 33 45 57 69 81 93 105 117 129 x 11 
A10 100-107 8 B10 10 22 34 46 58 70 82 94 106 118 130 x 11 
A11 111-121 11 B11 11 23 35 47 59 71 83 95 107 119 131 x 11 
A12 122-131 10 B12 12 24 36 48 60 72 84 96 x 120 x x 9 
 
Table 2.3: Positioning of OLP used in the Megamatrix in rows C and D 
 
Table 2.4: Positioning of OLP used in the Megamatrix in rows E and F 
Pool OLPs  
No. 
Peptides  
in pool Pool Peptides 
No. Peptides 
In pool 
E1 289-300 12 F1 289 301 313 325 337 349 361 373 385 397 409 421 12 
E2 301-312 12 F2 290 302 314 326 338 350 362 374 386 398 410 422 12 
E3 313-324 12 F3 291 303 315 327 339 351 363 375 387 399 411 423 12 
E4 325-336 12 F4 292 304 316 328 340 352 364 376 388 400 412 424 12 
E5 337-348 12 F5 293 305 317 329 341 353 365 377 389 401 413 425 12 
E6 349-359 11 F6 294 306 318 330 342 354 366 378 390 402 414  11 
E7 360-370 11 F7 295 307 319 331 343 355 367 379 391 403 415  11 
E8 371-381 11 F8 296 308 320 332 344 356 368 380 392 404 416  11 
E9 382-392 11 F9 297 309 321 333 345 357 369 381 393 405 417  11 
E10 393-403 11 F10 298 310 322 334 346 358 370 382 394 406 418  11 
E11 404-414 11 F11 299 311 323 335 347 359 371 383 395 407 419  11 
E12 415-425 11 F12 300 312 324 336 348 360 372 384 396 408 420  11 
	
Pool  OLPs  
No.  
Peptides  




C1 145-156 12 D1 145 157 169 181 193 205 217 229 241 253 265 277 12 
C2 157-168 12 D2 146 158 170 182 194 206 218 230 242 254 266 278 12 
C3 169-180 12 D3 147 159 171 183 195 207 219 231 243 255 267 279 12 
C4 181-192 12 D4 148 160 172 184 196 208 220 232 244 256 268 280 12 
C5 193-204 12 D5 149 161 173 185 197 209 221 233 245 257 269 281 12 
C6 205-216 12 D6 150 162 174 186 198 210 222 234 246 258 270 282 12 
C7 217-228 12 D7 151 163 175 187 199 211 223 235 247 259 271 283 12 
C8 229-240 12 D8 152 164 176 188 200 212 224 236 248 260 272 284 12 
C9 241-252 12 D9 153 165 177 189 201 213 225 237 249 261 273 285 12 
C10 253-264 12 D10 154 166 178 190 202 214 226 238 250 262 274 286 12 
C11 265-276 12 D11 155 167 179 191 203 215 227 239 251 263 275 287 12 
C12 277-288 12 D12 156 168 180 192 204 216 228 240 252 264 276 288 12 
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100,000 cells/well. For the controls, cells were added to 100 l of media only (R10) 
in 4 wells as negative controls and an additional 2 wells containing 
phytohemagglutinin (PHA) at a concentration of 1 g/ml/well were used as positive 
control. The plates were incubated at 37C and 5% CO2 overnight for 16 hours. 
Following this incubation, the wells were washed 6 times with 100 l of PBS and 0.5 
g/ml of biotinylated anti-IFN antibody (7-B6-1, MabTech, Stockholm, Sweden) 
was added into each well and the plate incubated in the dark for 90 minutes at room 
temperature. The wells were then washed 6 times with PBS and 0.5 g/ml of 
streptavidin-alkaline phosphatase conjugated antibody (MabTech) was added and the 
plate incubated for 45 minutes in the dark at room temperature. The wells were 
washed with PBS followed by addition of the alkaline phosphatase colour reagents 
(Bio-Rad Laboratories, Hercules, California, USA), allowing development of spots, 
which could be visualised directly. The plates were then finally washed with distilled 
water, blotted and left to dry prior to counting of spots.  
The IFN-secreting cells were quantified by counting the number of spots per well 
using an automated ELISpot plate reader (AID ELISpot reader system; 
AutoimmunDiagnostika GmbH, Strasburg, Germany). The magnitude of responses 
was expressed as the number of spot-forming cells (SFC) per million PBMCs after 
subtractions of values from background wells. A response was defined as positive if 
greater or equal to 100 SFC/million PBMCs and greater than or equal to 3 standard 
deviations above the mean of four background wells containing PBMCs but no 
peptide. The breadth of responses was determined by the number of peptides/epitopes 
that had a magnitude of greater than or equal to 100 SFC/million PBMCs. 
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2.3.6 Intra cellular cytokine staining (ICS) 
Freshly thawed cryopreserved PBMCs were left to rest at 37C with 5% CO2 for 4 
hours. A total of 200,000 PBMCs per well, resuspended in R10 were stimulated with 
consensus clade C Gag peptide pools at a final concentration of 2 g/ml/peptide and 
PHA (2 g/ml) as a positive control. Anti-CD107a-PE-Cy5 (BD-Biosciences, USA) 
antibody, Golgi stop and Golgi plug (BD-Biosciences) were added in each well and 
cells incubated overnight at 37°C with 5% CO2. 
Cells were then washed and stained with a live/dead marker (fixable blue dead cell 
stain) (Invitrogen, Paisley, United Kingdom) for 10 minutes, followed by surface 
stain with anti-CD3 APC H7, anti-CD4 Alexa 700, anti-CD8 HV 500 (BD-
Biosciences) and dump channel comprising of anti-CD14 pacific blue, anti-CD19 
pacific blue and anti-CD16/56 pacific blue antibodies (Biolegend, San Diego Cal. 
USA). The cells were incubated in the dark at room temperature for 20 minutes. 
Following 2 washes, the cells were then permeabilized using cytoperm/cytofix (BD-
Biosciences) to allow for intracellular staining with anti-IFN–PE Cy7, anti-
interleukin-2 (IL-2)–FITC, or anti-tumor necrosis factor alpha (TNF-)-APC and 
anti- macrophage inflammatory protein 1 beta (MIP1)-PE (all from BD 
Biosciences). Following a 30 minute incubation at room temperature, the cells were 
washed twice with 2% FCS/PBS. The cells were resuspended in 2% FCS/PBS and 
acquired on the flow cytometer (LSR II, BD Biosciences). Between 30,000 and 
100,000 events were acquired per well (sample). The acquired data was analysed by 
Flowjo version 9.6.2 (Tree Star, San Carlo, CA, USA). The initial gating was set on 
lymphocytes followed by the forward scatter height (FCS-H) versus forward scatter 
area (FSC-A) to eliminate doublets. We then gated on the live CD3+ T cell population 
followed by gating of CD8+ and CD4+ T cell populations. The individual gating for 
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respective functions followed (set based on the negative control (unstimulated cells)), 
these were used to identify positive responses. Boolean gating was performed in order 
to allow creation of a full array of possible combinations of up to 32 response 
patterns. Positive responses were reported after background correction and the 
percentage of epitope-specific CD8+ T cell responses had to be at least two times 
higher than background for each tested marker. PESTLE (version 1.6.2) and SPICE 
5.0 (Mario Roederer, ImmunoTechnology Section, Vaccine Research Center, NIH, 
Bethesda, MD, USA) were used to analyse the multifunctional data.   
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Table 2.5 Antibody panel 




CD3 APC-H7 SK7 Mouse 
IgG1 
BD 560176 1 




BD 557922 1 




BD 560774 1 
CD19 Pacific blue HIB19 Mouse 
IgG1 
Biolegend 302224 1 
CD16 Pacific blue 3G8 Mouse 
IgG1 
Biolegend 302037 1 














BD 340543 1 
CD107a PE Cy5 H4A3 Mouse 
IgG1 
BD 555802 2 
IFNγ PE Cy7 B27 Mouse 
IgG1 
BD 557643 1 




BD 340448 2 
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2.3.7 CFSE proliferation assay 
Freshly thawed cryopreserved PBMCs were left to rest at 37C with 5% CO2 for 4 
hours and then stained with carboxyfluorescein succinimidyl ester (CFSE) dye 
(Invitrogen) for 7 minutes at 37C with 5% CO2. CFSE labelling was then stopped 
with 2 ml of FCS and washed 3 times with R10. A total of 400,000 CFSE-labelled 
PBMCs per well from each individual, resuspended in 200 l R10 medium were then 
stimulated with Gag peptide pools at a final concentration of 2 g/ml and PHA at a 
final concentration of 2 g/ml as a positive control, followed by incubation at 37°C 
with 5% CO2 for 7 days. After 7 days, cells were then washed and stained with a 
live/dead marker (fixable blue dead cell stain) (Invitrogen) for 10 minutes, followed 
by surface stain with anti-CD3 APC H7, anti-CD4 Alexa 700, anti-CD8 HV 500 (BD-
Biosciences) and dump channel panel comprising of anti-CD14 pacific blue, anti-
CD19 pacific blue and anti-CD16/56 pacific blue antibodies (Biolegend). The cells 
were incubated in the dark at room temperature for 20 minutes. The cells were then 
washed twice with 2% FCS/PBS and resuspended in 2% FCS/PBS. Between 30,000 
and 100,000 events were acquired per well (sample). The acquired data was analysed 
by Flowjo version 9.6.2 (Tree Star, San Carlo, CA, USA). The initial gating was on 
lymphocytes followed by the forward scatter height (FCS-H) versus forward scatter 
area (FSC-A) to eliminate doublets. We then gated on the live CD3+ T cell population 
followed by gating of CD8+ and CD4+ T cell populations. The next gates were set on 
the CD8+ CFSE negative in order to identify proliferated CD8+ T cell populations. 
PRISM graph pad version 5.0a software (GraphPad software, San Diego, California, 
USA) was used to analyse group data sets. 
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2.3.8 Viral inhibition assay 
An ex vivo viral inhibition assay was carried out to determine the ability of CD8+ T 
cells to suppress virus replication by measuring the amount of HIV p24 antigen as 
previously described elsewhere (330).  
2.3.8.1 Separation of CD4+ and CD8+ T cells 
Cryopreserved whole PBMCs were thawed and CD4+ and CD8+ T cells separated 
using the CD8+ T cell Isolation kit (MACS; Miltenyi Biotech, Bergisch Gladbach, 
Germany) according to the manufacturer’s instructions. In brief, PBMCs were thawed 
as already described. After the cells were counted they were washed once with 10ml 
of cold MACS buffer, which was prepared from Bovine Serum Albumin (BSA) and 
PBS (Whitehead scientific). To prepare BSA solution, 10g of BSA concentrate was 
added to 100 ml of distilled water and placed in the refrigerator (4 ºC) for 24 hours to 
dissolve. MACs buffer was prepared by adding 49 ml of PBS (Whitehead Scientific) 
to 1 ml of BSA solution giving a concentration of 0.5% BSA/PBS and this buffer was 
placed on ice. R10/50 was prepared by adding 25 µl of interleukine-2 (IL-2) to 50 ml 
of R10 and kept on ice until used.  
Following addition of MACS buffer to the cells, the suspension was centrifuged at 
300 x g for 10 minutes and the supernatant was aspirated completely. The cell pellet 
was resuspended with cold MACS buffer at a concentration of 40 μl of the buffer per 
10 million cells. Ten microliters of the CD8+ T cell Biotin antibody cocktail (MACS; 
Miltenyi Biotech) per 10 million cells was added to the cell suspension and mixed 
well by pipetting. This was followed by a 10 minute incubation at 2-8°C. Following 
the incubation, 30 μl of the cold MACS buffer was added plus 20 μl of the CD8+ T 
cell microbead cocktail MACS; Miltenyi Biotech) per 10 million cells. The cell 
suspension was mixed well and incubated for an additional 15 minutes at 2-8°C.  The 
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cells were washed with 5ml of the cold MACS buffer, centrifuged at 300 x g for 10 
minutes at 4°C. The cells were resuspended in 500 μl of the cold MACS buffer. 
MACS LS separation columns (MACS; Miltenyi Biotech) were used to magnetically 
separate CD8 and CD4+ T cells. Firstly, the columns were placed on the magnetic 
field of the MACS separator and rinsed with 3ml of the cold MACS buffer. Once the 
3 ml of the MACS buffer has passed through the column, the cell suspension was then 
applied to the column. The unlabelled cells (CD8+ T cells) passed through the column 
in to the collection tube while the magnetically labelled cells (CD4+ T cells) remained 
magnetically stuck on the column. The column was washed three times using the 
same 3 ml of the cold MACS buffer. The unlabelled cell fraction represented the 
enriched CD8+ T cells while the magnetically labelled fraction represented the 
enriched CD4+ T cells. The column was carefully removed from the magnetic 
separator and placed over a new collection tube. A volume of 5ml of cold MACS 
buffer was pipetted on to the column and the magnetically labelled cells were 
immediately flushed out by firmly pushing the plunger into the column. The 2 cell 
types were washed and counted as described before. The CD8+ T cells were 
resuspended in R10 media while the CD4+ T cells in R10/50. 
The enriched CD4+ T cells were activated with CD3/CD8-bispecific antibody at a 
concentration of 0.5 μl/ml (generous gift from Dr. Johnson Wong, Ragon Institute of 
Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard 
University, Boston, Massachusetts) for 3 days and later used as target cells in the 
inhibition assay. The enriched CD8+ T cells were also cultured for 3 days in R10 
medium for use as the ex vivo CD8+ effector cells in the inhibition assay.   
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2.3.8.2 Infection of the enriched CD4+ T cells  
The stimulated CD4+ T cells were infected with the NL4-3 laboratory adapted HIV 
strain (258) at a multiplicity of infection (MOI) of 0.001. The NL4-3 virus stocks 
used in this assay were kindly donated by Dr. Jaclyn Wright and Dr. Ravesh Singh 
from our laboratory (HIV Pathogenesis Programme, Durban, South Africa). In brief, 
the generated recombinant stocks had been titrated so as to determine the 
concentration of virus. One million GXR-cells were infected with 400 µl of each of 
the stock for 4 hours. Following this, the infected cells were washed and 100,000 
cells/well plated in duplicate in a 96-well plate for 3 days. An aliquot of 100,000 
uninfected GXR-cells/well were also plated in duplicate alongside the infected cells 
as negative control. The percentage infectivity was used to determine the MOI. After 
titration of each stock, the following formula was then used to calculate the desired 
MOI used in the subsequent assays for each of the virus stock generated:  
Volume of virus to be used per 1 million cells = Desired MOI/Titre value * 400 
The virus stocks generated were then used to infect the CD4+ T cells that had been 
rested for 3 days after being separated from the CD8+ T cells; for 4 hours at 37°C with 
5% CO2. Following the 3 days, CD4+ T cells were counted and a proportion (300,000 
CD4+ T cells) left aside to be utilized in the 3 negative control wells. The rest of the 
CD4+ T cells were infected with the NL4-3 virus and incubated for 4 hours at 37°C 
with 5% CO2, flicking the tube every 30 minutes. Following infection, the cells were 
washed twice with R10 and co-culturing of infected CD4+ T cells with CD8+ T cells 
followed. 
 60 
2.3.8.3 Co-culturing of effector and target cells 
Following infection step, the infected CD4+ T cells were cultured with or without 
effector cells in an effector - to - target cell ratio of 1:1 and incubated over a period of 
7 days at 37°C with 5% CO2. This experiment was done in triplicates, that is, 3 wells 
for the negative control wells whereby each well contained 100,000 uninfected CD4+ 
T cells in 200 μl of R10/50; the positive control wells had 100,000 infected CD4+ T 
cells also in 200 μl R10/50 per well and finally the 3 test wells contained 100,000 
infected CD4+ T cells plus 100,000 CD8+ T cells in a total volume of 200 μl of 
R10/50. On days 3, 5 and 7 a volume of 90 μl of the culture supernatant was 
harvested without disturbing the adherent cells at the bottom of the well and 10 μl of 
the Triton X-100 solution added to the supernatant. The cells were fed with 90 μl of 
fresh R10/50 after each harvest and then placed back in to the incubator. The 
supernatants were cryopreserved at -80°C for later p24 antigen quantification. 
2.3.8.4 Enzyme Linked Immunosorbent assay (ELISA) 
The p24 antigen was quantified from the cryopreserved supernatants by enzyme-
linked immunosorbent assay (ELISA) using the Quick Titre HIV Lentivirus 
Quantitation kit (HIV p24 ELISA) (Cell Biolabs, San Diego, CA, USA) according to 
the manufacturer’s instructions.  
In brief, the standard curve was prepared by serially diluting the recombinant HIV-1 
p24 antigen (Cell Biolabs) in the concentration range of 100 ng/ml – 1 ng/ml by 
diluting the p24 stock solution in assay diluent (Cell Biolabs). There were 8 tubes; 
Tube 1 containing 990 μl of assay diluent and 100 ng/ml of the p24 HIV-1 p24 
antigen, Tube 2 (500 μl assay diluent + 50 ng/ml p24 antigen), Tube 3 (500 μl assay 
diluent + 25 ng/ml p24 antigen), Tube 4 (500 μl assay diluent + 12.5 ng/ml p24 
antigen), Tube 5 (500 μl assay diluent + 6.25 ng/ml p24 antigen, Tube 6 (500 μl assay 
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diluent + 3.125 ng/ml p24 antigen), Tube 7 (500 μl assay diluent + 1.5625 ng/ml p24 
antigen) and finally Tube 8 contained 500 μl assay diluent only. 
For the samples, 3 serial dilutions ranging from 10 to 1000 folds were prepared using 
R10 media. This was followed by transferring 225 μl of each of the samples into a 96 
well plate. These were mixed well and incubated at 37°C for 30 minutes to inactivate 
the virus. Each sample, HIV p24 standard, blank and control medium were assayed in 
duplicate. A volume of 110 μl of each of the inactivated samples and p24 standard 
tubes were added to an anti-p24 antibody coated plate. The plate was covered and 
incubated at 37°C for at least 4 hours after which the plate was emptied and microwell 
strips washed 3 times with 250 μl of X1 Wash buffer (Cell Biolabs) per well with 
thorough aspiration between each wash. After the last wash, the wells were emptied 
and microwell strips tapped on an absorbent paper to remove excess X1 wash buffer. 
This was followed by addition of 100 μl of diluted FITC-conjugated anti-p24 
monoclonal antibody (1:1000) (Cell Biolabs) to each well. The plate was then covered 
and incubated at room temperature for 1 hour. After which the plate was emptied and 
microwell strips washed 3 times with 250 μl of X1 Wash buffer (Cell Biolabs) per 
well with thorough aspiration between each wash. A volume of 100 μl of the diluted 
HRP-conjugated anti FITC monoclonal antibody (1:1000) (Cell Biolabs) was added 
to each well and plate covered and incubated at room temperature for 1 hour. After 
which the plate was emptied and microwell strips washed 3 times as already 
described. This was followed by an addition of 100 μl of warm (room temperature) 
substrate solution (Cell Biolabs) to each well; plate was covered and incubated at 
room temperature for about 2 to 30 minutes. The reaction was stopped by adding 100 
μl of the stop solution (Cell Biolabs). The absorbance of each microwell was read 
immediately on a spectrophotometer using 450nm as a primary wave length. 
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Log inhibition values were calculated by subtracting log10 p24 values of the infected 
CD4+ T cells co-cultured with CD8+ T cells from log10 p24 values of the infected 
CD4+ T cells without CD8+ T cells at day 7. PRISM graph pad version 5.0a software 
(GraphPad software, San Diego, California, USA) was used to analyse group data 
sets. 
2.4 MOLECULAR METHODS 
2.4.1 DNA extraction 
DNA was extracted from whole blood as previously described (298). In brief, 3 ml of 
whole blood was mixed with 9 ml of Red Blood Cell Lysis solution (Qiagen, 
Valencia, CA, USA) and left to stand at room temperature for 10 minutes. The 
mixture was centrifuged at 2,000 rpm (Eppendorf centrifuge 5810R, Merck) for 10 
minutes and the supernatant was discarded in a waste bucket containing 2% Virkon 
(DuPont de Demours, South Africa) followed by resuspension of the cell pellet in 3 
ml of cell lysis buffer (Qiagen). This cell suspension was left to stand at room 
temperature for at least 3 days. Following the 3-day incubation period, 1 ml of the 
protein precipitation solution was added and mixed well by inverting the tube several 
times. The mixture was centrifuged at 2,000 rpm (Eppendorf centrifuge 5810R, 
Merck) for 10 minutes. The supernatant was harvested and mixed with 3 ml of 
isopropanol by inverting the tube at least 20 times in order to precipitate the sample 
DNA. This mixture was centrifuged at 2,000 rpm for 3 minutes followed by washing 
the DNA with 5 ml of 70% ethanol and then left to dry. The DNA was then 
resuspended in 50 l of elution buffer (Qiagen) and stored at minus 20C till further 
use. One microlitre (1 l) of the DNA was used for quantification using the Nanodrop 
(Thermo Fischer Scientific, USA). 
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2.4.2 RNA extraction 
Viral RNA was extracted from plasma using a QIAamp Viral RNA Mini Kit from 
Qiagen (Qiagen) according to the manufacturer’s instructions. The eluded RNA was 
stored at minus 80C till use. One microlitre (1 l) of the RNA was used for 
quantification using the Nanodrop (Thermo Fischer Scientific). 
2.4.3 PCR primers for amplification of gag 
The following table (Table 2.6) is a list of the primers used for the nested PCR to 
amplify the HIV gag region.  




5’-CACTGCTTAAGCCTCAATAAAGCTTGCC-3’ C Gag Forward 
5’-TTTAACCCTGCTGGGTGTGGTATYCCT-3’ C Gag Reverse 
5’-GAGGAGATCTCTCGACGCAGGAC-3’ C Gag Forward 
5’- GGAGTGTTATATGGATTTTCAGGCCCAATT-3’ C Gag Reverse 
 
2.4.4 First (1st) round RT-PCR 
Complementary DNA (cDNA) synthesis and 1st round PCR were performed using the 
Invitrogen Superscript III One-step RT PCR kit (Invitrogen, Carlsbad, CA, USA). 
This kit allowed synthesis of cDNA and production of 1st round PCR product all in 
one step. The primers gag-specific primers used to generate 1st round PCR products; 
(5’-CACTGCTTAAGCCTCAATAAAGCTTGCC-3’ and 5’-
TTTAACCCTGCTGGGTGTGGTATYCCT-3’) as listed on Table 2.2 above. The 
reaction mixture was made up of the following proportions giving a total of 40 l: 
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14.4 l   DEPC water 
20.0 l   2x reaction buffer 
0.8 l    Forward primer 5’ UTR 2 (10 M) 
0.8 l    Reverse primer 3’2cRx (10 M) 
0.8 l   Taq enzyme 
4.0 l    RNA template 
The reaction was performed on a thermocycler (GeneAmp PCR system 9700, Applied 
Biosystems, Foster City, USA) using the PCR conditions described in the steps 
below: 
1. 30 minutes    55C 
2. 2 minutes   94C 
3. 35 cycles of; 
 i. 15 seconds   94C 
 ii. 30 seconds   55C 
 iii. 2 minutes   68C 
4. 5 minutes    68C 
5. Cooling at 4C. 
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2.4.5 Second (2nd) Round PCR  
A second/nested PCR mixture totalling 50 l was prepared using the TaKaRa Ex Taq 
HS enzyme kit (Takara, Shiga, Japan) using the primers (5’-
GAGGAGATCTCTCGACGCAGGAC-3’, and 5’- 
GGAGTGTTATATGGATTTTCAGGCCCAATT-3’) as listed on Table 2.2 and the 
following proportions: 
37.0 l   DEPC water 
5.0 l    10x Ex Taq buffer 
4.0 l    dNTPs 
0.8 l    Forward primer 5’ Gag+1 (10 M) 
0.8 l    Reverse primer 3’ RVP (10 M) 
0.25 l   Ex Taq enzyme 
2.0 l    first round PCR product 
The reaction was performed on a thermocycler (GeneAmp PCR system 9700, Applied 
Biosystems) using the PCR conditions described in the steps below: 
1. 2 minutes    94C 
2. 35 cycles of; 
 i. 15 seconds    94C 
 ii. 30 seconds    55C 
 iii. 1 min 30 seconds   72C 
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4. 7 minutes     72C 
5. Cooling at 4C. 
2.4.6 PCR product 
Gag amplification was confirmed by running 5 μl of the product on a 1% 
polyacrylamide gel, showing a band of 1.5 kb. 
2.4.7 PCR product purification 
Purification of the PCR products was carried out using either of the following 2 
methods: 
 i. QiaQuick PCR purification kit (QIAGEN, Hilden, Germany) according to 
the manufacturer’s instructions. 
 ii. IllustraTM GFXTM PCR DNA and Gel Band Purification Kit (GE 
Healthcare, Pittsburg, USA) according the manufacturer’s instructions. 
2.4.8 Sequencing primers 

















C Gag Forward 
5’- TAG AAG AAA TGA TGA CAG-3’ 
 
C Gag Forward 
5’- GGAGCAGATGATACAGTATT-3’ 
 
C Gag Forward 
5’- CTTGTCTAGGGCTTCCTTGGT-3’ 
 
C Gag Reverse 
5’- GGTTCTCTCATCTGGCCTGG-3’ 
 
B Gag Reverse 
5’- CAACAAGGTTTCTGTCATCC-3’ 
 
B Gag Reverse 
5’- CCT TGC CAC AGT TGA AAC ATT T-3’ 
 
C Gag Reverse 
5’- CAG CCA AGC TGA GTC AA-3’ 
 
C Gag Reverse 
 
2.4.9 Sequencing reaction 
The purified products were then sequenced using the ABI sequencing machine as 
described previously using Big Dye Terminator ready reaction mix V3 (Applied 
Biosystems, Foster City, CA, USA) (258) and the sequencing primers shown above 
on Table 2.3. A sequencing reaction mixture was prepared using the following 
proportions: 
0.4 l     Big Dye Terminator mix 
2.0 l     5x sequencing buffer 
2.6 l     Primer (2 M) 
4.0 l    DEPC water 
1.25 l    template 
The following thermocycler (GeneAmp PCR system 9700, Applied Biosystems) 
conditions were used: 
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1. 1 minute    96C 
2. 25 cycles: 96C for 10 seconds, 50C for 5 seconds, 60C for 4 minutes. 
3. Cooling at 4C for at least 10 minutes. 
The sequencing reaction clean-up was carried out on the same day. 
2.4.10 Sequencing reaction clean up 
The sequencing product was purified using the sodium acetate (NaOAC) (Sigma- 
Aldrich) precipitation method. In brief, 1 l of 125 mM ethylenediaminetetraacetic 
acid (EDTA) pH 8.0 (Sigma-Aldrich) was added to the reaction, followed by addition 
of 1 l of NaOAC pH 5.2 and 25 l of 100% ethanol and mixed well by pipetting. 
The mixture was then centrifuged at 3,000 x g for 20 minutes. The supernatant was 
discarded and the pellet washed by adding 35 l of cold 70% ethanol followed by 
centrifugation at 3,000 x g for 5 minutes. The supernatant was carefully discarded and 
samples dried at 50C for 5 minutes using a thermocycler (GeneAmp PCR system 
9700, Applied Biosystems). 
The purified products were then sequenced using the ABI 3130xl genetic analyzer 
(Applied Biosystems).  Escape was determined by evaluating the sequence variation 
within the known HLA epitopes and in the 5 amino acids on either side of the 
epitopes according to each participant’s HLA profile.  
2.4.11 Phylogenetic analysis 
In order to check for any contamination between the samples, a phylogenetic tree was 
constructed using the Neighbour-Joining method utilizing ClustalX or bootstrap and 
visualized using Figtree.  
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2.5 DATA ANALYSIS AND STATISTICS 
Sequence data were aligned to the HIV-1 subtype B reference strain HXB2 (Genbank 
accession number K03455) and insertions with respect to HXB2 were stripped before 
further analysis. Editing and alignment of sequences were carried out using 
Sequencher version 5 (Gene Codes, Corp., Ann Arbor, Michigan, USA) and SeAl 
version 2.0a11, (available online http://tree.bio.ed.ac.uk/software/seal/) (A. Rambaut, 
Department of Zoology, University of Oxford, Oxford, UK) software respectively. 
GraphPad Prism version 5.0a was used to analyse the results. Statistical analysis was 
performed on Prism using Mann-Whitney U test, Wilcoxon paired test and student t-
test as appropriate and detailed in the results for each analysis. Comparison between 
groups was corrected for multiple comparisons. The p value of below or equal to 0.05 
was considered significant.  
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CHAPTER 3: COHORT CHARACTERISTICS 
AND BASELINE CD8+ T CELL RESPONSES IN 
INDIVIDUALS WITH AND WITHOUT 




Previous studies have linked the control of HIV clade C viral replication to a number 
of factors including protective HLA class I alleles. Certain HLA class I alleles are 
protective (e.g. B*57, B*27, A*74:01, B*81:01, B*58:01) against disease 
progression, have been strongly associated with viral load control and are found to be 
overrepresented amongst HIV controller groups (289–291, 293, 328, 331). However, 
disease progression is often encountered in some individuals with these protective 
HLA class I alleles and the mechanisms behind this progression are not well 
understood. We aimed to assess this by studying the factors behind viral control and 
loss of virologic control in individuals with protective HLA class I alleles during 
chronic HIV-1 subtype C infection.  Individuals without protective HLA class I 
alleles were also included in this study for comparative purposes. Study participants 
were from a cohort of ARV naïve chronically HIV-1 subtype C infected adults in 
Durban, South Africa.  The initial study aims were to: 
1. Characterize viral load dynamics and clinical disease progression in ARV-
naïve HIV-1 subtype C chronically infected participants with and without 
protective HLA class I alleles. 
2. Study and describe the magnitude and breadth of HIV specific CD8+ T cell 
immune responses in individuals with and without protective HLA class I 
alleles and associate these parameters with disease progression. 
 
3.2 Viral load dynamics and clinical disease progression in study participants.  
A total of 70 individuals with HIV-1 C-clade infection were studied in order to 
understand the CD8+ T cell-based mechanisms of viral control and loss of control 
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amongst individuals with or without protective HLA class I alleles. The HLA types of 
the participants studied are shown in the Table 3.1 below. The number of females was 
55 (78.5%) and there were 15 (21.4%) males. The median age at the time of 
enrolment was 32 years, interquartile range (IQR) (28-37). 
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Table 3.1. HLA types data of study participants  
 
PID Gender Age HLA	Class1	A HLA	Class1	A2 HLA	Class1	B HLA	Class1	B2 HLA	Class1	CW HLA	Class1	CW2
SK-013 F 27 29:02 31:01 15:03 15:10 08:01 18:00
SK-014 F 29 29:02 29:02 44:03 57:03 07:01 07:01
SK-022 F 32 24:02 68:02 07:02 42:01 07:02 17:01
SK-023 F 41 66:01 80:01 18:01 58:02 02:02 06:02
SK-024 F 32 29:02 66:01 44:03 58:01 06:02 07:01
SK-031 M 32 26:02 74:00 08:01 15:10 02:02 08:01
SK-041 F 32 30:01 66:02 15:03 42:02 02:02 17:01
SK-049 M 36 23:01 31:00 15:10 35:01 04:01 16:01
SK-051 F 38 03:01 29:02 13:03 42:01 06:02 17:01
SK-055 F 38 30:01 30:02 08:01 42:02 07:01 17:01
SK-067 F 34 68:01 74:00 42:01 58:02 06:02 17:01
SK-070 F 32 03:01 68:01 08:01 15:03 07:02 18:01
SK-073 F 28 23:01 26:01 15:10 51:01 07:01 16:01
SK-079 F 30 02:05 29:02 44:03 58:01 07:01 07:01
SK-086 F 24 23:01 29:02 08:01 15:10 02:02 03:04
SK-089 F 26 23:01 74:00 15:03 58:01 02:02 03:02
SK-123 F 29 02:06 68:02 15:10 58:01 03:04 07:01
SK-135 F 28 34:02 68:01 41:03 44:03 04:01 17:01
SK-158 F 26 74:00 74:00 15:03 35:01 02:02 04:01
SK-165 F 27 33:01 68:01 42:01 58:02 06:02 17:01
SK-170 F 32 02:02 66:01 18:01 58:02 05:01 06:02
SK-175 M 42 02:01 30:02 18:01 39:10 12:03 12:03
SK-180 M 31 02:14 74:00 44:03 57:03 04:01 07:01
SK-187 F 25 30:02 68:02 08:01 58:01 03:02 07:01
SK-188 F 35 03:01 74:00 57:03 58:02 06:02 07:01
SK-199 F 27 29:02 74:00 13:02 57:03 06:02 07:01
SK-202 F 41 68:01 74:00 35:01 58:02 04:01 06:02
SK-208 F 22 02:01 23:01 08:01 58:02 06:02 07:01
SK-209 F 31 03:01 30:01 08:01 42:01 07:02 17:01
SK-224 F 31 02:05 68:02 07:02 57:02 03:04 18:00
SK-235 M 37 01:01 66:01 39:10 39:00 12:03 18:00
SK-242 F 28 01:01 66:01 81:00 39/67 12:03 18:00
SK-251 F 54 02:05 30:01 42:01 58:01 07:01 17:01
SK-275 F 26 03:01 30:01 08:01 39:10 07:02 12:03
SK-276 F 39 02:11 24:02 40:06 51:01 14:02 15:02
SK-282 M 46 02:05 34:02 44:03 58:01 04:01 07:01
SK-283 M 28 43:01 68:02 41:01 44:03 02:02 07:01
SK-292 F 34 02:01 30:02 39:10 40:01 03:04 12:03
SK-307 F 33 33:03 74:00 15:03 53:01 02:02 04:01
SK-315 F 28 30:01 30:02 42:01 42:01 17:01 17:01
SK-317 F 24 23:01 33:01 42:01 44:03 03:03 17:01
SK-321 M 25 23:01 80:01 18:01 81:01 02:02 04:01
SK-322 M 62 29:02 30:02 44:03 58:02 06:02 07:01
SK-324 F 53 02:01 02:05 45:01 58:01 06:02 16:01
SK-334 F 25 30:01 68:02 42:02 58:01 03:04 17:01
SK-342 F 25 29:02 30:01 42:01 45:01 06:02 17:01
SK-343 F 33 23:01 30:09 58:01 81:00 04:01 06:02
SK-346 F 24 30:04 68:01 58:01 82:02 03:02 06:02
SK-348 M 23 01:01 02:05/02:08 58:01 81:00 07:01 17:00
SK-354 F 38 30:01 74:00 35:01 81:00 04:01 04:01
SK-358 F 39 02:02 23:01 08:01 57:01 07:01 07:01
SK-362 F 30 03:01 74:00 15:03 15:10 02:02 04:01
SK-363 F 42 23:01 30:09 15:03 81:00 02:02 04:01
SK-374 F 30 23:01 34:02 14:02 44:03 04:01 08:02
SK-375 F 29 26:01 34:02 08:01 15:03 07:01 07:01
SK-378 F 35 33:03 68:01 15:10 53:01 03:04 04:01
SK-381 F 23 02:01 03:01 15:10 45:01 04:01 16:01
SK-382 F 28 03:01 29:02 42:01 81:00 04:01 17:00
SK-385 F 46 29:02 29:02 39:10 44:03 07:01 12:03
SK-387 F 48 02:02 29:11 13:02 15:16 06:02 14:02
SK-402 M 36 02:05 29:02 44:03 58:01 07:01 07:01
SK-404 M 34 23:01 29:01 15:03 15:03 02:02 04:01
SK-405 M 38 23:01 29:02 14:02 15:03 04:01 08:02
SK-407 F 32 01:01 74:00 35:01 81:01/02 04:01 18:01/02
SK-420 F 33 66:01 74:00 15:03 57:03 07:01 17:00
SK-422 M 29 30:02 30:02 15:10 42:01 03:04 17:00
SK-424 F 31 30:01 74:00 15:03 42:02 02:02 17:00
SK-425 F 37 03:01 30:02 15:10 58:02 03:04 06:02
SK-435 M 28 23:01 30:02 15:10 57:03 16:01 18:01
SK-445 F 33 23:01 33:01 42:01 58:02 06:02/7/10 17:00
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Characteristics of the study subjects are shown in Table 3.2. Thirty-five participants 
had protective HLA class I alleles (+), of which 20 were viremic controllers at 
baseline (bVC+) whereas 15 were progressors (Prog+). The median time of follow-up 
of the bVC+ group of individuals was 5 years (4-6); and 4 years (3-6) for Prog+. The 
remaining 35 participants did not have protective HLA class I alleles (-) and of these, 
10 were baseline viremic controllers (bVC-) and 25 were progressors (Prog-). The 
median follow-up time for individuals without protective HLA class I alleles was 5 
years (4-6) for bVC- and 3 years (2.5-4) for Prog- (Table 3.2).  
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Protective HLA alleles: HLAs B*57, B*58:01, B*81:01 and A*74:01 
There were no significant differences in the median VL between baseline viremic 
controllers with and without protective HLA class I alleles (p-value 0.77; Mann-
Whitney test). There was a trend towards higher absolute CD4+ T cell counts at 
baseline in viremic controllers without protective HLA class I alleles (bVC-) than 
baseline viremic controllers with protective HLA class I alleles (bVC+). Similarly, the 
median viral load and CD4+ T cell count differences were not significant between 
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progressors with and without protective HLA class I alleles  (p-value 0.26; (Mann- 
Whitney test) for viral load and p-value 0.56 (Mann-Whitney test) for CD4+ T cell 
count) (Figure 3.1). 
Study participants with baseline virologic control were followed longitudinally to 
assess viral load dynamics according to whether or not they expressed protective 
HLA class I alleles. Longitudinal follow-up of the 20 individuals with protective HLA 
class I alleles who controlled viremia at baseline (bVC+) allowed identification of 
two subgroups based on the VL dynamics: a subgroup of viremic controllers (VC+) 
that maintained viral load below 2,000 HIV RNA copies/ml for the entire study 
period and a second subgroup of failing viremic controllers (fVC+) who started with 
controlled viremia but eventually experienced virologic failure, with VL increasing up 
to more than 10,000 HIV RNA copies/ml in at least two consecutive time points 
during follow-up. There were some individuals whose viral load upon follow-up was 
above 2,000 but below 10,000 copies/ml and these individuals were excluded from 
some analysis as specified hereafter. Thus, the two subgroups showed divergent viral 
load dynamics despite viral load similarities at baseline (Figure 3.2A). Thirty five 
percent (n=7) of the bVC+ group maintained virologic control and were termed VC+ 
while another 35% (n=7) lost virologic control during follow up and were termed 
fVC+. The remaining 30% (n=6) fell into a third subgroup in which plasma VL were 
neither maintained below 2,000 nor increased to more than 10,000 HIV RNA 
copies/ml at any time point. We focussed on the 2 subgroups with extreme divergent 
outcomes in order to better understand the factors responsible for the control among 
the VC+ individuals and lack of viral control amongst fVC+ subgroups. Clinical 
parameters showed no differences in the CD4+ T cell counts over time between the 
VC+ and fVC+ subgroups (Figure 3.2B). In each of the 2 subgroups (VC+ and 
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fVC+), 2 individuals maintained an absolute CD4+ T cell count of less than 350 
cells/mm3 and the remaining 5 maintained an absolute CD4+ T cell count of 350 
cells/mm3 or more during the entire time of follow up. 
Longitudinal follow up of 10 bVC without protective HLA class I alleles allowed 
identification of a subgroup (VC-) defined as individuals who maintained virologic 
control (VL< 2,000 HIV RNA copies/ml) throughout the follow up period as shown 
in Figure 3.2C. Remarkably, sixty percent of the bVC- maintained virologic control 
(VC-, n=6) while none of the bVC- lost virologic control. The remaining 4 subjects 
(40%) did not fall in either of the 2 subgroups as their plasma VL were neither 
maintained below 2,000 nor increased to more than 10,000 HIV RNA copies/ml at 
any time point and these were excluded from further analysis. The changes in the 
absolute CD4+ T cell count within the VC- subgroup are shown in Figure 3.2D. In this 
subgroup, there were 2 individuals maintaining an absolute CD4+ T cell count of less 
than 350 cells/mm3 whereas the remaining 4 maintained a count of 350 cells/mm3 or 
more during the entire time of follow up. 
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Figure 3.1. Viral load (A) and absolute CD4 T cell count (B) amongst individuals with 
and without protective HLA class I alleles; baseline viremic controllers (bVC+/-) 
with/without protective HLA class I alleles (enrolled with a viral load of < 2,000 HIV 
RNA copies/ml) and progressors (Prog+/-) with/without protective HLA class I alleles 
(enrolled with a viral load of > 100,000 HIV RNA copies/ml). Statistical analysis was 
performed on Prism using One-way ANOVA to compare all groups and Mann-Whitney 
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 Figure 3.2. Longitudinal viral load (A, C) and absolute CD4 T cell count (B, D) patterns 
amongst baseline viremic controllers with and without protective HLA class I alleles 
respectively. Failing viremic controllers with protective HLA class I alleles (fVC+) were 
enrolled with a viral load of < 2,000 HIV RNA copies/ml and later lost control, n = 7; 
loss of control is defined by an increase in viral load to > 10,000 HIV RNA copies/ml at 2 
or more time points during follow up. Viremic controllers with or without protective 
HLA class I alleles (VC+/-) maintained viral load < 2,000 HIV RNA copies/ml for the 



































































































































We went on to determine whether there were viral load and CD4+ T cell count 
differences at enrolment between viremic controllers (VC+) and failing viremic 
controllers (fVC+) with protective HLA class I alleles that could explain or possibly 
predict the later loss of control among some individuals. There was a trend towards 
higher baseline viral load in fVC+ individuals compared to VC+ individuals (p-value 
0.06; Mann-Whitney test; Figure 3.3A) and we noted no significant differences in 
CD4+ T cell counts between the two subgroups at baseline (p-value 0.26; Mann-
Whitney test; Figure 3.3B). Taken together, these results reveal divergent viral load 
patterns amongst viremic controllers with protective HLA class I alleles.  
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Figure 3.3. Log viral load (A) and absolute CD4 T cell count (B) at baseline amongst 
viremic controllers (VC+) and failing viremic (fVC+) individuals with protective HLA 
class I alleles. Statistical analysis was performed on Prism using Mann-Whitney U test 
to compare 2 groups. 
 
  






















































3.3 HIV specific CD8+ T cell responses at baseline amongst study participants 
We next sought to understand whether the differences in viral load outcomes were 
attributed to CD8+ T cell responses.  We characterized the breadth and magnitude of 
HIV-specific CD8+ T cell immune responses in study participants with the ELISpot 
matrix assay. PBMCs were stimulated with consensus subtype C peptides spanning 
the entire proteome followed by confirmations with individual overlapping peptides 
within a reactive pool. Comparison of the overall responses across the entire HIV 
proteome between the bVC and Prog groups with or without protective HLA class I 
alleles showed no significant differences between the groups, with a median breadth 
of 7.5 responses for both bVC+ and Prog+ and a median of 8 and 8.5 for bVC- and 
Prog- respectively (Figure 3.4A). There were no significant differences in the overall 
magnitude of CD8+ T cell responses across the entire HIV proteome when comparing 
bVC+ to Prog+, with a median of 5,779 and 6,220 SFC/million PBMCs respectively; 
whereas the median magnitude for bVC- and Prog- were 2,763 and 5,574 SFC/million 
PBMCs respectively (Figure 3.4B). However, we observed a significant difference in 
the breadth of Gag-specific CD8+ T cell responses between the 4 groups (p-value 
0.01; Kruskal-Wallis), further analysis showed that the bVC with protective HLA 
class I alleles targeted a significantly higher number of Gag epitopes than Prog with 
protective HLA class I alleles (p-value 0.004; Mann-Whitney test) (Figure 3.4C). 
There were no significant differences between the groups when we analysed the 




Figure 3.4.  ELISpot screening of HIV-specific T cell responses at baseline; Breadth (A) 
and magnitude (B) of the whole HIV proteome; breadth (C) and magnitude (D) of Gag 
specific CD8+ T cell responses amongst individuals with or without protective HLA class 
I alleles (bVC+/- and Prog +/-). An ELISpot matrix assay followed by confirmations 
with overlapping peptides spanning the entire HIV-1 clade C proteome was used on 
thawed PBMCs. Gag overlapping peptides were represented by OLPs 1 to 66. bVC+ 
(baseline viremic controllers with protective HLA class I alleles, n =18), Prog+ 
(progressors with protective HLA alleles, n = 12), bVC- (baseline VC without protective 
HLA class I alleles, n = 9), Prog- (progressors without protective HLA class I alleles, n = 
20). Statistical analysis was performed on Prism using One-way ANOVA to compare all 
4 groups in each graph and where significant differences were found, Mann-Whitney U 
test was used to compare 2 groups that indicated significant differences.  
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No significant differences between the groups were found when comparing other 
proteins individually; Nef, Env, Pol, and Accessory (Vpr, Vpu and Vif) and 
Regulatory (Rev and Tat) proteins, however progressors without protective HLA class 
I alleles had a significantly higher magnitude of Nef-specific CD8+ T cell responses 
compared to baseline VC without protective HLA class I alleles (p-value 0.006; 
Mann-Whitney test) (Figure 3.5).  
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Figure 3.5.  ELISpot screening of HIV-specific T cell responses at baseline; Breadth and 
magnitude of Nef (A, B), Env (C, D), Pol (E, F) and Accessory and Regulatory proteins 
(G, H) specific CD8+ T cell responses amongst individuals with or without protective 
HLA class I alleles (bVC+/- and Prog +/-). An ELISpot matrix assay followed by 
confirmations with overlapping peptides spanning the entire HIV-1 clade C proteome 
was used on thawed PBMCs. Overlapping peptides were represented by OLPs 67-93 for 
Nef peptides; OLPs 289 - 401 for Env peptides; OLPs 145 – 277 for Pol peptides; 
Accessory and Regulatory proteins were grouped together and represented Rev peptides 
OLPs 94 -107; Tat peptides 111-122; Vpu peptides 123-131; Vpr peptides 278-288; and 
Vif peptides 402-425. bVC+ (baseline viremic controllers with protective HLA class I 
alleles, n =18), Prog+ (progressors with protective HLA class I alleles, n = 12), bVC- 
(baseline VC without protective HLA class I alleles, n = 9), Prog- (progressors without 
protective HLA class I alleles, n = 20). Statistical analysis was performed on Prism using 
Nef
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One-way ANOVA to compare all 4 groups in each graph and where significant 
differences were found, Mann-Whitney U test was used to compare 2 groups that 
indicated significant differences. 
 
 
Figure 3.6. ELISpot screening of HIV-specific T cell responses at baseline- Gag versus 
Nef; An ELISpot matrix assay followed by confirmations with overlapping peptides 
spanning the entire HIV-1 clade C proteome was used on thawed PBMCs. The breadth 
of Gag versus Nef responses were assessed amongst the study groups (A, B, C, D); bVC+ 
(baseline viremic controllers with protective HLA class I alleles, n =18), Prog+ 
(progressors with protective HLA class I alleles, n = 12), bVC- (baseline VC without 
protective HLA class I alleles, n = 9), Prog- (progressors without protective HLA class I 
alleles, n = 20). Statistical analysis was performed on Prism using Wilcoxon paired test. 
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CD8+ T cell responses to Gag have previously been associated with low viral load 
(252, 254) while responses to Nef have been previously associated with high viral 
load (233, 332). In order to further study the importance of targeting Gag as opposed 
to other HIV proteins amongst viremic controllers we first investigated the patterns of 
immunodominance of Gag responses compared with Nef responses in the 4 study 
groups. We found that there was a bias towards targeting of higher number of Gag 
epitopes (median breadth = 4) compared to Nef (median = 1.5) (p-value 0.0002; 
Wilcoxon matched pairs test) in baseline viremic controllers (bVC+) with protective 
HLA class I alleles (Figure 3.6A). This observation was similar to that in baseline 
viremic controllers without protective HLA class I alleles where a bias towards higher 
Gag breadth (median = 3) compared to Nef (median = 1) (p-value 0.009; Wilcoxon 
matched pairs test) was noted (Figure 3.6B). This bias towards higher Gag breadth 
than Nef was not observed amongst progressor groups with or without protective 
HLA class I alleles where no differences were found between the breadth of Gag and 
Nef (Figure 3.6C, D). Taken together these observations suggest that broad targeting 
of Gag may contribute to HIV control among viremic controllers. 
Additionally, to further investigate the importance of targeting Gag as opposed to 
other HIV proteins amongst viremic controllers we went on to investigate the patterns 
of immunodominance of Gag responses compared with other HIV proteins in the 4 
study groups. We examined Gag responses versus Env, Pol and accessory and 
regulatory protein responses. We observed a bias towards targeting of higher Gag 
versus Env breadth in all of the 4 groups of individuals with and without protective 
HLA class I alleles (p-value 0.002; Wilcoxon matched pairs test) for bVC+ subjects 
(Figure 3.7A), (p-value 0.009; Wilcoxon matched pairs test) for bVC- subjects 
(Figure 3.7B), (p-value 0.02; Wilcoxon matched pairs test) for Prog+ subjects (Figure 
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3.7C) and (p-value 0.009; Wilcoxon matched pairs test) for Prog- subjects (Figure 
3.7D).  
However when we analysed responses to Gag versus Pol, similar observations of 
higher targeting of Gag epitopes was noted in the baseline viremic controllers with 
and without protective HLA class I alleles (p-value 0.0007; Wilcoxon matched pairs 
test; for bVC+ and p-value 0.017; Wilcoxon matched pairs test for bVC- individuals) 
(Figure 3.8A, B). Among the progressors with and without protective HLA class I 
alleles, this bias was not evident (Figure 3.8C, D). 
Furthermore, we observed a bias towards targeting of higher Gag versus Accessory 
and Regulatory proteins among bVC+ subjects (p-value 0.0002; Wilcoxon matched 
pairs test) (Figure 3.9A), bVC- subjects (p-value 0.009; Wilcoxon matched pairs test) 
(Figure 3.9B), a trending bias among Prog+ subjects (p-value 0.08; Wilcoxon 
matched pairs test) (Figure 3.9C) and (p-value 0.008; Wilcoxon matched pairs test) 




Figure 3.7. ELISpot screening of HIV-specific T cell responses at baseline- Gag versus 
Env; An ELISpot matrix assay followed by confirmations with overlapping peptides 
spanning the entire HIV-1 clade C proteome was used on thawed PBMCs. The breadth 
of Gag versus Env responses were assessed amongst the study groups (Fig A, B, C, D); 
bVC+ (baseline viremic controllers with protective HLA class I alleles, n =18), Prog+ 
(progressors with protective HLA class I alleles, n = 12), bVC- (baseline VC without 
protective HLA class I alleles, n = 9), Prog- (progressors without protective HLA class I 











































































































































Figure 3.8. ELISpot screening of HIV-specific T cell responses at baseline- Gag versus 
Pol; An ELISpot matrix assay followed by confirmations with overlapping peptides 
spanning the entire HIV-1 clade C proteome was used on thawed PBMCs. The breadth 
of Gag versus Pol responses were assessed amongst the study groups (Fig A, B, C, D); 
bVC+ (baseline viremic controllers with protective HLA class I alleles, n =18), Prog+ 
(progressors with protective HLA class I alleles, n = 12), bVC- (baseline VC without 
protective HLA class I alleles, n = 9), Prog- (progressors without protective HLA class I 










































































































































Figure 3.9. ELISpot screening of HIV-specific T cell responses at baseline- Gag versus 
Acc & Reg proteins; An ELISpot matrix assay followed by confirmations with 
overlapping peptides spanning the entire HIV-1 clade C proteome was used on thawed 
PBMCs. The breadth of Gag versus Accessory and regulatory responses were assessed 
amongst the study groups (Fig A, B, C, D); bVC+ (baseline viremic controllers with 
protective HLA class I alleles, n =18), Prog+ (progressors with protective HLA class I 
alleles, n = 12), bVC- (baseline VC without protective HLA class I alleles, n = 9), Prog- 
(progressors without protective HLA class I alleles, n = 20). Statistical analysis was 
performed on Prism using Wilcoxon paired test. 
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3.4 Summary of results 
In Chapter 3, we characterized the baseline and longitudinal viral load and CD4 T cell 
dynamics in 35 chronic HIV-1 clade C infected individuals with protective HLA class 
I alleles and 35 individuals without protective HLA class I alleles. We show 
differential patterns in disease outcome amongst the individuals with protective HLA 
class I alleles despite similar viral load and CD4+ T cell counts at baseline time point. 
Furthermore, we demonstrate that virological control was associated with biased 
targeting of Gag compared to other proteins. In particular, baseline viremic controllers 
with protective HLA class I alleles targeted significantly higher breadth of Gag 
specific CD8+ T cells responses compared to progressors with protective HLA class I 
alleles.  To our surprise baseline viremic controllers without protective HLA class I 
alleles displayed limited Gag specific CD8+ T cell responses suggesting that 
mechanisms other than CD8+ T cells may mediate control.  An alternative hypothesis 
is that among individuals without protective HLA class I alleles, the CD8+ T cells 
targeting only a few epitopes mediated very effective antiviral effects. Furthermore, 
we showed that there was a bias towards targeting of Gag versus Nef, Pol, Env, 
Accessory and Regulatory proteins amongst baseline viremic controllers. Taken 
together these data emphasize the importance of broad targeting of Gag among 
viremic controllers and confirm previous studies documented in HIV-1 subtype C 




CHAPTER 4: LONGITUDINAL ANALYSIS OF 
CD8+ T CELL RESPONSES AND IMPACT OF 
VIRAL EVOLUTION ON DISEASE 
PROGRESSION IN HIV-1 SUBTYPE C 
CHRONICALLY INFECTED INDIVIDUALS 
WITH AND WITHOUT PROTECTIVE HLA 




HIV-specific CD8+ cytotoxic T lymphocytes (CTLs) have been demonstrated to play 
an important role in HIV control (237, 254, 290, 297). However, virus-specific CD8+ 
T cell immune responses are not equally effective in HIV control as the majority of 
infected individuals progress to disease despite the presence of these cells. One 
possible explanation is that HIV is able to evade immune responses by developing 
mutations that mediate escape from CTL recognition (149, 234, 248, 333–336). 
In the previous chapter we demonstrated that individuals with protective HLA class I 
alleles lost viral control and that Gag specific CD8+ T cells responses were related to 
the control of viremia at baseline. Although the majority of previous studies have 
associated CD8+ T cell responses with disease outcomes, there are some caveats: most 
of these studies characterized immune responses at a single time point which is 
usually the enrolment time point despite the study subjects displaying divergent 
disease progression pathways thereafter. In order to address this gap in knowledge, 
our study design afforded a unique opportunity to characterize CD8+ T cell responses 
of the individuals longitudinally in an attempt to determine whether the CD8+ T cell 
responses played any role in the control or loss of virologic control among individuals 
with and without protective HLA class I alleles. We also sought to determine whether 
viral evolution and escape due to CTL pressure explained the loss of viral control in 
these groups. 
Therefore we aimed to: 
1. Study and describe the evolution of HIV-specific immune responses and 
associate those with disease progression. 
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2. Study viral evolution within Gag in individuals with and without protective 
HLA class I alleles and determine the impact of viral evolution on disease 
progression 
4.2 Study participants 
Here we focused on individuals with and without protective HLA class I alleles but 
divergent disease progression status. These are described below: 
iii. Viremic controllers (VC) were defined as individuals who were enrolled 
with a VL of less than 2,000 HIV RNA copies/ml and maintained this low 
viral load for the entire period of follow up. 
iv. Failing viremic controllers (fVC) were defined as bVC that were enrolled 
with a VL of less than 2,000 HIV RNA copies/ml but lost virological 
control. We defined the loss of viral control as an increase in VL to more 
than 10,000 HIV RNA copies/ml at a minimum of 2 time points during the 
time of follow-up. 
We also included some progressors with protective HLA class I alleles depending on 
sample availability as a control group.  The schematic representation of these 
subgroups and HLA typing and general characteristics are illustrated on the flow chart 
(Figure 4.1) and Table 4.1 below. A total of 7 fVC+, 7 VC+, 6 VC- and 6 Prog+ 










Figure 4.1 Flow chart showing the breakdown of study groups in to subgroups. 
Table 4.1. HLA typing and general characteristics of study participants that 
were studied longitudinally. 
  
PID Gender Age HLA	Class1	A HLA	Class1	A2 HLA	Class1	B HLA	Class1	B2 HLA	Class1	CW HLA	Class1	CW2 Role
SK-024 F 32 2902 6601 4403 5801 602 701 fVC+
SK-079 F 30 205 2902 4403 5801 701 701 fVC+
SK-187 F 25 3002 6802 801 5801 302 701 fVC+
SK-188 F 35 301 7400 5703 5802 602 701 fVC+
SK-435 M 28 2301 3002 1510 5703 1601 1801 fVC+
SK-224 F 31 205 6802 702 5702 304 1800 fVC+
SK-242 F 28 101 6601 81 39/67 1203 1800 fVC+
SK-199 F 27 2902 7400 1302 5703 602 701 VC+
SK-282 M 46 205 3402 4403 5801 401 701 VC+
SK-235 M 37 101 6601 3910 39 1203 1800 VC+
SK-348 M 23 101 0205/0208 5801 8100 701 17 VC+
SK-354 F 38 3001 7400 3501 8100 401 401 VC+
SK-362 F 30 301 7400 1503 1510 202 401 VC+
SK-089 F 26 2301 7400 1503 5801 202 302 VC+
SK-209 F 31 301 3001 801 4201 702 1701 VC-
SK-342 F 25 2902 3001 4201 4501 602 1701 VC-
SK-292 F 34 201 3002 3910 4001 304 1203 VC-
SK-275 F 26 301 3001 801 3910 702 1203 VC-
SK-315 F 28 3001 3002 4201 4201 1701 1701? VC-
SK-317 F 24 2301 3301 4201 4403 303 1701 VC-
SK-334 F 25 3001 6802 4202 5801 304 1701 Prog+
SK-324 F 53 201 205 4501 5801 602 1601 Prog+
SK-307 F 33 3303 7400 1503 5301 202 401 Prog+
SK-358 F 39 202 2301 801 5701 701 701 Prog+
SK-363 F 42 2301 3009 1503 8100 202 401 Prog+




With protective HLA 




Without protective HLA 
































4.3 Loss of virologic control is associated with the loss of CD8+ T cell responses  
In order to identify HIV-specific CD8+ T cell immune response changes associated 
with control and loss of viral control, the ELISpot assay was used to determine CD8+ 
T cell responses following stimulation with HLA-matched optimal peptides at the 
time point of virological failure. Thus, for VC+, VC- and Prog+ participants, samples 
were assessed by an ELISpot assay at baseline (earliest time point) and the latest time 
point available, whereas for failing viremic controller (fVC+) participants, samples 
were evaluated at baseline (viremic control time point) and at the time point of first 
increase of VL to above 10,000 copies/ml (post loss of virologic control) and 
thereafter. 
Firstly, we assessed the CD8+ T cell response profiles between the subgroups at 
baseline in order to determine predictors of loss of viral control. We found that there 
was a significant difference in the overall breadth of HIV specific CD8+ T cell 
responses across the entire HIV proteome between the 4 subgroups (p-value 0.005; 
Kruskal-Wallis). Further analysis showed that the progressors with protective HLA 
class I alleles targeted a significantly higher number of total epitopes than VC without 
protective HLA class I alleles (p-value 0.006; Mann-Whitney test) (Figure 4.2A). 
Similarly we further observed significant differences in the overall magnitude of 
CD8+ T cells responses between the 4 subgroups (p-value 0.002; Kruskal-Wallis), 
with further analysis showing that fVC+ subjects displayed a significantly higher 
overall magnitude of CD8+ T cells responses compared to VC without protective 
HLA class I alleles (p-value 0.005; Mann–Whitney test). Furthermore, Prog+ 
displayed a significantly higher magnitude of overall CD8+ T cell responses when 
compared to VC without protective HLA class I alleles (p-value 0.004; Mann-
Whitney test) (Figure 4.2B). There were no significant differences in the breadth and 
 97 




Figure 4.2. ELISpot screening of HIV-specific T cell responses at baseline amongst the 4 
subgroups- Overall and Gag; ELISpot assay was used on thawed PBMCs to determine 
CD8+ T cell responses following stimulation with HLA-matched optimal peptides 
spanning the entire HIV-1 clade C proteome. Breadth and magnitude to the whole HIV 
proteome (A, B) and the breadth and magnitude of Gag specific CD8+ T cell responses 
(C, D). VC+; (viremic controllers with protective HLA class I alleles, n =7), fVC+; 
(failing viremic controllers with protective HLA class I alleles, n=7), VC-; (viremic 
controllers without protective HLA class I alleles, n=6), Prog+; (progressors with 
protective HLA class I alleles, n = 6). Statistical analysis was performed on Prism using 
Kruskal-Wallis test to compare all 4 groups in each graph and Mann-Whitney U test to 
compare 2 groups that indicated significant differences. 
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We extended the analysis to all other proteins; Nef, Env, Pol, accessory and 
regulatory proteins (Figure 4.3). Here we found a significant difference in the breadth 
of Nef between the subgroups (p-value 0.003; Kruskal-Wallis), further analysis 
showed that the difference was between fVC+ and VC+ with fVC+ displaying a 
significantly higher breadth of Nef specific CD8+ T cell response than VC+ (p-value 
0.005; Mann–Whitney) (Figure 4.3 A). Similarly we observed a significant difference 
in the magnitude of Nef between the subgroups (p-value 0.0007; Kruskal-Wallis), 
further analysis showed that Prog+ and fVC+ subgroups had significantly higher 
magnitude of Nef responses compared to VC+/- protective HLA class I alleles. The 
differences were as follows: between VC+ and fVC+ (p-value 0.006; Mann–Whitney 
test); VC+ and Prog+ (p-value 0.007; Mann–Whitney test); fVC+ and VC- (p-value 
0.004; Mann–Whitney test) and between VC- and Prog+ subgroups (p-value 0.005; 
Mann–Whitney test) (Figure 4.3B). 
No significant differences were observed between the subgroups when we analysed 
the breadth and magnitude of CD8+ T cell responses to the Env and accessory and 
regulatory proteins (Figure 4.3C, D, G, H). We observed significant differences 
between the subgroups when we assessed responses to Pol optimal peptides (breadth, 
p-value 0.03, Kruskal–Wallis; magnitude, p-value 0.007, Kruskal–Wallis), with 
further analysis revealing that Prog+ targeted higher breadth (p-value 0.02; Mann–
Whitney test) and magnitude (p-value 0.007, Mann–Whitney test) of Pol specific 
CD8+ T cell responses than VC without protective HLA class I alleles (Figure 4.3E, 
F). 
Taken altogether these data may suggest that broad targeting of Nef by viremic 
controllers with protective HLA class I alleles is a predictor of loss of virologic 
control. Only 2 VC+ subjects targeted Nef epitopes at baseline compared to all 7 
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fVC+ subjects. It is noteworthy that all individuals either targeted very few epitopes 
within the envelope, accessory and regulatory regions or none at all. Viremic 
controllers without protective HLA class I alleles targeted very few numbers of 
epitopes suggesting a possible alternative mechanism for the control of viremia in 
these individuals. 
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Figure 4.3.  ELISpot screening of HIV-specific T cell responses at baseline among the 4 
subgroups- Nef, Env, Pol, Acc & Reg proteins; ELISpot assay was used on thawed 
PBMCs to determine CD8+ T cell responses following stimulation with HLA-matched 
optimal peptides spanning the entire HIV-1 clade C proteome. Breadth and magnitude 
of Nef (A, B), Env (C, D), Pol (E, F) and accessory and regulatory proteins (G, H) 
specific CD8+ T cell responses amongst individuals with or without protective HLA class 
I alleles (bVC+/- and Prog +/-).  VC+ (viremic controllers with protective HLA class I 
alleles, n =7); fVC+ (failing viremic controllers with protective HLA class I alleles, n=7); 
VC- (viremic controllers without protective HLA class I alleles, n=6); Prog+ 
(progressors with protective HLA class I alleles, n = 6). Statistical analysis was 
Nef
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performed on Prism using Kruskal-Wallis test to compare all 4 groups in each graph 




















We next studied the evolution of CD8+ T cell responses among the subgroups. Figure 
4.4A and B represent the evolution of responses among the VC+ subgroup where no 
significant changes in the overall responses across the entire HIV proteome and Gag 
specific CD8+ T cell responses were observed. However, we noted a significant 
reduction in the overall breadth of CD8+ T cell responses across the entire HIV 
proteome amongst the fVC+ over time (p-value 0.02; Wilcoxon matched pairs test) 
and a significant reduction of Gag targeted epitopes over time (p-value 0.003; 
Wilcoxon matched pairs test) (Figure 4.4C, D). This change was associated with 
increases in viral load in these individuals. No changes in overall responses across the 
entire HIV proteome but a trend in reduction of Gag targeted epitopes were observed 
in VC- subgroup (Figure 4.4E, F). Prog+ subgroup showed a trend in reduction of 
overall breadth of CD8+ T cell responses across the entire HIV proteome (p-value 
0.06; Wilcoxon matched pairs test) and a trend in reduction of Gag targeted epitopes 
over time amongst Prog+ (p-value 0.09; Wilcoxon matched pairs test) (Figure 4.4G, 
H). These changes were associated with further increases in viral load in these 
individuals. This analysis was performed while taking into account the duration of 
time between the tested time points for all participants since this time differed from 
participant to participant. 
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Figure 4.4. Longitudinal ELISpot screening of HIV-specific T cell responses amongst 
viremic controllers (VC+, n = 7, A-B), failing viremic controllers (fVC+, n = 7, C-D) and 
progressors (Prog+, n = 6, E-F) with protective HLA class I alleles and viremic 
controllers (VC-, n = 5, G-H) without protective HLA class I alleles – Overall and Gag. 
PBMCs were stimulated with optimal peptides restricted only to individuals HLA-B 
alleles and spanning the whole HIV proteome. Here we show overall responses across 
the entire HIV proteome and Gag specific CD8+ T cell responses over time for the 4 
subgroups. Latest TP represents latest time point. Statistical analysis was performed on 
Prism using the Wilcoxon matched pairs test to compare responses between the two 
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This longitudinal analysis of the evolution of CD8+ T cell responses was extended to 
other proteins. No significant differences were observed in the breadth of Nef and 
Env amongst the subgroups. However we noted a trend towards a reduction in the 
breadth of Nef-specific CD8+ T cell responses among the fVC+ over time (p-value 
0.09; Wilcoxon matched pairs test) and Prog+ subgroup over time (p-value 0.09; 
Wilcoxon matched pairs test) (Figure 4.5). This analysis was performed taking in to 
consideration differences in follow up duration for participants. The VC- subgroup 
did not have any detectable CD8+ T cell responses to Env. 
No significant differences were observed in the breadth of Pol amongst the VC+ and 
VC- subgroups overtime. However, there was a significant reduction in the breadth of 
Pol-specific CD8+ T cell responses among the fVC+ over time (p-value 0.03; 
Wilcoxon matched pairs test) and Prog+ subgroup over time (p-value 0.04; Wilcoxon 
matched pairs test) (Figure 4.6). No significant differences were observed in the 
breadth of responses to accessory and regulatory proteins amongst the subgroups.  
This analysis was performed while controlling for participant length of follow up. The 
VC- subgroup did not have any detectable CD8+ T cell responses to accessory and 
regulatory proteins. Taken together these data demonstrate that the immunological 
parameter most strongly associated with of loss of viral control is the loss of overall 
responses across the entire HIV proteome, and in particular Gag specific CD8+ T cell 
responses. 
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Figure 4.5. Longitudinal ELISpot screening of HIV-specific T cell responses amongst 
viremic controllers (VC+, n = 7), failing viremic controllers (fVC+, n = 7) and 
progressors (Prog+, n = 6) with protective HLA class I alleles and viremic controllers 
(VC-, n = 5) without protective HLA class I alleles – Nef and Env. PBMCs were 
stimulated with optimal peptides restricted only to individuals HLA-B alleles and 
spanning the whole HIV proteome. Here we show Nef and Env specific CD8+ T cell 
responses over time for the 4 subgroups. Latest TP represents latest time point. 
Statistical analysis was performed on Prism using the Wilcoxon matched pairs test to 
compare responses between the two time points. Time between the time points was 























































































































































































































































































Figure 4.6. Longitudinal ELISpot screening of HIV-specific T cell responses amongst 
viremic controllers (VC+, n = 7), failing viremic controllers (fVC+, n = 7) and 
progressors (Prog+, n = 6) with protective HLA class I alleles and viremic controllers 
(VC-, n = 5) without protective HLA class I alleles – Pol and Acc & Reg proteins. 
PBMCs were stimulated with optimal peptides restricted only to individuals HLA-B 
alleles and spanning the whole HIV proteome. Here we show Pol and Accessory and 
regulatory protein specific CD8+ T cell responses over time for the 4 subgroups. Latest 
TP represents latest time point. Statistical analysis was performed on Prism using the 
Wilcoxon matched pairs test to compare responses between the two time points. Time 
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In order to further characterize factors that may be associated with loss of virologic 
control amongst individuals with protective HLA class I alleles, we focused on the 
fVC+ subgroup and identified the exact HIV-specific CD8+ T cell responses lost over 
time. Table 4.2 shows longitudinal changes in HIV-specific CD8+ T cell responses 
highlighting optimal peptides targeted at baseline, those no longer detectable at the 
time of virologic failure and those that persisted over time.  
We noted that within the fVC+ subgroup, the majority (73%) of the total CD8+ T cell 
responses were no longer detectable by ELISpot at the time of virological failure, and 
these responses were never regained despite the emergence of a few new CD8+ T cell 
specificities at this latter time point in 3 individuals (e.g. SK-435, SK-224 and SK-
079 gained responses to B*15:10-WI9 Vif, B*57-KAF9 Nef and B*57-QY10 Rev 
epitopes respectively) (Table 4.2). The decrease in the overall breadth of CD8+ T cell 
responses was noted across the whole proteome post loss of control. Taken together 
these findings further demonstrate that virological failure in individuals with 
protective HLA class I alleles is associated with loss of overall CD8+ T cell responses 
across the entire HIV proteome.  
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[B8-DI8 (p24), -FL8 (Nef), -
GL9 (RT),  -EL8 (p15), -
NL11 (gag)], [B58:01-TW10 
(p24), -QW9 (p24), -IAW9 
(RT), -SW10 (Int)]
9 2240
[B8-EL8 (p15), -NL11 (gag)], 
B58:01-SW10 (Int) 
3 460
[B8-DI8 (p24), -FL8 (Nef), -
GL9 (RT)], [B58:01-TW10 




B*57:03/       
B*15:10 





AF10 (RT), -QL11 (gp120), -
LW9 (Vif), -VI9 (POL)]  
13 6580
 [B15:10-RI11 (Vif)], [B57-
WF9(p17), -TW10(p24), -
AW9(Vpr), -VF9(Vif), -
KAF9(Nef), -AF10 (RT), -
QL11 (gp120), -LW9 (Vif), -









[B7-GL9(p24), -RM9 (Nef), -
TL10(nef)], [B57-ISW9(p24), 
-TW10(p24), -QW9 (p24), -




TW10(p24),  B57-KI13 (RT)]   
3 540
 [B7-RM9 (Nef), -
TL10(nef)], [B57-
ISW9(p24), -QW9 (p24), -
IW9(RT), -AF10 (RT), -





[B39-GL9(p24), -TL9 (p24), -
NL11 (p24)], [B81-TL9(p24), -
RM9 (Nef), -RGF9(nef), -
LI9(Int), -SL10 (RT)]    
8 9740
[B39-GL9(p24), -NL11 (p24), -
TL9(p24)], [B81-RM9 (Nef), -
RGF9(nef), -LI9(Int), -SL10 
(RT)]    





(NEF), -QY9 (NEF)], 
[B58:01-SW10(Int), -YY8 
(Nef), -YT9 (Nef), -KY11 
(Nef)] 
7 4740
[B44-SL9(P24), -KY11 (NEF), -
QY9 (NEF)], [B58:01-
SW10(Int), -YY8 (Nef), -YT9 
(Nef), -KY11 (Nef)] 




[B44-MY9 (gp120), -KY11 





QL11, -YY8 (Nef), -YT9 
(Nef), -NW9 (Nef), -
KAF9(Nef), -KY11 (Nef), -
HQ10 (Nef)]  
17 26700
[B44-MY9 (gp120), -KY11 
(NEF), -QY9 (NEF)], [B58:01-
TW10(p24), -HW9(nef),  -
SW10(Int), -KW11(Env), -
VF9(Vif), -KAF9(Nef), -QL11, -
YY8 (Nef), -YT9 (Nef), -NW9 
(Nef), -KAF9(Nef), -KY11 










AF10 (RT), -FF9 (RT)]  
5 3640
[B57-ISW9(p24), -HW9(nef), -
AF10 (RT), -FF9 (RT)]  
4 1480 B57-KF11(p24) 1 110
68 60920 50 40720 21 17805TOTAL
PID HLA
POST LOSS OF VIROLOGIC CONTROL TIME POINTSBASELINE TIME POINT
EPITOPES LOST EPITOPES TARGETEDEPITOPES TARGETED
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4.4 Escape mutations in Gag only partially explain the loss of virological control 
in fVC with protective HLA class I alleles 
The ability of HIV to evade CTL recognition by developing mutations that escape 
recognition and undermine the immune response is well documented in HIV infection 
(149, 333–339). We next investigated whether the observed loss of virologic control 
associated with loss of immune responses was linked to the presence of mutations that 
potentiate immune escape. We hypothesized that the loss of CD8+ T cell responses 
will primarily be due to the presence of escape mutations. In the current study, 
longitudinal gag population sequencing was performed from plasma samples at 
baseline and post loss of control on the fVC+ subjects and at baseline and available 
later time points for the viremic controllers with and without protective HLA class I 
alleles (VC+ and VC-). We assessed mutations within epitopes restricted by the 
patients’ protective HLA class I alleles plus epitopes restricted by the other HLA-B 
alleles that the subjects possessed. HIV-1 clade C Gag consensus sequence was used 
as reference for comparison in this analysis. 
For the fVC+ subjects, we assessed a cumulative total of 67 epitopes at baseline and 
69 at the first time point when the subjects had a viral load increase to more than 10, 
000 HIV RNA copies/ml (post loss of viral control) (Figure 4.7).  Of the 67 epitopes 
assessed at baseline, 28% (19 of 67) induced detectable CD8+ T cell responses. 
Furthermore, still at baseline, 51% (34 of 67) of the epitopes evaluated had variant 
sequences either within the epitope or in the 5 flanking regions and of these, 32% (11 
of 34) elicited detectable CD8+ T cell following stimulation with peptides 
corresponding to the wild type epitopes. Forty nine percent (33 of 67) of the epitopes 
had wild type sequences and of these, 24% (8 of 33) were capable of inducing a 
detectable CD8+ T cell response. At the post loss of viral control time point we 
 111 
analysed a cumulative total of 69 epitopes. Of these, 53% (37 of 69) epitopes had 
variant sequences either within the epitope or in the 5 flanking regions with 11% (4 of 
37) having elicited detectable CD8+ T cell following stimulation with peptides 
corresponding to the wild type epitopes that persisted.  
The number of epitopes with wild type or variant sequences did not change much pre- 
and post-loss of control, however we observed a drop in the number of epitopes that 
induced detectable CD8+ T cell responses post loss of control (Figure 4.7). We 
observed that of the 11 variant epitopes that elicited a CD8+ T cell response at 
baseline, 7 responses were no longer detectable post loss of viral control. In addition 
we observed that of the 8 wild type epitopes that elicited a CD8+ T cell response at 
baseline, 6 responses were lost at post loss of control time point. Of these 6, 3 
epitopes did not elicit a CD8+ T cell response as a result of escape while the other 3 
remained wild type despite failure to elicit a detectable CD8+ T cell response. This 
data may suggest that the accumulation of these escape mutations may have abrogated 
the immune responses in some individuals while the reason for the loss of responses 
in some individuals are not known. 
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Figure 4.7. Immunogenicity and escape of fVC+ subjects before and after loss of viral 
control. We evaluated if the epitopes within the Gag region had variant sequences either 
within the epitope or in the 5 flanking regions. HIV-1 clade C Gag consensus sequence 
was used as reference for comparison in this analysis.  
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We narrowed down the analysis and focussed on escape mutations in known 
immunodominant epitopes. Of the 7 fVC+, there are 2 B*57:03-, 1 B*57:02-, 3 
B*58:01- and 1 B*81:01-positive individuals. We evaluated the presence or absence 
of escape mutations within the 4 well-defined B*57:02/03-restricted 
immunodominant Gag epitopes; TW10, ISW9, KF11 and QW9 among subjects 
possessing HLAs B*57:02/03 and B*58:01 over time (Table 4.3). We observed that 
the most common mutation was the T242N and reversion to wild type occurred in 2 
subjects with no detectable CD8+ T cell responses. Escape in the KF11 epitope was 
seen in only 1 subject.  
For one of the subjects we evaluated escape mutations within the 3 B*81:01-restricted 
immunodominant epitopes; SV9, TL9 and HA9. Amongst individuals possessing 
HLA B*81:01, increase in viremia may be associated with escape mutations in the 
immunodominant TL9 and HA9 epitopes resulting in the loss of these CD8+ T cell 
responses.  However, in HIV-1 subtype C, mutations in the TL9 epitopes, unless 
accompanied by compensatory mutations, may severely compromise viral fitness 
resulting in clinical benefit to the patient (258).  In our study we had only 1 fVC (SK-
242) possessing HLA B*81:01 (Table 4.3). This subject had one wild type epitope 
(SV9) with no detectable CD8+ T cell response while 2 of the 3 had variant sequences 
with a detectable CD8+ T cell response induced by stimulation with wild type 
epitopes. We noted sequence variations within the TL9 with a detectable CD8+ T cell 
response at baseline; the mutation was present after the loss of control and reverted 
back to wild type in the subsequent time point following post loss. We also noted a 
mutation (H219Q) within the HA9 epitope with no detectable CD8+ T cell response at 
baseline; the mutation was still present post loss of control time point. Furthermore, 
this subject did not respond to SV9 epitope at baseline and no mutation was observed 
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post loss of control time point. The overall observation of the fVC+ subgroup 
supports the view that accumulation of escape mutations within Gag may abrogate 
immune responses in some individuals. The reasons for the loss of responses in the 
absence of escape require further investigation. 
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Table 4.3. Sequence variation within HLAs B*57:02/03/58:01 and B*81:01 restricted immunodorminant epitopes 
 
Epitope KF11(gag 162-172) Epitope ISW9 (gag 147-155) Epitope TW10 (gag 240-249) Epitope QW9 (gag 296-304)
KVIEEKAFSPEVIPMFTALSE MVHQAISPRTLNAWVKVIE DIAGTTSTLQEQIAWMTSNP TLRAEQATQDVKNWMTDLL
B*57 
subjects
0 ..................... + ....PL............. + .......N.........G.. - ................... -
10 ..................... + ....PL............. - .......N.........G.. - ................... -
0 ..................... - ....P.............. + .......N............ + ................E.. +
7 ..................... - ....P.............. + .......N.....T...... - ................E.. +
14 ..................... - ....P.............. + .......N.....T...... - ................E.. +
20 ..................... - ....P.............. - .......N.....T...... - ................E.. +
71 ..................... - ....P.............. - .......N.....T...... - ................E.. +
0 ..................... + ....VL............. + .......N.....T...... + ................... -
6 ..................... - ....VL............. + .......N.....T...... - ................... -
12 ..................... + ....VL............. + .......N.....T...... - ................... -
21 ..V.............S.... + .................V. + .............G...R.. - ................... -
0 ..................... - ................... - .................N.. - .........E......... -
21 ..................... - ................... - .................N.. - .........E......... -
0 ..................... - ............T...... - n/a + n/a +
21 ..................... n/a ................... n/a .......N............ n/a .......S.E......E.. n/a
34 ..................... n/a ................... n/a .......N............ n/a .......S.E......E.. n/a
41 ..................... - ................... - .......N............ - .......S.E......E.. -
0 ..................... - ....P.............. - .......N.....T...... + ................... +
10 ..................... - ................... - .................... - ................... +
26 n/a - n/a - n/a - n/a -
55 ..................... - ................... - ...............I.G.. - ................... -
Epitope SV9 (gag 148-
156)
Epitope TL9 (gag 180-
188)
Epitope HA9 (gag 216-
224)
VHQAISPRTLNAWVKVIEE LSEGATPQDLNTMLNTVGG EWDRLHPVHAGPIAPGQMR
SK-242 fVC 0 ................... - .........Y.....A... + ........Q.......... -
20 ................... n/a .........Y.....A... n/a ........Q.......... n/a






























































































































































































































































4.5 Maintenance of low viral load despite the presence of Gag escape mutations 
among viremic controllers with protective HLA class I alleles  
We also assessed epitope sequences of the VC+ and VC- subjects at baseline and later 
time point. However due to limited sample availability only 2 subjects were 
sequenced at both baseline and later time points. Evaluation of epitope sequences 
allowed us to assess a cumulative total of 67 epitopes at baseline for the VC+ 
subgroup. Of the 67, 30% (20 of 67) were wild type with 20% (4 of 20) inducing a 
positive CD8+ T cell response while 70% (47 of 67) had variant sequences and 21% 
(10 of 47) elicited detectable CD8+ T cell following stimulation with peptides 
corresponding to the wild type epitopes (Figure 4.8).  Furthermore, in the VC- 
subgroup, a cumulative total of 47 epitopes were evaluated. Fifty one percent (51%) 
(24 of 47) were wild type sequences and 33% (8 of 24) induced a positive CD8+ T 
cell response, while 47% (23 of 47) had variant sequences with 13% (3 of 23) having 
elicited detectable CD8+ T cell responses following stimulation with peptides 
corresponding to the wild type epitopes. 
Tables 4.4 and 4.5 show the sequences of the immunodominant epitopes restricted by 
the patients’ HLA B alleles of VC with and without protective HLA class I alleles at 
baseline. Although the number of subjects studied here is limited, these data 
demonstrate that VC+ maintained viral control despite having the highest prevalence 
of variant sequences either within the epitope or in the 5 flanking regions when 
compared to individuals lacking protective HLA class I alleles.
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Figure 4.8. Immunogenicity and escape of VC+ and VC- subjects at baseline. We 
evaluated if the epitopes within the Gag region had variant sequences either within the 
epitope or within 5 amino acids flanking the epitope. HIV-1 clade C Gag consensus 
sequence was used as reference for comparison in this analysis.



























































































Table 4.4. Sequence variation within HLAs B*57:03/58:01, B*81:01 and A*74:01 restricted immunodominant epitopes  
 
Epitope KF11(gag 162-172) Epitope ISW9 (gag 147-155) Epitope TW10 (gag 240-249) Epitope QW9 (gag 296-304)
KVIEEKAFSPEVIPMFTALSE MVHQAISPRTLNAWVKVIE DIAGTTSTLQEQIAWMTSNP TLRAEQATQDVKNWMTDLL
B*57 
subjects
0 ......G.............. + ....PM............. + .......N....V....... - ................... +
82 N/A + N/A + N/A - N/A +
0 ...........I......... - ................... - .......N............ - ................... -
43 N/A - N/A - .......N.....T...... - ................... +
0 ...........I......... - ................... - .......N.........N.. + .........E......... +
67 ......G.............. - ....P.............. - .......N............ - ......C............ -
0 ..................... - ................... - .................N.. + ................... +
47 N/A - N/A - N/A - N/A -
Epitope SV9 (gag 148-156) Epitope TL9 (gag 180-188) Epitope HA9 (gag 216-224)
VHQAISPRTLNAWVKVIEE LSEGATPQDLNTMLNTVGG EWDRLHPVHAGPIAPGQMR
0 ................... - ................... + ............V....I. -
47 N/A - N/A - N/A -
0 ....L.............. - ......G............ + ............V...... +
36 N/A - N/A + N/A +
Epitope KK9 (gag 18-26) Epitope RH9 (gag 20-28) Epitope RLY10 (gag 20-29)
LDKWEKIRLRPGGKKHYML KWEKIRLRPGGKKHYMLKH KWEKIRLRPGGKKHYMLKHL
0 ..R....N.......K.R. - R....N.......K.R... - R....N.......K.R...I -
50 N/A - N/A - N/A -
0 .......S.......R... - .....S.......R..... - .....S.......R...... -
36 N/A - N/A - N/A -
0 .....R.........Q.R. - ...R.........Q.R... - ...R.........Q.R...I -
43 N/A - N/A - N/A -
0 .....R.K.......K... - ...R.K.......K..... - ...R.K.......K...... -







































































































































































































































































































































Table 4.5. Sequence variation within immunodominant epitopes among VC subjects without protective HLA alleles 
 
 
Epitope SV9 (gag 148-156) Epitope TL9 (gag 180-188) Epitope HA9 (gag 216-224)
VHQAISPRTLNAWVKVIEE LSEGATPQDLNTMLNTVGG EWDRLHPVHAGPIAPGQMR
0 ................... - ................... + ................... -
18 ................... - ................... + ........Q.......... -
0 ................... - ......G............ + ............V...... -
44 N/A N/A N/A N/A N/A N/A
0 ................... - .......T........... - ........Q...V...... -
38 N/A - N/A - N/A -
0 ................... - ................... + .....V........V...... -
28 N/A - N/A + N/A -
0 ................... - ................... + .................V. -














































































4.6 Summary of results 
In Chapter 4 we studied longitudinal CD8+ T cell responses and sequence variation 
within CTL epitopes and associated these parameters with divergent disease 
progression and loss of CD8+ T cell responses in the 4 subgroups; VC+, fVC+, VC- 
and Prog+ subjects. We showed that the loss of viral control seen in the failing 
viremic controller subgroup with protective HLA class I alleles (fVC+) was related to 
a significant loss of overall CD8+ T cell responses across the whole HIV proteome 
and of Gag specific CD8+ T cell responses. Additionally we demonstrated that fVC+ 
subjects targeted significantly higher Nef epitopes at baseline compared to VC+ 
subjects suggesting that targeting of Nef may be a predictor of loss of viral control. 
We also showed that the viral control seen among the viremic controller subgroup 
with protective HLA class I alleles (VC+) was associated with the maintenance of the 
CD8+ T cell responses over time. Interestingly VC- subjects targeted fewer epitopes 
despite maintaining viral control throughout the time of follow up suggesting an 
alternative mechanism of viral control for these individuals. 
We also studied CD8+ T cell immune-driven sequence variation within Gag and 
associated escape with divergent disease progression. We demonstrated that escape 
and potential escape mutations were evident in the fVC+ subgroup and in some 
instances the loss of CD8+ T cell responses were as a result of escape in some 
individuals while the loss of some of the responses could not be explained by escape. 
Interestingly some VC+ maintained viral control throughout despite the presence of 
escape mutations within Gag, and persistence of responses irrespective of sequence 
variation appeared to be a better correlate of viral control. VC- on the other hand had 
fewer escape mutations within Gag and maintained low viral load throughout. 
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CHAPTER 5: CD8+ T CELL FUNCTIONAL 
ANALYSIS AND ASSOCIATION WITH 
DISEASE PROGRESSION IN CHRONICALLY 
HIV-1 SUBTYPE C INFECTED INDIVIDUALS 
WITH AND WITHOUT PROTECTIVE HLA 




The maintenance of a highly polyfunctional CD8+ T cell profile has been well 
documented elsewhere amongst elite controllers (ECs) and long-term non-progressors 
(LTNPs) where CD8+ T cells from these individuals have demonstrated to be more 
polyfunctional, to have a higher proliferative capacity and greater ability to suppress 
viral replication compared to progressors (302, 324, 325, 340, 341).  These data 
suggest that a more polyfunctional CD8+ T cell phenotype is associated with viral 
control. However, there are some caveats; firstly, the extent to which this highly 
polyfunctional and proliferative CD8+ T cell phenotype is maintained in some 
individuals or lost in some individuals who experience loss of viral control is not fully 
understood. Secondly, most of the previous studies characterized the functional 
properties of CD8+ T cells at only one time point. To address this gap in knowledge, 
we characterized longitudinally the functional properties of CD8+ T cells for 
polyfunctionality, proliferation and ability to suppress viral replication from study 
participants in an attempt to determine whether these functional properties of CD8+ T 
cells played any role in the control or loss of virologic control among individuals with 
and without protective HLA class I alleles. 
We hypothesised that viremic controllers with or without protective HLA class I 
alleles will present with highly polyfunctional and proliferating CD8+ T cells able to 
suppress viral replication in an ex vivo viral inhibition assay compared to progressors. 
We further hypothesized that the CD8+ T cells amongst failing viremic controllers 
(individuals that were controlling vireamia and later experienced loss of viral control) 
with protective HLA class I alleles will show reduced polyfunctionality, reduced 
proliferative capacity and reduced ability to suppress viral replication post loss of 
virologic control.  
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In order to test these hypotheses we aimed to: 
1. Study the polyfunctionality of CD8+ T cells amongst individuals with 
controlled vireamia and associate these CD8+ T cell properties with viral 
control or lack of control upon longitudinal follow up. 
2. Study the proliferative capacity of CD8+ T cells amongst individuals with 
controlled vireamia and associate these CD8+ T cell properties with viral 
control or lack of control upon longitudinal follow up. 
3. Study the ex vivo ability of CD8+ T cells to suppress HIV replication and 
associate this function with disease progression or the lack thereof. 
5.2 Study participants 
For this sub-study, we focused on individuals with divergent disease progression 
status with and without protective HLA class I alleles. These are described below: 
i. Viremic controllers (VC) were defined as individuals who were enrolled 
with a VL of less than 2,000 HIV RNA copies/ml and maintained this low 
viral load for the entire period of enrolment. 
ii. Failing viremic controllers (fVC) were defined as bVC that were enrolled 
with a VL of less than 2,000 HIV RNA copies/ml but lost virological 
control. We defined the loss of viral control as an increase in VL to more 
than 10,000 HIV RNA copies/ml at a minimum of 2 time points during the 
time of follow-up. 
We also included some progressors with protective HLA class I alleles as a control 
subgroup. 










Figure 5.1 Flow chart showing the breakdown of study groups in to subgroups. 
5.3 No significant differences in the polyfunctionality of CD8+ T cells between the 
4 subgroups; VC+, fVC+, VC- and Prog+ 
We first studied the ability of CD8+ T cells to produce diverse cytokines as previously 
described (340). This is for consistency with previously studies so that we can 
compare our findings. We assessed 5 functions; interferon gamma (IFN), interleukin-
2 (IL-2), tumour necrosis factor alpha (TNF-), macrophage inflammatory protein 1 
beta (MIP1) and CD107a at baseline and later time points for VC+, VC- and Prog+; 
and pre and post loss of viral control time points for fVC+ subjects. The gating 
strategy for this analysis is summarized on Figure 5.2. Our data show that there were 
no significant differences in CD8+ T cell polyfunctionality to explain the divergence 
in disease progression amongst the subgroups (VC+, fVC+, VC- and Prog+) at 
baseline and later time points (Figure 5.3). Although the profiles of the different 
Baseline viremic 
controllers 
With protective HLA 




Without protective HLA 
































subgroups seem different, we were underpowered by the small sample size to make 
conclusions. 
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Figure 5.2. Polyfunctionality of CD8+ T cells upon stimulation with Gag peptide pools – 
gating stratergy. The initial gating was on lymphocytes followed by the forward scatter 
height (FCS-H) versus forward scatter area (FSC-A) to eliminate the doublets. 
Subsequently live CD3+ T cell population was gated on followed by gating of CD8+ and 
CD4+ T cell populations. The individual gating for respective functions followed (set 
based on the negative control (‘NO STIM’)), these were used to identify positive 
responses.  
















































































































































































































































































NO	STIM	 Gag	s mulated	 PHA	
Gag	s mulated	 Gag	s mulated	

















































































































Figure 5.3. Polyfunctionality of CD8+ T cells upon stimulation with Gag peptide pools - amongst viremic controllers (VC+), failing viremic 
controllers (fVC+), progressors (Prog+) with protective HLA class I alleles and viremic controllers without protective HLA class I  alleles; At 
baseline and at later time points. The 5 functions studied were CD107a, IFNg, IL2, MIP1b and TNFa. On the pie charts, red represents 5 functions, 
orange; 4 functions, yellow; 3 functions, green; 2 functions and blue; 1 function. Gating strategy is shown in Figure 5.1. Boolean gating was 
performed in order to allow creation of a full array of possible combinations of up to 32 response patterns. Positive responses were reported after 
background correction and the percentage of epitope-specific CD8+ T cell responses had to be at least two times higher than background for each 
tested marker. PESTLE (version 1.6.2) and SPICE 5.0 (Mario Roederer, ImmunoTechnology Section, Vaccine Research Center, NIH, Bethesda, 
MD) were used to analyze the multifunctional data. Later TP represents later time point. 
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We extended our analysis to determine whether there were any similarities of 
differences in the expression of single/mono functional CD8+ T cells upon stimulation 
with Gag pool peptide between the 4 subgroups at baseline that may possibly predict 
the later divergence of disease progression observed. We did not observe any 
significant differences in the mono expression any of the five markers at baseline; 
CD107a, IL-2, IFN-γ, MIP1-β and TNF-α (Figure 5.4). This analysis may have been 




Figure 5.4. The expression of single functions by CD8+ T cells upon stimulation with 
Gag peptide pools - amongst viremic controllers (VC+), failing viremic controllers 
(fVC+), progressors (Prog+) with protective HLA class I alleles and viremic controllers 
without protective HLA class I alleles at baseline. The 5 functions studied were CD107a, 
IFNγ, IL-2, MIP1-β and TNF-α. Gating strategy is shown in Figure 5.1. Positive 
responses were reported after background correction by subtracting the proportion of 
unstimulated CD8+ T cells from the Gag stimulated CD8+ T cells. Statistical analysis was 
performed on Prism using Kruskal-Wallis test to compare all 4 groups in each graph 
and Mann-Whitney U test to compare 2 groups that indicated significant differences.
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We also determined whether there were any changes in the single function of CD8+ T 
cells over time, that is, for VC+, VC- and Prog+ subjects we assessed these responses 
at baseline and later time points. Expression of these markers was assessed at baseline 
(pre loss time point) and post loss of viral control time point for the fVC+ subjects. 
We did not observe any significant differences in the mono expression of the 5 
markers over time in all the 4 subgroups (data shown Appendix A) and neither did we 
find any CD8+ functionality patterns that could explain the loss of viral control in the 
fVC+ subjects. 
5.4 No significant differences in the proliferative capacity of CD8+ T cells 
between the 4 subgroups 
We further studied the ability of CD8+ T cells to proliferate upon stimulation with 
Gag peptide pool. We assessed the subjects’ whole PBMCs at baseline and later time 
points for VC+, VC- and Prog+; and pre- and post-loss of viral control time points for 
fVC+ subjects. The gating strategy is summarized in Figure 5.5. Our data show that 
there were no significant differences in proliferative capacity of the CD8+ T cell to 
explain the divergence in disease progression amongst the compared subgroups (VC+, 
fVC+, VC- and Prog+) at baseline and later time points (Figure 5.6).  However, at 
baseline (when all were controlling) there was a trend towards a higher proliferative 
capacity of CD8+ T cells from viremic controllers (VC+) compared to those who 
subsequently lost control (fVC+) among individuals with protective HLA class I 
alleles (p-value 0.09; Mann-Whitney test). No significant differences were observed 
at later time points for all subgroups (Figure 5.6 B).  
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Figure 5.5. The proliferative capacity of CD8+ T cells upon stimulation with Gag peptide 
pools – gating stratergy. The initial gating was on lymphocytes followed by gating on the 
live CD3+ T cell population and further followed by gating of CD8+ and CD4+ T cell 
populations. The next gates were set on the CD8+ CFSE negative in order to identify 
proliferated CD8+ T cell populations. The individual gating for proliferating cells was 
set based on the negative control (no stimulation), these were used to identify positive 
responses by subtraction from stimulated proliferating population.  
Figure 5.6. The proliferative capacity of CD8+ T cells upon stimulation with Gag peptide 
pools - amongst viremic controllers (VC+; n=7), failing viremic controllers (fVC+, n=7), 
progressors (Prog+, n=6) with protective HLA class I alleles and viremic controllers 
(VC-, n=6) without protective HLA class I alleles at baseline (A) and latest time point 
(B). The gating strategy is shown on Figure 5.5. Statistical analysis was performed on 
Prism using Kruskal-Wallis test to compare all 4 groups in each graph and Mann-


















































































































































































































































and whisker plots show the median and the error bars represent the minimum and 
maximum values.  
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Taken together these data showed that polyfunctionality and proliferative capacity of 
CD8+ T cells did not play a role in the maintenance of low viral load among VC+/- 
individuals or loss of control in the fVC+ subjects, suggesting that other mechanisms 
may be responsible for the observed divergent disease progression outcomes in our 
cohort. 
5.5 Viremic controllers without protective HLA class I alleles display limited ex 
vivo CD8+ T cell inhibition capacity compared to viremic controllers with 
protective HLA class I alleles.  
We further investigated the ability of CD8+ T cells to suppress viral replication ex 
vivo as a possible mechanism of viral control.  Viral inhibition assay was used to 
directly compare the virus inhibitory activity of CD8+ T cells ex vivo amongst VC+, 
fVC+, VC- and Prog+ subgroups at baseline and later time points. Figure 5.7 shows 
representative data for the 5 VC+ subjects studied at baseline and 4 subjects at later 
time points (due to limitations of sample availability, fewer samples were analysed at 
more than one time point). We show here that VC+ displayed enhanced ex vivo CD8+ 
T cell inhibition capacity. This phenotype was maintained at a later time point 
suggesting that this particular CD8+ T cell function may be important for viral 
suppression in VCs with protective HLA class I alleles. 
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Figure 5.7. Viral inhibition of the NL4-3- infected autologous CD4+ T cells by ex vivo 
CD8+ T cells - VC+ subjects. Infected CD4+ T cells were cultured with ex vivo CD8+ T 
cells at a ratio of 1:1. Blue lines represent infected CD4+ T cells alone, black lines 
represent the negative control; uninfected CD4+ T cells alone and the red lines represent 
coculture of infected CD4+ T cells with ex vivo CD8+ T cells. Representative data are 
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For the fVC+ subjects, we observed a reduced inhibitory capacity by the CD8+ T cells 
for the 3 individuals assessed (Figure 5.8). Furthermore, one fVC+ subject studied 
over time (i.e. pre- and post-loss of viral control), demonstrated a reduced ex vivo 
CD8+ T cell inhibitory capacity at baseline with a further reduction in T cell 
inhibitory capacity following loss of viral control. These data may suggest that the 
loss of viral control may be associated with reduced capacity of the CD8+ T cells to 
suppress viral replication. For the two other fVC+ subjects, samples were not 
available at the post loss of control time point. 
For the 5 VC- subjects, we observed a reduced inhibitory capacity of the CD8+ T cells 
(Figure 5.9). In addition, in the 4 VC- subjects studied over time (baseline and latest 
time point), despite the subjects displaying a reduced ex vivo CD8+ T cell inhibitory 
capacity at baseline, we saw a similar reduction in the ex vivo CD8+ T cell inhibitory 
capacity at a later time point. These data may suggest that the CD8+ T cells may not 
be involved in the control of viral replication among VC without protective HLA 
class I alleles. 
A representative data set for one Prog+ subject showed a reduced inhibitory capacity 
of the CD8+ T cells. In addition, in the one Prog+ subject studied over time (baseline 
and latest time point), the subject displaying a reduced ex vivo CD8+ T cell inhibitory 
capacity at baseline, this low ex vivo CD8+ T cell inhibitory capacity was maintained 
at a later time point. These data may suggest that the CD8+ T cells of the progressors 
are not as functional as CD8+ T cells from viremic controllers. 
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Figure 5.8. Viral inhibition of the NL4-3- infected autologous CD4+ T cells by ex vivo 
CD8+ T cells – fVC+ subjects. Infected CD4+ T cells were cultured with ex vivo CD8+ T 
cells at a ratio of 1:1. Blue lines represent infected CD4+ T cells alone, black lines 
represent the negative control; uninfected CD4+ T cells alone and the red lines represent 
coculture of infected CD4+ T cells with ex vivo CD8+ T cells. Representative data for 3 

































































Figure 5.9. Viral inhibition of the NL4-3- infected autologous CD4+ T cells by ex vivo 
CD8+ T cells – VC- subjects. Infected CD4+ T cells were cultured with ex vivo CD8+ T 
cells at a ratio of 1:1. Blue lines represent infected CD4+ T cells alone, black lines 
represent the negative control; uninfected CD4+ T cells alone and the red lines represent 
coculture of infected CD4+ T cells with ex vivo CD8+ T cells. Representative data are 
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Figure 5.10. Viral inhibition of the NL4-3- infected autologous CD4+ T cells by ex vivo 
CD8+ T cells – Prog+ subject. Infected CD4+ T cells were cultured with ex vivo CD8+ T 
cells at a ratio of 1:1 Blue lines represent just infected CD4+ T cells alone, Red lines 
represent the negative control; uninfected CD4+ T cells alone and the black lines 
represent coculture of infected CD4+ T cells with ex vivo CD8+ T cells. Representative 
data are displayed for 1 prog+ subject at baseline (n=1) and later time points (n=1). 
 
Figure 5.11. Log10 p24 viral inhibition of the NL4-3- infected autologous CD4+ T cells by 
ex vivo CD8+ T cells. Infected CD4+ T cells were cultured with ex vivo CD8+ T cells at a 
ratio of 1:1. Log10 p24 inhibition of individual subjects was calculated by subtracting 
log10 p24 values of CD4+ T cells co-cultured with CD8+ T cells from log10 p24 values of 
CD4+ T cells without CD8+ T cells at day 7, here we compared data from 5 VC+, with 3 
fVC+ and 5 VC- individuals. Statistical analysis was performed on Prism using Kruskal-
Wallis test to compare all 3 subgroups in each graph and Mann-Whitney U test to 
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For a combined assessment of the impact of ex vivo CD8+ T cell inhibition capacity 
on disease outcome, we evaluated the subgroups at baseline. Interestingly, we noted a 
significant difference in the log10 p24 inhibition between the viremic controllers with 
protective HLA class I alleles and viremic controllers without protective HLA class I 
alleles, with the former having CD8+ T cells with greater viral inhibition capacity (p-
value 0.02; Mann- Whitney test; Figure 5.11). Overall, viremic controllers with 
protective HLA class I alleles (VC+) displayed significantly higher ex vivo CD8+ T 
cell inhibition capacity compared to viremic controllers without protective HLA 
alleles (VC-) and failing viremic controllers with protective HLA class I alleles 
(fVC+).  The VC+ participants tended to maintain this inhibitory capacity to suppress 
virus replication over time. Taken together these data may suggest that whereas CD8+ 
T cells from viremic controllers with protective HLA class I alleles are associated 
with control of viremia, those of viremic controllers without protective HLA class I 
alleles display less ability to inhibit virus replication.  These results are consistent 
with our hypothesis that among viremic controllers without protective HLA class I 
alleles there is an alternative mechanism of viral control other than CD8+ T cells. 
5.6 Summary of results 
In chapter 5, we characterized the function of CD8+ T cells and associated the 
function with divergent disease progression that we observed in the 4 subgroups; 
VC+, VC-, fVC+ and Prog+. We found that there were no significant differences in 
the polyfunctionality of CD8+ T cells between the subgroups at baseline and later time 
points. We also observed no significant changes in the polyfunctionality of CD8+ T 
cells over time in the subgroups. Additionally, similar findings were reported when 
we assessed the proliferative capacity of CD8+ T cells in the same subgroups at 
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baseline and longitudinally. The statistical insignificance of these data may have been 
largely due to our very small sample numbers. 
We went further to investigate the ex vivo ability of CD8+ T cells to suppress HIV 
replication and associated this function with disease progression. Here we 
demonstrated that VC+ displayed enhanced ex vivo CD8+ T cell inhibitory capacity to 
suppress viral replication while fVC+, VC- and Prog+ subjects displayed a reduced ex 
vivo CD8+ T cell inhibitory capacity at baseline with a further reduction in T cell 
inhibitory capacity at later time points (for VC- and Prog+ subjects) and following 
loss of viral control (for the fVC+ subjects). Overall these data reveal that the viral 
control observe in VC subjects with protective HLA class I alleles is primarily driven 
by the CD8+ T cells and their ability to suppress virus replication. These data also 
suggest that VC without protective HLA class I alleles may possess an alternative 
mechanisms to maintain viral control.  Future studies will require investigation of 








Few HIV infected individuals are able to control viremia naturally without the need 
for treatment. Studying HIV infected individuals who naturally control virus 
replication can provide some invaluable information to better understand HIV 
pathogenesis, virus-host interactions and inform vaccine design. HIV controllers serve 
as an ideal model for effective HIV vaccine development. Research on HIV has 
undergone some considerable milestones in the past years to better define the 
mechanisms of viral control of HIV. Although the natural control of HIV has been 
linked to a number of factors including immunological factors, host genetics and viral 
factors in the HIV controller groups (viremic controllers, LTNPs and ECs), the 
evolution of such factors and their association with divergent disease progression 
patterns have rarely been characterized longitudinally in chronic HIV infection. 
Additionally, the cross-sectional findings regarding the mechanisms of viral control in 
HIV controllers have been inconclusive and therefore need resolving. There is need to 
clearly identify and define the correlates of immune protection from disease 
progression in individuals who naturally control HIV.  
In this thesis, we explored the mechanisms of viral control and lack of viral control 
amongst individuals with protective HLA class I alleles. We investigated viremic 
controllers with similar baseline clinical characteristics but progressing to divergent 
viral load status with one subgroup maintaining control, while the other subgroup lost 
viral control. Both immunological and viral factors were addressed in a longitudinal 
study design.  
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6.2 Protective versus non-protective HLA class I alleles and alternative 
mechanisms of viral control 
HLA class I alleles have previously been associated with differential control of 
viremia, where the expression of certain HLA class I alleles such as HLAs B*57, 
B*81:01, B*58:01 and B*27 have been strongly associated with low viral load hence 
termed ‘protective HLA class I alleles’, while other alleles have been termed ‘non-
protective HLA class I alleles’ because of their strong association with high viral load 
(222, 223, 254, 289–293). However, the exact mechanisms of viral control amongst 
individuals with protective HLA class I alleles are not fully understood. Furthermore, 
the majority of individuals with protective HLA class I alleles experience progressive 
infection suggesting that protective HLA class I alleles alone are not sufficient to 
account for the control of HIV replication. In chapter 3 we identified chronically HIV 
infected individuals with controlled viremia at enrolment (VL<2,000 HIV RNA 
copies/ml), some possessing protective HLA class I alleles while others did not and 
these were termed baseline viremic controllers (bVC). These individuals were 
followed over time to assess viral load dynamics based on whether they expressed 
protective HLA class I alleles or not. Interestingly we observed that the loss of control 
was only evident amongst baseline viremic controllers with protective HLA class I 
alleles, while none of the viremic controllers without protective HLA class I alleles 
lost viral control despite the two groups displaying viral load similarities at baseline. 
This unexpected finding suggests that viremic controllers without HLA class I alleles 
are less likely to subsequently progress in disease status. The question still remains as 
to why only those with protective HLA class I alleles lost viral control. At this point, 
it was not clear whether immunological or other mechanisms of viral control were 
involved in viral control or loss of control in these individuals. Previous studies have 
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shown that HLA class I alleles present viral peptides on the surface of antigen 
presenting cells to CTLs, and therefore protective HLA class I alleles are thought to 
mediate their effects primarily through CTLs. Our data shows that protective HLA 
class I alleles alone do not account for viral control in all controllers.  This is 
consistent with data from subtype B infection elite controllers, among whom it has 
been shown that whereas protective HLA class I alleles are overrepresented in this 
group, not all such individuals possess the protective alleles (272, 297).  Our data also 
suggest that the mechanisms responsible for viremic control may differ between those 
with versus those without protective HLA class I alleles.  Furthermore, the 
mechanisms of control in those without protective HLA class I alleles may be more 
durable than in those with protective HLA class I alleles. We next characterized HIV-
specific CD8+ T cell immune responses in the study participants with the ELISpot 
assay using overlapping consensus subtype C peptides spanning the entire proteome 
followed by confirmations with individual peptides within a reactive pool. 
6.3 The Gag responses in individuals with protective HLA class I alleles 
There is mounting evidence that Gag specific CD8+ T cells responses play a 
beneficial role in HIV disease outcome. CD8+ T cell responses to Gag have 
previously been associated with low viral load (252, 254) whereas broad or high 
magnitude responses to Nef correlate positively with viral load (233, 332). In chapter 
3 we showed that baseline viremic controllers with protective HLA class I alleles had 
significantly higher breadth of Gag specific CD8+ T cell responses compared to 
progressors with protective HLA class I alleles confirming what other studies have 
previously shown that targeting of Gag is associated with viral control in chronic HIV 
infection. We further observed that there was a bias towards targeting of Gag 
compared to Nef amongst baseline viremic controllers regardless of whether they 
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possessed protective HLA class I alleles or not. This was not evident amongst 
progressors with and without protective HLA class I alleles as we did not observe 
significant difference between the breadth of Gag versus Nef CD8+ T cell responses. 
Further analysis showed a bias towards targeting of Gag than other proteins such as 
Pol, Env, Accessory and Regulatory proteins in the bVC with and without protective 
HLA class I alleles. These findings suggest that targeting epitopes within regions of 
low entropy (highly conserved regions of the virus such as Gag) in HIV as opposed to 
high entropy proteins (highly variable regions of the virus such as Nef) may be 
protective. Furthermore, Nef targeting irrespective of HLA class I alleles appears to 
be detrimental and is associated with high viral load.   
We did not observe any significant differences when we assessed the breadth of Gag 
specific CD8+ T cell responses between baseline viremic controllers and progressors 
without protective HLA class I alleles. This finding suggests that mechanisms other 
than Gag specific CD8+ T cells may mediate control in baseline viremic controllers 
without protective HLA class I alleles. It is possible that these individuals may have 
robust innate immunity or cytolytic CD4+ T cell responses, which may compensate 
for the ineffective CD8+ T cell responses, however we did not characterize these 
alternative potential mechanisms in the present study. Previous studies have described 
cytotoxic CD4+ T cell responses to be associated with HIV control and suggested that 
less effective CD8+ T cell responses can be compensated for by robust CD4+ T cell 
responses (315, 342). However in those studies, strong CD4+ T cell responses were 
maintained through into the chronic phase but ultimately lost which suggests that if 
the individuals are still maintaining control, other mechanisms other than CD4+ and 
CD8+ T cell may take over the control of chronic HIV infection (315). Furthermore, 
central memory T cells have been associated with viral control which can be detected 
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using the peptide based cultured ELISpot (330), which were not investigated in this 
study. Overall, our data on individuals with protective HLA class I alleles support the 
‘Gag hypothesis’ that responses to Gag are protective and associate with controlled 
viremia which is consistent with other reports (252, 254). However, we provide new 
evidence in controllers without protective HLA class I alleles, Gag CD8+ T cell 
responses do not appear to play a significant role in viral control. 
6.4 Evolution of CD8+ T cell responses 
Many studies of chronic HIV infection have assessed CD8+ T cell responses at only 
one time point (cross-sectionally) and associated these responses with 
contemporaneous viral load. Here we analyzed CD8+ T cell responses longitudinally 
using optimal peptides allowing us to assess the evolution of these responses and 
associate them with viral load dynamics (chapter 4). We were able to assess not only 
the specificity of the responses but also their persistence. Here we focused our 
analysis on 4 subgroups described in detail in chapter 2; VC+/VC-: viremic 
controllers with and without protective HLA class I alleles who controlled their 
viremia throughout the time of follow-up; (maintaining a VL< 2,000 HIV RNA 
copies/ml), fVC+: failing viremic controllers with protective HLA class I alleles; 
individuals who had controlled viremia at baseline and later lost viral control (VL 
increased to >10,000 HIV RNA copies/ml at a minimum of 2 time points) and Prog+ 
subjects; progressors with protective HLA class I alleles. We assessed responses at 
baseline and later time points for VC+, VC- and Prog+ subjects and baseline and post 
loss time point for the fVC+ subjects. 
We first determined whether there were differences in the CD8+ T cell responses at 
baseline. The reason for this analysis was to determine if there were differences in 
CD8+ T cell responses at baseline that may be predictive of the divergent disease 
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progression patterns observed in the 4 subgroups. No significant differences were 
observed when comparing overall CD8+ T cell responses across the whole HIV 
proteome and Gag specific CD8+ T cell responses between VC+ and fVC+ subgroups 
despite the individuals displaying similar VL at baseline. Failing VC+ displayed a 
trend towards higher breadth of overall CD8+ T cell responses across the whole HIV 
proteome and Gag specific CD8+ T cell responses. The reasons for this observation 
are not known. However, these responses may not be effective in restricting virus 
replication in subsequent time points since high viral load was noted in these fVC+ 
subjects. Further analysis revealed that fVC+ subjects targeted significantly higher 
breadth of Nef at baseline compared to VC+ despite similarities in viral load at this 
point. Nef has previously been shown to be associated with increased viral load (233, 
332, 343). Our observation in this study suggests that targeting of Nef while still 
displaying controlled viremia may predict subsequent virologic failure. However, this 
needs further investigation. It is also possible that the high Nef responses observed in 
the fVC+ subjects might be driving the elevated overall responses observed in this 
subgroup at baseline.  
Longitudinal analysis of CD8+ T cell responses among VC with and without 
protective HLA class I alleles (VC+/-) revealed that there was maintenance of overall 
CD8+ T cell responses across the whole HIV proteome (Gag, Pol, Nef, Env and 
accessory and regulatory proteins) over time. These data suggest that the maintenance 
of CD8+ T cell responses over time is important for sustained viral control during 
chronic HIV infection. Further analysis of the longitudinal CD8+ T cell responses of 
the fVC+ subgroup revealed that the overall CD8+ T cell responses across the whole 
HIV proteome, Pol and Gag specific CD8+ T cell responses were lost over time 
(comparing baseline to first time point of viral load increase to more than 10,000 HIV 
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RNA copies/ml (post loss). These observations suggest that the loss of CD8+ T cell 
responses may be related to the loss of viral control in these individuals. However, we 
are unable to determine whether the loss of responses arose as a result of the increase 
in viral load or the other way round. This phenomenon was also seen in progressors 
with protective HLA class I alleles with near-significant p-values. We also observed a 
trend in the reduction of Nef specific CD8+ T cell responses with increasing viral load 
in the fVC+ and Prog+ subgroups. Although previous studies have linked targeting of 
Nef with high viral load (233, 332) suggesting that Nef responses are driven by 
antigenemia, in our study we observed that as the viral load was increasing, there was 
a reduction in the Nef responses suggesting that the increase in viremia may 
ultimately lead to impairment of CD8+ T cell responses to Nef. These data also 
suggest that Nef responses do not seem to play a role in viral control, as they appeared 
to wane with disease progression. Overall, so far our data suggest that maintenance of 
CD8+ T cell responses is important for sustained viral control especially in individuals 
with protective HLA class I alleles while the loss of CD8+ T cell responses is 
associated with loss of viral control. Increasing viremia is related to the impairment of 
the CD8+ T cell responses.  
It is important to note that the ex vivo ELISpot assay can underestimate the true 
breadth and magnitude of CD8+ T cell responses (232) and the fact that we stimulated 
the cells with optimal peptides based on HIV reference strain as opposed to 
autologous viruses may have resulted in non-detection of some responses because 
autologous virus sequences are different from reference strains. Additionally, the 
ELISpot assay may not have detected low frequency CD8+ T cell responses or the 
control may be associated with central memory T cells which are usually low in 
frequency and can only be assessed by a cultured ELISpot (330). In future, the use of 
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autologous optimal peptides to stimulate cells or the employment of a cultured 
ELISpot assay may provide more information. 
6.5 Viral escape and CD8+ T cell responses 
Gag specific responses are known to contribute significantly to viral control by 
reducing virus replication. Previous studies have consistently demonstrated that HIV 
is able to evade CTL recognition by developing escape mutations (149, 333–339). 
Here we hypothesized that the loss of CD8+ T cell responses we observed in the 
failing viremic controllers with protective HLA class I alleles (fVC+) subgroup will 
primarily be as a result of escape mutations. In the second half of chapter 4, 
longitudinal population gag sequencing was performed from plasma samples at 
baseline and post loss of control on the fVC+ subjects and at baseline and available 
later time points for the viremic controllers with and without protective HLA class I 
alleles (VC+ and VC-). Here, we determined whether the changes in the CD8+ T cell 
responses were a result of sequence evolution on targeted Gag epitopes or their 
flanking regions.  
Analysis of the fVC+ subjects showed that escape was already present in 51% of the 
Gag epitopes and of these, 32% (11 of 34) elicited detectable CD8+ T cell following 
stimulation with peptides corresponding to the wild type epitopes. At post loss time 
point only 53% (an additional 2%) of the Gag epitopes had escaped and of these, 11% 
(4 of 37) had detectable CD8+ T cell responses to the wild type epitopes that 
persisted, representing a 21% reduction in the number of T cell epitopes with a 
detectable CD8+ T cell response. These data suggested that only a minority of CD8+ T 
cell responses were lost as result of sequence variation (viral escape) within the 
cognate epitopes. Further analysis showed that 7 CD8+ T cell responses were no 
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longer detectable at the post loss time point. At this point it is not very clear why 
these responses were lost. It is possible that the loss of these CD8+ T cell responses 
represents a natural waning of responses to the wild type antigenic peptide following 
escape. It is also possible that these cells eventually died due to lack of continued 
stimulation because they were no longer seeing the antigen (cognate epitope). These 
data also reveal that the loss of viral control did not occur as a result of escape. This is 
because there were no significant differences in the level of escape at baseline versus 
post loss of control time point, suggesting that the loss of control is primarily related 
to the loss of CD8+ T cell responses. Furthermore, previous studies have described 
mutations such as T242N, A163G and T186S as reverting mutations in HIV infection 
possibly due to their fitness cost (344, 345). In our study, the T242N mutation was the 
most common mutation and reversion to wild type occurred in only 2 fVC+ subjects 
with no detectable CD8+ T cell response indicating that reversion in these 2 subjects 
resulted from the loss of CTL pressure. However, in some individuals there was no 
reversion observed despite the loss of CD8+ T cell responses.  We know from 
previous studies that some mutations within Gag have a fitness cost to the virus (258, 
346), however compensatory mutations can develop and restore viral fitness or 
reversion can occur especially when the CTL pressure is lost. In our study, it is 
possible that the fVC+ individuals may have developed compensatory mutations that 
restored viral fitness hence the increasing viral load in these individuals. We also 
observed that 4 CD8+ T cell responses were maintained although escape was evident 
in those epitopes. This is clear evidence that the subjects responded to the wild type 
optimal peptides that the cells were stimulated with.  
In addition, there were 8 wild type epitopes that elicited detectable CD8+ T cell 
responses at baseline and 6 of these responses were not detected at the post loss time 
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point. We observed that in 3 of these 6 epitopes, sequence variation had occurred at 
time of virologic failure, which may explain that the loss of these responses was due 
to viral escape.  However the other 3 epitopes remained wild type post loss of control 
and yet did not elicit detectable CD8+ T cell responses. It remains unclear why these 3 
responses were lost in the absence of escape. Overall, we observed that some CD8+ T 
cell responses in the fVC+ subgroup were lost as a result of viral escape but escape 
cannot explain the loss of some of the responses. The mechanisms that underlie the 
loss of CD8+ T cell responses in the absence of viral sequence changes requires 
further investigation, however we can speculate that we may not have been able to 
detect these responses because of their low frequencies. More sensitive assays such as 
cultured ELISpot, intracellular staining or tetramer staining may have given a more 
accurate result to check whether these responses were actually lost or not. It might be 
that the frequency was reduced below the level of detection of a conventional 
ELISpot. It is also possible that the cells may be prone to apoptosis or were 
exhausted. Nevertheless, our data unequivocally show that these CD8+ T cell 
responses underwent functional or phenotypic changes and the mechanisms involved 
will require further investigation. 
We also assessed the presence or absence of escape in the VC+ and VC- subgroups. 
Interestingly we show that VC+ subjects had a high level of escape, with 70% of the 
epitopes at baseline having variant sequences. Viral control was sustained in these 
individuals despite ongoing evolution in plasma viruses and this is in agreement with 
some previous studies that showed that some elite controllers maintained viral control 
despite ongoing viral replication and evolution in plasma viruses and they were able 
to develop de novo immune responses to variant peptides (347, 348). However, not all 
escaped epitopes were targeted. One possible explanation is that responses to the wild 
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type peptides were lost and could not be elicited by stimulation with the peptide.  We 
cannot rule out that in these cases de novo CD8+ T cell responses to the viral variant 
epitopes were present since we did not test for these using autologous peptides in this 
thesis.  Future work will be needed to assess whether de novo responses to variant 
epitopes were elicited in some of these cases.  
Overall these data reveal that while as expected viral escape was associated with the 
loss of CD8+ T cell responses and this is consistent with other studies (149, 339, 349). 
However, not all loss of response could be explained by viral escape. Deciphering the 
underlying mechanisms for loss of these responses (not explained by viral escape) 
will require further investigation.  
6.6 The impact of CD8+ T cell functionality on disease progression 
The ability of CD8+ T cell to produce diverse cytokines (polyfunctionality) and 
proliferate upon stimulation has been extensively studied in HIV infection. Previous 
studies have shown that a highly polyfunctional and proliferative CD8+ T cell 
phenotype play a significant role in HIV control especially in LTNPs and ECs (235, 
325, 350, 351). However, whether or not this phenotype plays a role in the divergent 
disease progression patterns in chronic HIV infection remains understudied, as most 
previous studies have been cross-sectional. In chapter 5 we describe longitudinal 
analysis of the functional properties of CD8+ T cells, proliferation and ability to 
suppress viral replication in vitro.  The goal of this analysis was to determine whether 
these functional properties of CD8+ T cells played any role in the sustained viral 
control observed in a subset of individuals and loss of viral control in some 
individuals. 
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In our study we observed no significant differences in the polyfunctionality and 
proliferative capacity of CD8+ T cells at enrolment amongst the subgroups studied; 
VC+, VC-, fVC+ and Prog+ subjects. Further analysis of the longitudinal 
polyfunctionality data revealed no differences between the subgroups and at different 
time points. We did not observe significant changes in the polyfunctionality of the 
CD8+ T cells over time or as the viral load was changing in some individuals. We 
could not link this function to the differences in divergent disease progression patterns 
observed in the subgroups. Therefore we concluded that polyfunctionality of CD8+ T 
cells might not be playing a role in disease progression patterns in our cohort.  
Analysis of the proliferative capacity of the CD8+ T cells also revealed no significant 
differences between the subgroups at baseline and longitudinally. However VC+ 
subjects had a trend towards displaying a higher proliferative capacity compared to 
fVC+ subjects. This could signal a role proliferation plays in the control of viremia as 
demonstrated in previous studies (350).  Some limitations of our study are worth 
highlighting here, first, limited sample numbers may have reduced our statistical 
power to detect differences and secondly due to study limitations, polyfunctionality 
and CD8+ T cell proliferation were studied in bulk and not virus-specific CD8+ T 
cells.   Further investigations with a larger sample size and focusing on HIV-specific 
CD8+ T cell may yield additional insights on these CD8+ T cell properties. 
One of the main functions of the CD8+ T cells is to kill virally infected cells. We 
hypothesized that viral control will be associated with CD8+ T cells capable of 
blocking viral replication in an ex vivo viral inhibition assay. Our data revealed that 
VC+ subjects displayed enhanced ability of CD8+ T cells to suppress viral replication 
in an ex vivo viral inhibition assay while fVC+ and VC- subjects displayed reduced 
ability of CD8+ T cells to suppress viral replication. The VC+ subjects maintained this 
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function throughout while the fVC+ subject studied showed a further reduction in the 
ability of the CD8+ T cells to suppress viral replication. These data suggest that fVC+ 
possessed CD8+ T cells that are dysfunctional or impaired in their function compared 
to CD8+ T cells from the VC+ subjects. It is important to note the fVC+ subjects 
displayed reduced ability to suppress viral replication at the time when they had 
controlled viremia (at baseline when their VL was below 2,000 HIV RNA copies/ml). 
These data suggest that the loss of viral inhibitory capacity of CD8+ T cells prior to 
the rise in viremia indicates dysfunction even before the subsequent clinical 
consequences.  Our data is partly in agreement with previous studies which 
demonstrated that the CD8+ T cells from controllers and elite controllers differed to 
those of progressors in their ability to inhibit viral replication (330, 352).  
However, it is important to note that not all viremic controllers in our cohort exhibited 
this effective CD8+ T cell viral inhibition capacity.  In chapter 4 we showed that VC- 
targeted fewer epitopes and these findings led us to hypothesize that either CD8+ T 
cell responses do not play a major role in viral control in these individuals or that the 
few virus-specific CD8+ T cells in these persons are highly suppressive despite their 
limited overall breadth. In chapter 5 we showed that the VC- subjects displayed 
significantly lower ability of CD8+ T cells to suppress viral replication in an ex vivo 
viral inhibition compared to VC+. These data therefore indicate that mechanisms 
other that CD8+ T cells are responsible for sustained viral control in these individuals.  
It is possible that these individuals may have strong CD4+ T cell responses that are 
capable of displaying cytolytic activity as previously shown in some studies (315, 
342). Other mechanisms of control in these individuals may involve innate immunity 
or differential expression of host restriction or replication cofactors, attenuated and 
defective viruses.  Overall our data support the view that CD8+ T cells play an 
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important role in the sustained control of HIV replication, particularly in individuals 
with protective HLA class I alleles, whereas in those without protective HLA class I 
alleles, alternative mechanisms of viral control may be at play. 
6.7 Conclusion 
In this thesis we explored the possible mechanisms of viral control and lack of viral 
control in individuals possessing protective HLA class I alleles and those without 
protective HLA class I alleles as control groups. We utilized a longitudinal study 
design in an attempt to overcome some of the bias inherent in cross-sectional studies 
where the long-term outcome of progression is unknown.  We explored longitudinally 
the immunological and virological factors that may explain the divergent disease 
progression patterns observed in our cohort. We first showed that there was loss of 
viral control amongst individuals who had controlled viremia at enrolment and this 
phenomenon was only evident in those individuals possessing protective HLA class I 
alleles. Our findings strengthen the important role CD8+ T cell responses play in 
sustained viral control as we showed that Gag specific CD8+ T cells were associated 
with low viral load. We went further to demonstrate that the loss of viral control in 
some individuals was related to the loss of Gag specific CD8+ T cell responses while 
sustained viral control was related to persistence of Gag specific CD8+ T cell 
responses. Interestingly, only a minority of Gag specific CD8+ T cell responses that 
did not persist could be explained by viral escape. This data therefore suggest that 
mechanisms other than viral sequence may be playing a more important role in lack 
of persistence of CD8+ T cell responses than previously appreciated.  
Additionally, we found no evidence of differences in the polyfunctionality and 
proliferative capacity of CD8+ T cells and these parameters did not play a role in the 
loss of viral control. However, individuals with protective HLA class I alleles 
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possessed CD8+ T cells with high virus inhibition capacity, and loss of viral control 
was associated with diminution of virus inhibition capacity. In contrast viremic 
controllers without protective HLA class I alleles had CD8+ T cells with poor virus 
inhibition capacity, suggesting that CD8+ T cell-independent mechanisms may 
potentiate viral control in these individuals.  
Taken together, the finding in this thesis highlight the importance of Gag specific 
CD8+ T cells in mediating viral control particularly in individuals with protective 
HLA class I alleles. These data suggest that maintenance of CD8+ T cell responses is 
crucial for control even in the face of viral escape. However, viral escape does not 
fully explain the loss of CD8+ T cells in chronic HIV infection and alternative 
mechanisms require further investigation. Finally, in viremic controllers without 
protective HLA class I alleles viral control occurred in the absence of broad CD8+ T 
cell responses and poor virus inhibition capacity of CD8+ T cells highlighting the 
need to study alternative mechanisms in these individuals. More work still needs to be 
done in order to further determine the correlates of immune protection. Other factors 
such as protective antibodies may play an important role in the control of viremia 
however we do not know how. There may be other unknown immunological factors 
associated with control. 
We had initially hypothesized that the control of viremia in viremic controllers with 
protective HLA class I alleles will be as a result of a combination of the following 3 
factors: 
1. Immune responses targeted towards specific epitopes located in highly conserved 
Gag regions, 
2. Viral evolution and/or unusual polymorphisms that affect viral fitness, 
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3. And highly polyfunctional CD8+ T cells that are capable of inhibiting viral 
replication ex vivo.  
We were able to show that indeed HIV control was associated with CD8+ T cell 
responses to Gag; which is the region of the virus that is highly conserved. Although 
polyfunctionality of CD8+ T cells was not associated with viral control in our study, 
the small sample numbers hampered the statistical significance in this analysis. We 
were able to demonstrate that the control of viremia was associated with increased 
viral mutation rates among viremic controllers with protective HLA class I alleles but 
we did not test whether these mutations affected viral fitness. In agreement with our 
hypothesis we were able to show that viral control was associated with CD8+ T cells 
capable of inhibiting viral replication as demonstrated in an ex vivo assay. 
6.8 Limitations of the study 
There were some noteworthy limitations in this thesis study.  The overall frequency of 
the CD8+ T cell response may have been underestimated in our study since we only 
used consensus viral peptides rather than autologous ones, and as noted, this has been 
shown to underestimate the frequency of virus-specific CD8+ T cells.  The cohort was 
relatively small and limited sample availability at key time points prevented extensive 
investigations. For example, polyfunctionality, proliferation and viral inhibition 
assays could only be performed with bulk instead of virus-specific CD8+ T cells due 
to sample limitations.  We also had technical challenges amplifying the gag gene 




6.9 Future work 
There are a number of directions that one could take from the findings in this thesis. 
i. The loss of CD8+ T cells in the absence of viral escape. It would be 
interesting to determine why these responses were lost despite no evidence 
of escape.  Mechanisms may include changes in the T cell receptor 
sequences as has been previously documented (352, 353), antigen 
processing defects of antigen presenting cells (337, 354) and changes in 
the virus sequence that affect antigen processing  (333, 355). Other 
mechanisms may include T cell exhaustion or continuous immune 
activation leading to clonal deletion or apoptosis.  It is also possible that 
these CD8+ T cells persist but become functionally defective and unable to 
secrete IFNγ.  CD8+ T cells may also become defective by failure to 
express molecules associated with long-term survival and memory such as 
the IL-7Rα (356–358).  Tetramer staining may help clarify whether this is 
indeed the case. Other markers that should be studied include T cell 
exhaustion markers (HLA DR and CD38). To study T cell apoptosis, 
Annexin V and Propidium Iodide assay may be used. 
 
ii. The persistence of CD8+ T cells despite viral escape. It would be 
interesting to investigate why some CD8+ T cell response to the wild type 
viral peptide persisted long after escape.  It is possible that some wild type 
viral sequences persist as minor variants and continually stimulate an 
immune response.  Alternatively, the variant peptides may themselves 
stimulate de novo CD8+ T cell response that cross-react with the wild type 
peptide sequence.  Whatever the mechanisms, our data suggest that these 
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persistent CD8+ T cells are important and mediate viral control even in the 
face of viral escape.  Our data underline persistence of CD8+ T cell 
responses as an important correlate of viral control among individuals with 
protective HLA class I alleles. 
 
iii. Further studies on the mechanisms of viral control among viremic 
controllers without protective HLA class I alleles. There is need to 
investigate the role of cytotoxic and cytolytic activity of CD4+ T cells in 
these individuals (315, 342). It is possible that HIV host restriction factors 
or differentially expressed replication cofactors may be playing a role in 
the control of viremia in these individuals. Other innate mechanisms of 
viral control cannot be ruled out.   Therefore further investigations are 
required. 
 
iv. To isolate and study the virus and check for infectivity (infectiousness) 
and competence. It is also possible that the virus in the viremic controllers 
may be defective virus or have lowered replication fitness (275, 276). This 
requires further investigation in order to fully determine mechanisms of 
viral control especially in individuals without protective HLA class I 
alleles. 
6.10 Final remarks 
Although ART has been very effective reducing HIV related deaths and morbidities, 
better strategies to prevent infection are needed and an HIV vaccine would be ideal in 
cutting the spread of the virus. However, there is still no efficacious preventative 
vaccine available. For an effective HIV vaccine to be developed, we need to 
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accelerate our efforts and better understand HIV pathogenesis, host-virus interactions, 
and define clearly the correlates of viral control. A lot can be leant from the long-term 
non-progressors, elite controllers and viremic controllers. Currently, the mechanisms 
of natural HIV control without antiretroviral therapy are incompletely understood. 
The general consensus is that the mechanisms of viral control are multifactorial and 
may differ between cohorts or populations. However, CD8+ T cell responses to Gag 
have consistently been shown to be a correlate of control in chronic HIV infection. 
These data suggest that an effective HIV vaccine should elicit CD8+ T cell responses 
to Gag. However, it should be noted that despite association of Gag responses with 
better control, the majority of HIV infected people eventually progress to full blown 
disease.  Therefore, it is important to understand the mechanisms that lead to loss of 
Gag specific responses and also how these responses can be enhanced or augmented. 
We also cannot rule out other important factors, which may enhance the partially 
effective natural immune responses.  This may lead to design of better vaccines.  
 This thesis contributed to the body of knowledge by providing data on the evolution 
of immunological and virological events associated with viral control and lack of viral 
control in chronic HIV-1 subtype C infection in the presence or absence of protective 
HLA class I alleles. The data indicated that not all CD8+ T cell responses among 
viremic controllers are effective at suppressing viral replication. We were able to 
demonstrate that while viremic control in individuals with protective HLA class I 
alleles was associated with broad CD8+ T cell responses, viremic control in those 
without protective HLA class I alleles seemed dependent on alternative mechanisms. 
Further investigations of what mechanisms these individuals use to sustain controlled 
viremia are warranted as it may lead to design of better immunogens. 
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CHAPTER 8: APPENDICES 
The following graphs represent changes in the proportion of CD8+ T cells expressing 
CD107a, IFNγ, MIP1-β and TNF-α over time, that is, for VC+, VC- and Prog+ subjects, 
we assessed these responses at baseline and later time points. Expression of these 
markers was assessed at baseline (pre loss time point) and post loss of viral control 
time point for the fVC+ subjects.  
Figure A1. Longitudinal results showing the proportion of CD8+ T cells  expressing 
CD107a upon stimulation with Gag peptide pools - amongst viremic controllers (VC+), 
failing viremic controllers (fVC+), progressors (Prog+) with protective HLA class I 
alleles and viremic controllers without protective HLA class I alleles at baseline and 
later time point. Gating strategy is shown in Figure 5.1. Positive responses were 
reported after background correction by subtracting the proportion of unstimulated 































































































































































Figure A2. Longitudinal results showing the proportion of CD8+ T cells  expressing 
MIP1-β upon stimulation with Gag peptide pools - amongst viremic controllers (VC+), 
failing viremic controllers (fVC+), progressors (Prog+) with protective HLA class I 
alleles and viremic controllers without protective HLA class I alleles at baseline. Gating 
strategy is shown in Figure 5.1. Positive responses were reported after background 
correction by subtracting the proportion of unstimulated CD8+ T cells from the Gag 



























































































































































Figure A3. Longitudinal results showing the proportion of CD8+ T cells  expressing 
IFNγ upon stimulation with Gag peptide pools - amongst viremic controllers (VC+), 
failing viremic controllers (fVC+), progressors (Prog+) with protective HLA class I 
alleles and viremic controllers without protective HLA class I alleles at baseline. Gating 
strategy is shown in Figure 5.1. Positive responses were reported after background 
correction by subtracting the proportion of unstimulated CD8+ T cells from the Gag 



























































































































































Figure A4. Longitudinal results showing the proportion of CD8+ T cells  expressing 
TNF-α upon stimulation with Gag peptide pools - amongst viremic controllers (VC+), 
failing viremic controllers (fVC+), progressors (Prog+) with protective HLA class I 
alleles and viremic controllers without protective HLA class I alleles at baseline. Gating 
strategy is shown in Figure 5.1. Positive responses were reported after background 
correction by subtracting the proportion of unstimulated CD8+ T cells from the Gag 
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